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ACE   angiotensin converting enzyme 
ADM   abductor digiti minimi 
AMH   A-mechanoheat sensitive afferent 
ANA   antineuronal antibody 
AP-1 activator protein-1, a family of dimeric basic leucine zipper 
(bZIP) transcription factors, comprising members of the Jun, 
Fos and activator transcription factor (ATF) subfamilies 
APC   antigen presenting cell  
ASIC   acid-sensing ion channel 
ASIC3   acid-sensing ion channel 3 
ATF   activating transcription factor 
ATP   adenosine triphosphate 
α-MSH   alpha-melanocyte stimulating hormone 
 
BNaC   acid-sensing ion channel (see also ASIC) 
BK   bradykinin 
BM-DC   bone-marrow derived dendritic cell 
BDNF   brain-derived neurotrophic factor 
 
CaMKII   Ca2+/calmodulin-dependent protein kinase II 
cAMP    cyclic adenosine monophosphate 
CCI   chronic constriction injury 
CCL (2, 5, 17, 22) chemokine (C-C motif) ligand 
CD11c   cluster of differentiation 11c (Integrin, a dendritic cell marker) 
CD1a   cluster of differentiation 1a (Langerhans cell marker) 
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CD4 cluster of differentiation 4 (Th subset cell marker (also 
monocyte, macrophage & dendritic cells) 
CD8 cluster of differentiation 8 (Natural killer T-cell marker (also 
dendritic cells)) 
CD 45   cluster of differentiation 45 (leucocyte common antigen) 
CD 68   cluster of differentiation 68 (monocyte / macrophage marker)  
CD 207 cluster of differentiation 207 (Langerin, Langerhans cell 
marker)  
CDT   cold detection threshold 
c-Fos human oncogene homologous to Finkel-Biskis-Jinkins (FBJ) 
murine osteosarcoma virus oncogene. 
CGRP   calcitonin gene-related peptide 
CIDP   chronic inflammatory demyelinating polyradiculoneuropathy 
c-Jun homolog of the oncogene v-Jun (putative transforming gene 
of avian sarcoma virus) 17 
CMH   C-mechanoheat sensitive afferent 
CMiHi   C-mechano and heat insensitive afferent 
CMT   Charcot-Marie Tooth (disease) 
COX-2   cyclooxygenase-2 
CPT   cold pain threshold 
CXCL (2, 3, 10)  chemokine (C-X-C motif) ligand 
 
DAB   3,3’-Diaminobenzidine 
DAG   diacylglycerol 
DAMP   damage-associated molecular pattern 
DC   dendritic cell 
DFNS   Deutsches Forschunsnetz (German Research Network) 
DMA   dynamic mechanical allodynia 
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DM   demyelination / demyelinating 
DML   distal motor latency 
DPX   dibutyl phthalate 
DRG   dorsal root ganglion 
dsDNA   double-stranded deoxyribonucleic acid 
 
EDB   extensor digitorum brevis 
ELISA    enzyme-linked immunosorbant assay 
EMG   electromyography 
ENA   extractable nuclear antigen 
ERG2   early growth response gene 2 (human analog to Krox-20) 
ERK 1/2  extracellular-signal-regulated kinase 1/2 
ERT   enzyme-replacement therapy 
 
FRAP   fluoride-resistant acid phosphatase 
 
Gb3, GL-3  globotriaosylceramide 
GBS   Guillain-Barré sydrome 
GDNF   glial cell line-derived neurotrophic factor 
GM-CSF  granulocyte macrophage colony stimulating factor 
GTP   guanosine triphosphate 
 
HaCaT   immortal keratinocyte cell line 
HADS   Hospital Anxiety and Depression Scale 
HPT   heat pain threshold 
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IB4   isolectin B4 
IENFD   intraepidermal nerve fibre density 
IFN-Υ   interferon-gamma 
IL (1β, 2, 3, 4, 6, 10, 12, 17, 21, 22) interleukin (1β, 2, 3, 4, 6, 10, 12, 17, 21, 22) 
iNOS   inducible nitrogen oxide synthetase 
IP-10   interferon gamma-induced protein 10 (also known as CXCL10) 
IP3    inositol triphosphate 
 
JNK   c-Jun N-terminal kinase 
 
Krox-20 Murine homonolog of human EGR 2 (early growth response 
gene 2) 
 
LC   Langerhans’ cell 
LLOQ   lower limit of quantification 
LOB   limit of blank 
LOD   limit of detection 
 
MAPK   mitogen-activated protein kinase 
MKP   MAPK phospholipase 
MKK   MAPK kinase 
MBP   myelin basic protein 
MCP-1   monocyte chemoattractant protein-1 (also known as CCL2) 
MCV   motor conduction velocity 
mDC   monocyte-derived dendritic cell 
MDT   mechanical detection threshold 
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MHCII   major histocompatibility complex class II 
MMP-1  matrix metalloproteinase-1 
MPS   mechanical pain sensitivity 
MPT   mechanical pain threshold 
mRNA   messenger ribonucleic acid 
MSH   melanocyte stimulating hormone 
MΦ   macrophage 
 
NADA   N-arachidonoyl dopamine (a TRPV1 agonist) 
NALP-1  NACHT, LRR and PYD domains-containing protein 1 
NEP   neutral endopeptidase 
NF-κB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NF200   neurofilament (200kDa subunit) 
NGF   nerve growth factor 
NGFβ   nerve growth factor (beta subunit) 
NK1   neurokinin 1 (substance P receptor) 
NO   nitric oxide 
NP   neuropathy 
NPSI   neuropathic pain symptom inventory 
NSF    N-ethylmaleimide sensitive fusion proteins 
NT3   neurotrophin-3 
 
OCT   optimal cutting temperature mounting medium 
OX-40   CD134 (TNFRSF4, a member of the TNF receptor superfamily) 
 
P2X(3, 4, 7)  purinergic receptor type 2X (ligand-gated ion channel type) 
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P2Y1   purinergic receptor type 2Y (G-protein-coupled receptor) 
p38-MAPK  p38 mitogen-activated protein kinase 
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PGE2   prostaglandin E2 
PGP 9.5  protein gene-product 9.5 
PHS   paradoxical heat sensation 
PICK   proinflammatory cytokine 
PIP2   phosphatidylinositol 4,5-biphosphate 
Pirt phosphoinositide-interacting regulator of transient receptor 
potential channels 
PKA   protein kinase A 
PKC   protein kinase C 
PLA2   phospholipase A2 
PLC   phospholipase C 
PLP   proteolipid protein 
PMP22   peripheral myelin protein 22 
POEMS syndrome of polyneuropathy, organomegaly, 
endocrinopathy, monocloncal paraprotein and skin changes 
PPT   pressure pain threshold 
 
RacGTP  subfamily of Rho guanosine triphosphatases 
RANK   receptor activator of nuclear factor kappa B 
RANKL   receptor activator of nuclear factor kappa B ligand 
RANTES regulated on activation, normal T-cell expressed and secreted 
(also known as CCL5) 
Ret  rearranged during transfection (tyrosine kinase receptor for 
GDNF family ligands)  
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RF   receptive field 
RhoA   Ras homolog gene family, member A (small GTPase) 
RIA   radioimmuoassay 
RP1   retinitis pigmentosa 1 protein 
 
S-100   family of small, dimeric calcium and zinc binding proteins. 
SAP   sensory action potential 
SC   Schwann cell 
SCV   sensory nerve conduction velocity  
SFN   small fibre neuropathy 
SG   substantia gelatinosa 
SM   sensorimotor 
SNARE   SNAP (soluble NSF attachment protein) receptor 
SOM   somatostatin 
SP   substance P 
V-SNARE  vesicle SNARE 
 
TBS   Tris-buffered saline 
TGF   transforming growth factor 
TGF-β   transforming growth factor beta 
Th(1, 2, 17)  T-helper(1, 2, 17) 
TLI   terminal latency index 
TNF-α   tumour necrosis factor alpha 
Tris   2-Amino-2-hydroxymethyl-propane-1,3-diol  
TrkA   tropomyosin receptor kinase A (high affinity NGF receptor) 
TRP   transient receptor potential channel 
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TRPA1   transient receptor potential ion channel (ankyrin) 
TRPM8   transient receptor potential ion channel (melastatin) 
TRPV   transient receptor potential ion channel (vanilloid) 
TSL   thermal sensory limens 
TTR   tranthyretin 
TTX-R   tetrodotoxin resistant 
TTX-S   tetrodotoxin sensitive 
 
 
UVB   ultraviolet B 
 
VAS   visual analogue scale 
VD3   Vitamin D3 
VDR   vitamin D receptor 
VDT   vibration detection threshold 
VIP   vasoactive intestinal peptide 
VR1   transient receptor potential ion channel (vanilloid) 
 
 
WDT   warm detection threshold 
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The Skin as a Window on Mechanisms of Neuropathy and 
Neuropathic Pain 
Abstract 
Neuropathies are common, yet the pathogenic mechanisms of many remain 
incompletely understood. Animal and cell models have provided much useful 
information about disease mechanisms, and yet translation of this knowledge to 
clinical practice and disease therapies is often disappointing. One of the difficulties 
in studying human nerves is limited availability of tissue, due to the morbidity of 
peripheral nerve  (usually sural nerve) biopsy. I sought to evaluate the utility of 
cutaneous nerves, both generally as a tool to assess the relevance of pathogenic 
mechanisms identified in animal studies in human disease, and also specifically in 
evaluating whether immune changes in the skin may play a role in the development 
of neuropathic pain. 
Animal models have suggested that proinflammatory cytokines exert algesic effects 
on nerves, whilst anti-inflammatory cytokines have a counter-regulatory analgesic 
effect (Üçeyler et al., 2009). More recently, support for a link between variability in 
systemic and / or local cytokine balance and pain in neuropathy has begun to 
emerge (Üçeyler et al., 2007c, Üçeyler et al., 2010). Despite some support for a link 
between painful neuropathies and increased inflammatory and / or decreased anti-
inflammatory cytokines, it remains unclear whether the immune changes reflect 
underlying neuropathological processes, a response to nociceptor activation, 
variability in individual immune response to nerve damage or are a biomarker of 
another factor indirectly modulating both pain and immune function. It is also 
unclear whether immune-nerve interactions are unidirectional or bidirectional: 
 22 
does increased nociceptor firing modulate local immune function or does immune 
response to nerve damage modulate activity of remaining undamaged fibres, or is 
there a combination of these factors?  I sought to understand the effect of acute 
nociceptor activation on skin immune profile, as well as whether changes in chronic 
neuropathy would be associated with the presence and intensity of pain.  
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Chapter 1: Introduction 
The skin has important protective and homeostatic roles. It acts as a sensor and 
effector organ for initial immune responses to pathogens, autonomic regulatory 
responses, hormonal regulation, and physical sensing of the environment.  
Previously considered to be a simple inert barrier, recent research has elucidated a 
number of important bidirectional neuroimmune interactions which may be 
pertinent in understanding both neuropathic pain and the modulation of skin 
integrity by nerves, a key issue in preventing the ulceration and infection suffered 
by many patients with peripheral neuropathy. These include the role of neurogenic 
inflammation in chronic skin inflammatory conditions  (Chapman and Moynihan, 
2009), Langerhans cell function (Ding et al., 2008, Hosoi et al., 1993), wound healing 
(da Silva et al., 2010)  and regulation of hair growth cycling (Hendrix et al., 2008). 
Conversely, cytokines (Üçeyler et al., 2009), growth factors (Pezet and McMahon, 
2006), and purines (Dussor et al., 2009) released by skin cells modulate neural 
plasticity and function, with the potential to contribute to the persistence of 
neuropathic pain and itch. 
Why study skin nerves? 
Histological study of the skin is an attractive model in which to study human 
neuropathic mechanisms. It is easily accessible, with punch biopsy an easy 
technique with minimal morbidity and the ability to study changes over time. This 
provides a distinct advantage over sural nerve biopsy, which has hitherto been the 
only method available to examine nerve biology. Skin biopsies have been used for 
nearly 20 years to examine small fibre innervation density (McCarthy et al., 1995), 
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but the idea of exploring pathogenic mechanisms using epidermal and dermal 
nerves is in its infancy (Katona et al., 2009). There are also some exciting 
developments in the use of skin biopsy to diagnose CNS disease, such as 
synucleinopathies, tauopathies and neuronal intranuclear inclusion disease with 
leucoencephalopathy (Brennan et al., 2015, Jerath and Shy, 2015, Shy et al., 1996). 
In order to understand the pathogenic mechanisms in neuropathy, particularly the 
frequently ‘idiopathic’ small fibre neuropathy, the ability to study human pathology 
in a relatively non-invasive fashion would be of immense benefit in understanding 
disease mechanisms and developing treatment strategies. It may also allow better 
evaluation of the efficacy of therapies, which are often disappointing in their 
translation from animal to human models. Study of skin nerves could help bridge 
this gap. 
How could skin nerves help us understand neuropathic pain? 
Neuropathy, and particularly neuropathic pain, are conditions with significant 
morbidity, but very limited therapeutic options.  Although pain is more commonly 
associated with particular types of neuropathy, we do not understand why different 
individuals with the same underlying disease vary widely in both the presence and 
intensity of pain that they suffer, but also in their pharmacological response. The 
skin is an attractive site to study both disease mechanisms in neuropathy, and 
potential biomechanisms in neuropathic pain for a number of reasons: 
 It is readily accessible, and suitable for repeated studies over time. This is 
particularly important in pathological studies in humans, as other sources of 
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nerve tissue for study, such as sural nerve biopsy, involve morbidity and may 
only be studied once. 
 It is the site of target action of many sensory nerves, allowing study of the fibres 
in the context of their terminal receptive field, and the factors in that field 
which may affect their function; and  
 It allows correlation of pathological, biochemical and functional mechanisms 
through the use of quantitative sensory testing in combination with histological 
and biochemical techniques, providing a more complete understanding of the 
environment in which sensory nerves function. 
This PhD project was designed to demonstrate the utility of skin nerves for studying 
mechanisms in neuropathy, and in particular to try to understand mechanisms 
affecting the genesis of pain in humans, with a view to potentially identify new 
approaches to treatment.  
The focus of my thesis is to explore the utility of the skin as a window through 
which to study pathobiological process in neuropathy, and more particularly 
neuropathic pain, using methods with minimal patient morbidity. The skin is a 
readily accessible tissue, with rich innervation by several different fibre types and 
has potential as a window through which to examine neuropathological processes, 
both from a natural history and response to therapy perspective. Currently studies 
of cutaneous innervation have centred on studies of epidermal nerve fibre density 
as a measure of small fibre neuropathy. This is beginning to expand to include 
studies of myelinated fibres (Li et al., 2005, Katona et al., 2009) and methods to 
quantify autonomic innervation (Nolano et al., 2010, Sommer and Lauria, 2007). 
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There remains, however, much scope for using skin nerves to study mechanisms of 
disease, and in pain to try to elucidate mechanisms in order to develop new 
therapeutic options. In particular, a focussed study using a broader range of 
immunohistochemical and biologic methods, combined with functional and 
behavioural correlates offers potential for evaluating the pathogenic relevance of 
recently proposed immune pathways in human neuropathic pain.  
The first part of the project explores the utility of dermal nerve fibres in 
understanding whether mechanisms recently identified in animal models of 
demyelination are also relevant in human disease. The second explores whether 
acute activation of nociceptors can evoke immune response in the skin. The final 
section examines whether cellular or humoral immune changes in the skin are 
linked with pain in a genetic human small fibre neuropathy, Fabry’s disease.  
Overall structure of PhD thesis 
1. Use of cutaneous nerves to evaluate pathogenic mechanisms in 
neuropathy 
This section of the project is a pilot study to establish whether nerves in human skin 
undergo changes in signalling kinases identified in animal research. c-Jun is a 
transcription factor recently identified as a key modulator of Schwann cell 
dedifferentiation and demyelination in injured nerves in animal studies (Jessen and 
Mirsky, 2008). This project used a combination of sural and dermal nerve biopsies 
to determine whether c-Jun expression was increased in human neuropathies, and 
whether these changes could be identified in dermal nerves as well as sural nerves. 
The work has recently been published in the Journal of the Peripheral Nervous 
System (Hutton et al., 2011). 
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2. Use of dermal microdialysis to determine the immune effect of acute 
nociceptor activation 
The second part studied whether acute activation of cutaneous nociceptors by 
topical capsaicin would alter the skin’s immune profile, which is the focus of this 
MPhil upgrade submission and will be discussed below. The aim of this section of 
the project was two-fold. Firstly, I wished to establish that dermal microdialysis in 
normal controls was able to detect the cytokines of interest, and to establish the 
operating range of the assay. Secondly, I wished to determine whether acute 
activation of nociceptors altered the levels of cutaneous cytokines, as this has not 
previously been established. 
3. Neuropathologic, immune and functional study of patients with Anderson-
Fabry disease: does pain in neuropathy correlate with changes in skin 
immune profile 
The final part of the project is a detailed clinical, neurophysiological, immunological 
and anatomical study of subjects with Anderson-Fabry neuropathy, to determine 
whether patients with greater pain related to their neuropathy exhibit pro-
inflammatory changes in cutaneous immune profile, examining soluble factors and 
changes in the intrinsic epidermal immune cell, the Langerhans cell.  
PhD research site and duration: 
The work presented in this thesis was carried out in laboratories at the Institute of 
Child Health (Neural Plasticity Laboratory), and The Institute of Neurology 
(Neuroimmunology Laboratory), London School of Hygiene and Tropical Medicine 
(Wolfson Cell Biology Facility (Luminex)) and the MRC Centre for Neuromuscular 
Diseases. The research work was conducted between January 2009 and May 2012.
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Chapter 2: Background: Neuroimmune and cutaneous biology, 
and their possible links with neuropathic pain. 
Skin Innervation 
The skin is densely innervated by free and specialised sensory nerve endings in the 
epidermis and dermis that supply the blood vessels and sweat glands. These nerves 
and their accessory structures detect various types of environmental stimuli 
(mechanical, chemical, thermal) and control autonomic components that regulate 
vascular tone in arteries and arterioles and the secretion of sweat from sweat 
glands (Rice and Albrecht, 2008).  
The innervation of human skin varies depending on location. Skin is divided into two 
main types, namely glabrous skin, found on the palms and soles of the feet, and 
hairy skin. Glabrous skin has a thick epidermis which is penetrated by dermal 
papillae and lacks hair follicles (Rice and Albrecht, 2008). It contains Meissner’s 
corpuscles and Pacinian corpuscles, which are absent in hairy skin, and more 
frequent Merkel cells than hairy skin. It also contains a higher proportion of larger 
myelinated afferents (Li et al., 2005). Cutaneous nerves enter the skin from 
collateral branches of the major nerves, e.g. branches of the digital nerves in the 
hand. These branches form a deep plexus that lies superficial to the level of the 
sweat glands and Pacinian corpuscles. Branches pass more superficially to form the 
superficial dermal plexus, a network of fibres running parallel to the skin surface, 
just deep to the dermal-epidermal junction (Wang et al., 1990). Nerve fibres 
decrease in diameter from around 5 μm in the dermal plexus to around 3 μm as 
they enter the dermal papillae in glabrous skin.  
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From dermal networks, fibres innervate cutaneous structures such as sweat glands, 
hair follicles, specialised sensory organs and blood vessels, or penetrate the 
epidermis as free nerve endings to run vertically between the keratinocytes. Ninety 
per cent of the dermal nerve fibres are unmyelinated on electron microscopy, and 
all fibres lose their myelin sheath at the dermal-epidermal junction (Ebenezer et al., 
2007, McGlone and Reilly, 2010). Large, deep dermal nerves have an intact 
perineurium, but smaller, superficial nerves often lack perineurium, and are instead 
associated with partially encircling fibroblast-like cells without a basal lamina. 
Remak bundles are surrounded by collagen fibres, with closely applied Remak basal 
lamina (Ebenezer et al., 2007).  Figure 1 below illustrates some of the key features 
of glabrous and hairy skin innervation. 
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Primary Sensory Afferents 
Primary sensory afferents are specialised neurons that are activated by 
environmental stimuli rather than synaptic input from another nerve cell. Their cell 
bodies are located in the dorsal root ganglia with a process that bifurcates into an 
axon with a proximal and distal branch (pseudobipolar). These branches may both 
branch to form several central and peripheral connections for a single axon 
(Navarro et al., 2007, Schmidt and Rathjen, 2011). The proximal arm passes into the 
dorsal horn of the spinal cord, where some fibers form synapses with the neurons 
of the central nervous system, whilst others course caudally or rostrally to form 
synapses at other sites. The distal arm passes along the spinal and peripheral nerves 
to terminate as a free nerve ending or specialised sensory structure in the skin. As 
the skin is subject to a variety of sensory stimuli (mechanical, thermal and 
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chemical), normal sensory function is dependent on the ability to perceive and 
integrate a variety of sensory inputs in parallel. Within the skin, each ending 
responds to stimuli of its specialised modality over a defined area of skin, known as 
the receptive field. The size of the field varies with the type of sensory ending and 
the anatomical location (Rice and Albrecht, 2008, Bolton et al., 1966, Schmelz and 
Schmidt, 2010). 
Sensory afferents may be classified according to neurophysiological, anatomical and 
biochemical characteristics, but there is often substantial overlap between 
subgroups. Fibres may share a common classification in one system of 
categorisation, but vary in other characteristics, precluding a clear subdivision of 
sensory neurons. Cutaneous sensory neurons are traditionally classified according 
to three key neurophysiological parameters: conduction velocity, the optimal 
modality for generation of an action potential, and rate of adaptation (time taken to 
stop responding to a continuously applied stimulus) (Rice and Albrecht, 2008). The 
large, myelinated Aβ are the fastest conducting sensory axons (35-75 ms-1), 
followed by the smaller, thinly myelinated A (5-30 ms-1) with the thinnest, 
unmyelinated C fibres having the slowest conduction velocity (0.5 – 2 ms-1). Figure 2 
illustrates the central connections of the sensory afferents in different laminae of 
the dorsal horn. 
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Specialised transducers in the skin and other tissues translate sensory inputs into 
the electrical impulses transmitted to higher centres. Sensory neurons carry this 
information about mechanical force, change in temperature or chemical stimuli, 
with some responding selectively to low (mild) or high threshold stimuli (Scholzen 
et al., 1998). Chemical responses may be subdivided by the nature of the ligand, 
and include capsaicin, menthol, H+, glutamate and ATP responsiveness, among 
others. Mechanical receptors may be divided by their response to the rate of 
application, duration and direction of the stimulus. Sensory neurons are classified as 
slowly adapting if they generate a prolonged train of action potentials in response 
to a sustained optimal stimulus, or as rapidly adapting if they generate a brief burst 
of action potentials when the stimulus is applied. Rapidly adapting afferents 
typically also generate a brief impulse train when the stimulus is removed (Gardner 
and Martin, 2000). 
Nociceptors are defined as sensory nerve cells which make a response to noxious 
stimuli, with the resultant potential generating a perception of pain. These stimuli 
can be of the same modalities as those that generate nonnociceptive responses, but 
are considered to be of an intensity that has the potential to generate tissue 
damage. Nociception differs from other forms of sensation in a number of ways. 
Nociceptors are often polymodal, where other sensory modalities are specific or 
unimodal. Nociceptors often sensitise (that is increase their response) to repeated 
stimuli, whereas other sensory receptors typically adapt. Nociceptors are 
subdivided by stimulus response into thermal, chemical, mechanical or polymodal 
nociceptors. Another class of nociceptor, termed a metaboreceptor has been 
described near blood vessels in muscle. These co-express the acid-sensing ASIC3 
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receptor and CGRP and are thought to detect metabolic stress, triggering 
nociceptive signalling if there is insufficient oxygen to meet demand (Molliver et al., 
2005).  
Generally, low threshold mechanoreceptors tend to be faster conducting Aβ 
afferents, whilst high threshold mechanoreceptors, thermoreceptors, 
chemoreceptors and nociceptors tend to have afferents conducting in the A or C 
fibre range (Rice and Albrecht, 2008). These divisions are not, however, absolute 
and the final perception of a tactile stimulus is a central product of the integration 
of a number of parallel inputs from individual fibre subtypes firing at variable 
intensities. 
Free Nerve Endings 
The majority of human cutaneous sensory neurons are unmyelinated free nerve 
endings, terminating primarily in the epidermis. These comprise the endings of a 
sensory axon in the target organ that lacks both a unique morphology and 
accompanying terminal glia or other accessory cells. Structurally, intraepidermal 
nerve fibres are unmyelinated, and their cytoskeletal composition is primarily of 
microtubules, with scant phosphorylated neurofilaments (Lauria et al., 2004). Fibres 
lose their Schwann cell wrapping at the dermal-epidermal junction, and are 
classified into two major subclasses, peptidergic and nonpeptidergic (McGlone and 
Reilly, 2010). The peptidergic fibres terminate in the deeper layers of the epidermis, 
whilst the nonpeptidergic fibres course between the keratinocytes to terminate 
more superficially (Zylka et al., 2005) (see figure 3). 
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Peptidergic and non-peptidergic innervation  
Neuropeptides are small peptide molecules that mediate signalling between 
neurons, but also with other cell types and are often co-expressed with other 
neurotransmitters. They include several large families, but the ones most important 
in neurocutaneous biology are calcitonin gene-related peptide (CGRP) and 
substance P (SP). On depolarisation of peptidergic cutaneous nerves, neuropeptides 
are released from both the central terminal, to signal to dorsal horn neurons, and 
the peripheral collaterals, to exert local modulatory changes in the skin. These 
include mediation of the axonal flare reflex, as well as modulating the behaviour of 
keratinocytes, mast cells, Langerhans cells and other immune cells in the skin. 
In the rat lumbar DRG, around 45% of cells are immunopositive for CGRP (compared 
to around 30% in the mouse), with a number co-expressing other neuropeptides, 
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such as substance P (SP) (Averill et al., 1995, Zwick et al., 2002). Most of these cells 
also express the NGF receptor, TrkA which labels around 45% of the total DRG 
population. The remaining cells (30% of DRG population) are composed of the 
small, isolectin B4 (IB4) / fluoride-resistant acid phosphatase (FRAP) positive 
population, most of which are peptide-negative, and cell bodies of larger, 
myelinated afferents (RT97 / NF200 positive), of which around 5% also express 
CGRP (Averill et al., 1995). Figure 4 illustrates the relative composition of DRG 
neurons based on rodent studies. 
The innervation of the skin, mucosal surfaces and muscles differ in the relative 
proportions of peptidergic and nonpeptidergic fibres involved. In the rat, non-
peptidergic fibres project predominantly to the skin and viscera, with few 
projections to skeletal muscle, whilst skeletal muscle and the viscera receive a 
higher proportion of CGRP-positive afferents (Bradbury et al., 1998, Perry and 
Lawson, 1998). Figure 5 illustrates the relative innervation of different target 
organs, based on data from rat studies, with the expression of neuropeptides and 
IB4 the same throughout the nerve fibre, from the DRG to the skin. The site of 
termination within the dorsal horn also varies, with nonpeptidergic afferents 
terminating in lamina II inner, whilst peptidergic ones terminate in lamina II outer 
and lamina I of the dorsal horn (see figure 2) (Basbaum and Bràz, 2010, Bradbury et 
al., 1998, Molliver et al., 1995).  
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The innervation of the epidermis and hair follicles is predominantly composed of 
non-peptidergic fibres, with CGRP positive fibres found mainly around blood 
vessels, sebaceous glands and sweat glands, with scant fibres terminating in the 
deep layers of the epidermis. There is limited data detailing epidermal CGRP 
innervation in humans, however a few studies in patients with pain or itch found 
CGRP innervation to comprise around 14% of the total fibre epidermal population 
(Wallengren and Sundler, 2004, Chao et al., 2007). The epidermal peptidergic fibres 
are thicker than their nonpeptidergic neighbours, with fewer branches but more 
varicosities, (Taylor et al., 2009). The nonpeptidergic fibres in the skin are 
predominantly P2X3 positive fibres, which largely overlap with the IB4 positive / 
GDNF-sensitive population of the DRG. Around 90% of IB4 positive neurons also 
show positive immunolabelling for P2X3. P2X3 is a cation-selective ligand-gated 
(ATP) channel, which generally exists as a dimer, either a homodimer or as a 
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heterodimer with P2X2 (Lewis et al., 1995, Bradbury et al., 1998, Zwick et al., 2002). 
TRPV1 is expressed on both peptidergic and non-peptidergic fibres, although there 
is more frequent expression on peptidergic fibres. Figure 3 illustrates epidermal 
innervation terminations of peptidergic and non-peptidergic fibres. Note that non-
peptidergic fibres represent around 85% of epidermal innervation, and peptidergic 
15%, but are not illustrated proportionately in order to demonstrate the 
termination levels in the epidermis.  
Differences have been observed between peptidergic and non-peptidergic 
epidermal nerve fibres in the context of neuropathy. In a model of murine 
streptozotocin-induced diabetic neuropathy, early loss of the peptidergic 
population correlated with reduced mechanical, thermal and chemical sensitivity, 
with nonpeptidergic fibre loss occurring later, with no accompanying change in 
sensory phenotype (Johnson et al., 2008). Recovery of cutaneous innervation 
following chronic constriction injury in rats also showed greatly delayed recovery of 
myelinated and non-peptidergic fibres compared to peptidergic reinnervation 
(Peleshok and Ribeiro-da-Silva, 2011). 
The peptides of unmyelinated nerve fibres in skin 
1. CGRP 
Calcitonin gene-related peptide (CGRP) has a variety of effects on the skin. It 
induces keratinocyte proliferation and production of cytokines (TNF-α, IL-1α, IL-8) 
and NGF (Takahashi et al., 1993, Yu et al., 2009, Dallos et al., 2006). CGRP positive 
fibres are closely apposed to other non-neural cells in the epidermis, with up to 80% 
of Langerhans’ cell bodies found in relation to CGRP-IR nerve fibres (Hosoi et al., 
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1993, Gaudillere et al., 1996). Possibly as a result Langerhans’ cells alter with neural 
modifications. Langerhans cell numbers increase following peptidergic denervation, 
whether by nerve injury or selective denervation of the capsaicin-sensitive, 
primarily peptidergic population, reducing to previous levels with epidermal 
reinnervation (Stankovic et al., 1999, Hsieh et al., 1996, Beresford et al., 2004). 
Neuropeptides released by peptidergic fibres can also modulate Langerhans’ cell 
function (Asahina et al., 1995, Ding et al., 2007, Ding et al., 2008). In this context, 
CGRP exerts a tonic anti-inflammatory effect by reducing Langerhans’ cell (LC) 
density, suppressing antigen presentation and cell migration, as well as shifting LC 
cytokine production toward an anti-inflammatory Th2 profile. This results in 
reduced antigen presenting ability and a shift in cytokine and chemokine 
production, such that LCs secrete increased Th2 and decreased Th1 chemokines and 
cytokines. Close contacts exist between intraepidermal nerve fibres and LCs, and 
denervation, with loss of the tonic effect of CGRP, shifts their cytokine and 
chemokine profiles to a more inflammatory, Th1 profile. (Hosoi et al., 1993, Ding et 
al., 2007, Ding et al., 2008, Niizeki et al., 1997).  
Mast cells also have close contacts with CGRP positive fibres (Botchkarev et al., 
1997). CGRP increases TNF-α (Niizeki et al., 1997) and promotes release of 
histamine from mast cells, although less potently than SP (Piotrowski and Foreman, 
1986).  
Keratinocytes also express receptors for CGRP, with stimulation inducing cAMP and 
calcium mobilisation (Peters et al., 2006). CGRP also promotes melanogenesis, 
through stimulating keratinocyte α-MSH release (Toyoda et al., 1999).  
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Substance P 
SP is produced in neurons of the peripheral and central nervous system. Substance 
P (SP) is an undecapeptide belonging to the tachykinin family, which on binding to 
its high affinity receptor NK1, can activate two key G-protein pathways: 
phospholipase C (PLC) activation, which cleaves PIP2 (phosphatidylinositol 4,5-
biphosphate) to DAG (diacyleglyceral) and IP3 (inositol (1,4,5) triphosphate); and 
activation of adenylate cyclase to increase cAMP (Douglas and Leeman, 2011). SP is 
used as an excitatory neurotransmitter by nociceptors, where it is often colocalised 
with CGRP.   
SP release also acts on the skin in a number of ways. It regulates wound healing, 
hair follicle cycling (Delgado et al., 2005, Peters et al., 2001), has effects on mast 
cells and modulates the cytokine profile of Langerhans’ cells (Mathers et al., 2007). 
The effects of substance P are dose dependent, with lower concentrations (10-11M) 
mediating trophic and immunomodulatory effects, higher concentrations (10-8M) 
inducing plasma extravasation, but only the highest concentrations (10-5M) causing 
mast cell degranulation (Weidner et al., 2000).  
Mast cells are highly expressed at sites of exposure to external antigen, including 
the upper dermal skin, respiratory tract and bowel mucosa, as well as being 
prominent perivascularly and near neurons, with frequent close apposition to 
peptidergic nerve fibres observed (Harvima et al., 2010). Substance P-induced mast 
cell degranulation releases a variety of other inflammatory mediators, including 
histamine, TNF-α, chemotactic chemokines (MCP-1, IP-10, RANTES, IL-8) and IL-3. 
These mediators promote recruitment and activation of T-lymphocytes, eosinophils 
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and other inflammatory cells (Kulka et al., 2008, Ansel et al., 1993, Cocchiara et al., 
1999, Maggi, 1993).  
Langerhans’ cells express the Substance P receptor, NK1. Activation of NK1 
promotes a shift in Langerhans’ cells to a more inflammatory, Th1 phenotype, with 
increased antigen presenting capability, MHC II expression, NF-κB activation, and 
inflammatory cytokine (IL-2, IL-12 and IFN-γ) production (Marriott and Bost, 2001, 
Lambrecht, 2001). Thus, SP acts on immune tone in Langerhans’ cells in an opposite 
manner to CGRP.  
Human keratinocytes (particularly in the deeper half of the epidermis) also express 
the substance P receptor, NK1 (Pincelli et al., 1993, Scholzen et al., 1998, Peters et 
al., 2006). Binding of SP activates keratinocytes through PLC, increasing inositol 
1,4,5-triphosphate (IP3), calcium mobilisation, and activation of activated protein C 
activation and NF-B (Peters et al., 2006). Activation of keratinocytes increases 
release of IL-1α, IL-1β, IL-8, NGF and TNF- (Dallos et al., 2006). In addition to 
increasing synthesis of pro-IL-1β, substance P also increase keratinocyte production 
of the NALP-1 inflammasome (nucleotide-binding domain, leucine-rich repeat-
containing receptor protein) and caspase-1, which are necessary to cleave pro-IL-1β 
into its active form (Feldmeyer et al., 2010).  
Neurogenic inflammation and the flare response 
Activation of the terminal receptive field of nociceptors may produce a flare 
response, as well as sensitisation, which has both peripheral and central aspects. 
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Neurogenic inflammation 
Neurogenic inflammation is the inflammatory response generated by antidromic 
depolarisation of local arborisation of the terminal branches of peptidergic 
nociceptors that occurs in addition to orthodromic central signalling. It is the 
mechanism underlying the neurogenic flare that may be recorded using laser 
Doppler imaging (see Chapter 4). Neuropeptide release (particularly substance P 
and CGRP) acts on blood vessels to cause vasodilatation and protein extravasation. 
SP induces a brief peak of vasodilation with a more prolonged increase in plasma 
extravasation, whilst CGRP induces greater and more sustained vasodilation, but 
not plasma extravasation (Weidner et al., 2000, Scholzen et al., 1998). Plasma 
extravasation is much less prominent in humans than in rodents (Sauerstein et al., 
2000). 
 Antidromic axonal reflex activation and subsequent substance P release induces 
degranulation of mast cells, which in addition to releasing histamine, also release 
cellular stores of SP. Mast cell SP is particularly important in the production of the 
wheal element of the reaction. Nociceptor blockade by local anaesthetic or 
capsaicin inhibits the flare, but not the wheal (Cocchiara et al., 1999, Ansel et al., 
1993, Foreman et al., 1983).  
A potentially positively reinforcing cycle of peptidergic neuroinflammation is 
terminated by the action of peptidases, particularly angiotensin converting enzyme 
(ACE) and neutral endopeptidase (NEP), which are produced by keratinocytes, 
vascular endothelial cells and fibroblasts (Roosterman et al., 2006). 
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Nociceptor sensitisation 
Following injury or nociceptor activation with heat or mechanical stimuli, changes in 
sensory response occur in the stimulated area and the surrounding skin. The area of 
initial nociceptor activation develops primary mechanical and thermal hyperalgesia, 
that is, a decrease in pain threshold (Treede et al., 1992). Primary hyperalgesia 
occurs to heat and mechanical stimuli, whilst secondary hyperalgesia is considered 
only to occur to mechanical stimuli (Treede et al., 1992).  In primary hyperalgesia 
nociceptors are sensitised, with left-shift of the stimulus-response curve, reduced 
thresholds, an augmented response to suprathreshold stimuli and ongoing 
spontaneous activity (Meyer et al., 2006). The type and extent of sensitisation is 
dependent upon the tissue involved and the type of nociceptor. C-mechanoheat 
sensitive afferents (CMH) in hairy skin become sensitised to heat, whilst those in 
glabrous skin do not, with heat sensitisation occurring in Type I A-mechanoheat 
(AMH type I) sensitive afferents in glabrous skin (Campbell and LaMotte, 1983, 
Meyer and Campbell, 1981).  
Secondary mechanical hyperalgesia develops in a zone around the area of injury or 
activation, and extends beyond the region of the flare response. Local anaesthetic 
blockade of myelinated fibres blocks development of the flare response, but not 
mechanical hyperalgesia, suggesting that while flare is dependent on local 
innervation, mechanical hyperalgesia is not (Klede et al., 2003).  Secondary dynamic 
mechanical allodynia is prevented by compression block of larger myelinated 
afferents, indicating a myelinated-fibre dependent central modulation, while 
spontaneous pain, heat hyperalgesia and static pressure pain threshold are not 
affected by compression block, indicating dependence of peripheral unmyelinated 
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afferents (Koltzenburg et al., 1992). Cooling also reduces primary, but not 
secondary hyperalgesia, indicating a peripheral site of modulation (Koltzenburg et 
al., 1992).  Figure 6 illustrates some of the key features of the flare response and 
regions of hyperalgesia following injury or nociceptor activation. 
In humans, microneurography and microdialysis studies have confirmed that the 
flare response is mediated by C- fibre afferents that are not responsive to 
mechanical or heat stimulation (CMiHi). However these become responsive to these 
stimuli following sensitisation. They have a larger receptive field than C-
mechanosensitive fibres, and are activated by pungent chemicals, such as capsaicin. 
Some fibres in this population mediate itch (Schmelz et al., 2000, Schmelz and 
Schmidt, 2010). In humans and pigs, the flare response is primarily mediated by 
CGRP-induced vasodilatation, with little SP induced plasma extravasation, while rats 
show a larger SP component to the flare (Schmelz et al., 2000, Schmelz et al., 1997). 
 
 




Sensory receptors transduce stimulus characteristics and induce the initial neural 
responses in the sensory system. In addition to their location, neurophysiological 
characteristics and morphology, the activation of sensory receptors is dependent 
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upon the combination of molecular transduction molecules that they express and 
these can be modified by the surrounding milieu. Normal sensory transduction of 
thermal, mechanical and chemical stimuli is mediated by a variety of ion channels 
and G-protein coupled receptors within the transducers themselves. These include 
the transient receptor potential channels (TRP), brain sodium channel / acid-sensing 
ion channels (BNaC/ASIC), purinergic receptors (P2X, P2Y) and others (Lumpkin and 
Caterina, 2007). These receptors and channels may be modulated by mediators 
released in pathological conditions, such as inflammation or nerve injury 
contributing to peripheral sensitisation.  
Capsaicin & its receptor, TRPV1 
Effects of capsaicin in models of pain 
Capsaicin applied topically to the skin induces acute burning pain, and has been 
used as a model of acute sensitisation in normal healthy subjects. Topical capsaicin 
results in primary hyperalgesia over the treated area. Intracutaneous capsaicin 
elicits a dose dependent response, with increasing severity, pain duration and area 
of hyperalgesia with increasing dose from 0.1 – 100 μg (Simone et al., 1989). 
Surrounding the area of primary hyperalgesia, a region of secondary hyperalgesia 
develops.  
Sensitisation techniques are useful to assess the functional changes associated with 
nociceptor activation, however they are less helpful in completely modelling 
neuropathic pain biology, as despite the ability to simulate some aspects of 
neuropathic pain (e.g. hyperalgesia), they are all limited in their inability to evoke 
ongoing, severe spontaneous pain, a characteristic of patients with neuropathic 
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pain. As such, our current human models can only partially mimic the clinical picture 
of neuropathic pain. Topical capsaicin is, however an established non-invasive 
method of robustly activating nociceptors, evoking axonal flare and visibly inflaming 
the skin without inducing tissue damage. Although the vascular and sensory 
components of neurogenic inflammation are well established, the effect of acute 
activation of nociceptors on the local immune profile has not been determined, and 
is explored further in chapter 4 of this thesis. This is of interest in light of recent 
studies suggesting immune activity may play a role in neuropathic pain. 
Discovery of TRPV1 
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is a crystalline, lipophilic 
odourless alkaloid in the vanilloid family. Columbus made the first Western reports 
of the hot spicy effects of capsaicin in his journal in 1493. The active component, 
capsaicin (then called ‘capsicol’) was first crystallised in 1876 by Tresh, and its 
molecular structure was determined in 1919 by Dawson (Reyes-Escogido et al., 
2011). A selective action of capsaicin on sensory neurons was proposed in 1878 by 
Hogyes (Caterina and Julius, 2001), but it was not until the 1950s that Jancsó et al. 
reported that in addition to stimulating nociceptors, capsaicin could also induce 
their desensitisation, rendering animals insensitive to painful stimuli (Szolcsányi, 
1993). Caterina, Julius and colleagues identified the molecular target of capsaicin 
after finding a single DRG-derived cDNA clone that showed a robust response to 
capsaicin stimulation in transfected cells (Caterina et al., 1997). Further 
characterisation demonstrated this was a calcium-permeable, non-selective cation 
channel activated by capsaicin as well as heat, protons and resiniferatoxin, and 
blocked by the capsaicin antagonist capsazepine and ruthenium red. It also exhibits 
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desensitisation kinetics and cytotoxicity with prolonged stimulation. It was named 
vanilloid receptor type I (VR1) in recognition of the vanilloid moiety that forms the 
core of the capsaicin molecule.  
VR1 was the first ion channel in the TRPV family to be identified and characterised. 
Structurally, it displays homology with the TRP family of channels in the Drosophila 
retina, so was renamed transient receptor potential vanilloid receptor type 1 
(TRPV1) (Clapham et al., 2001, Montell et al., 2002). Polymorphisms of the TRPV1 
receptor in humans have been associated with different phenotypes in patients 
with neuropathic pain (Binder et al., 2011). 
Functional characteristics of TRPV1 
Activation and modulation 
TRPV1 is a multistate ion channel whose state (open, closed or refractory) may be 
modulated by a variety of factors, including temperature, voltage and certain 
agonists. TRPV1 is activated by noxious heat (>43°C), phosphorylation of the 
channel and a wide variety of endogenous and exogenous chemicals. These include 
protons, ethanol, lidocaine, capsaicin, piperine (black pepper), resiniferatoxin, 
ruthenium red, endogenous cannabinoids (anadamide, N-arachidonoyl-dopamine 
(NADA)), and a variety of inflammatory lipid metabolites (Szallasi and Blumberg, 
2007, Vay et al., 2012). Low concentrations of capsaicin, heat, protons and other 
activating ligands may all shift the channel towards an open state even if they do 
not directly activate it in isolation (Rosenbaum and Simon, 2007). 
The TRPV1 receptor usually exists in a balance between the open (activated) state 
and the closed (resting) state. TRPV1 exhibits two types of desensitisation: acute 
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desensitisation, the rapid loss of activity following agonist binding, mediated by 
conformational change; and tachyphylaxis, a gradual reduction in subsequent 
response with repeated administration of an agonist, mediated by activation of 
intracellular signalling pathways (Rosenbaum et al., 2004). Figure 7 illustrates TRPV1 
structure and key binding sites, as well as summarising the key factors modulating 
its functional state.  
The activation of TRPV1 on nociceptors triggers excitatory neurotransmitter release 
(glutamate, neuropeptides) from the central terminals of associated neurones in 
the dorsal horn of the spinal cord. It also stimulates local release of neuropeptides 
from the terminal branches of the stimulated fibre, contributing to neurogenic 
inflammation (Maggi, 1993) (see above). 
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(Nagy et al., 2004, García-Sanz et al., 2004, Suh and Oh, 2005) 
TRPV1 is modulated through regulation of key intracellular pathways which 
modulate protein phosphorylation, including PKC, PKA, CaMKII, and ERK1/2 (Zhang 
et al., 2011). Intracellular PIP2 binds to TRPV1, inhibiting its activation, which can be 
overcome by either PLC activation, releasing PIP2, or by binding of PIP2 by Pirt (Kim 
et al., 2008). Calcium pathways regulate TRPV1 desensitisation, with 
dephosphorylation by the calcium-dependent phosphatase calcineurin and binding 
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of the calcium-binding protein calmodulin both acting to increase TRPV1 inhibition 
(Rosenbaum and Simon, 2007, Docherty et al., 1996). 
TRPV1 may also be sensitised by a variety of extracellular inflammatory mediators, 
via modulation of key intracellular pathways (see figure 8). These lower the thermal 
activation threshold to below body temperature and thereby have the potential to 
generate spontaneous pain. ATP modulates TRPV1 activity both directly and 
indirectly. Indirect modulation is mediated through extracellular ATP binding to the 
metabotropic (G-protein coupled) P2Y1 receptor, activating PLC cleavage of PIP2 
into IP3 and DAG, which activates PKC. Activated PKC reduces the thermal activation 
threshold from around 42°C to 35°C (Tominaga et al., 2001). Intracellular ATP also 
sensitises TRPV1 directly through binding to one of the ankyrin domains (Lishko et 
al., 2007). Once activated, an influx of calcium and magnesium ions release ATP 
from its binding site and free the channel to interact with Ca-Calmodulin, which 
desensitises TRPV1 (Lishko et al., 2007). Extracellular bradykinin modulates TRPV1 
through the same intracellular pathway, acting via its receptor, BK2 (Sugiura et al., 
2002). Histamine induces inward calcium channels through binding to the G 
protein-coupled H1 receptor, and activation of TRPV1 via PLA2-arachidonic acid-
eicosanoid pathways (Shin et al., 2002, Shim et al., 2007). TRPV1-/- mice do not 
exhibit histamine-induced scratching, while serotonin-induced scratching is 
preserved (Shim et al., 2007). 
As well as the TRPV1 channel characteristics, the numbers of TRPV1 receptors can 
also be a key modulator of TRPV1 currents in the longer term, thereby modulating 
signalling intensity. This is executed by altering membrane trafficking, whereby 
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TRPV1 is translocated to the cell surface by exocytosis in v-SNARE associated 
vesicles. The SNARE protein partners snapin and synaptogamin IX facilitate neuronal 
exocytosis in a Ca2+-dependent manner. This process is induced by PKC and is 
inhibited by botulinum toxin A (Planells-Cases and Ferrer-Montiel, 2007). Thus, 
agents which can activate TRPV1 through phosphorylation of the channel by PKC 
also increase membrane translocation of the channel, further increasing their 
overall excitatory effect of the cell. Figure 7 summarises TRPV1 structure and 
binding sites of key modulatory molecules, as well as a summary of channel 
kinetics. Figure 8 illustrates key modulatory pathways of TRPV1 activation. 
Cutaneous non-neuronal TRPV1 expression 
In addition to neuronal expression of TRPV1 as discussed above, TRPV1 is expressed 
by other cutaneous cells, which may have implications for neuroimmune 
communication and co-regulation. TRPV1 protein (immunohistochemistry) and 
mRNA (PCR) have been detected in normal human epidermal keratinocytes (NHK) 
and immortalised keratinocyte cell lines (HaCaT) (Ständer et al., 2004, Southall et 
al., 2003). Functional studies exposing cultured keratinocytes to capsaicin have 
described calcium influx, elevation of proinflammatory mediators (COX-2, IL-8, 
PGE2, ATP), keratinocyte proliferation and increased expression of heat shock 
protein, MMP-1 (also evoked by heat) (Southall et al., 2003, Li et al., 2007, Denda et 
al., 2010) possibly suggesting TRPV1 activity. These effects were inhibited by prior 
application of the TRPV1 antagonist, capsazepine, or in TRPV1 knockout cell lines 
supporting this assertion. A recent study using TRPV1 reporter mice to examine 
TRPV1 expression did not report keratinocyte TRPV1 expression. However the 
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authors do not specifically comment on their observations in the skin and thus it is 
not clear whether TRPV1 was or was not seen (Cavanaugh et al., 2011). 
The evidence concerning TRPV1 expression in Langerhans’ cells is difficult to 
interpret. Some authors report increased TRPV1 mRNA expression when cultured 
monocyte-derived dendritic cells (mDC) cells mature into functional dendritic cells. 
These cells have corresponding functional TRPV1 responses. In mature mDC, 
capsaicin inhibits a number of immune responses, including cytokine-induced 
differentiation, phagocytosis, activation and pro-inflammatory cytokine secretion 
(Toth et al., 2009) implying receptor presence. Conversely, a study of bone-marrow 
derived dendritic cells (BM-DC) did not find TRPV1 mRNA or evidence of capsaicin-
induced calcium currents (O'Connell et al., 2005). No studies exist reporting on the 
effect of TRPV1 agonists on native Langerhans’ cells. The data derived from studies 
of cultured dendritic cells may not accurately predict Langerhans’ cell responses in 
vivo, as there has been recent debate concerning their origins. Many studies are 
conducted on dendritic cells cultured from monocyte or bone marrow-derived 
precursors, previously thought to be the source of Langerhans’ cells, however 
recent evidence suggests that Langerhans’ cells may actually originate primarily 
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Evidence for cytokine dysfunction in painful human neuropathies 
Some recent studies have found imbalance in immune tone to be a common factor 
in several neuropathic pain states, with pain linked to increased proinflammatory 
cytokines and diminished pain to anti-inflammatory cytokine levels. For example, 
serum from patients with complex regional pain syndrome showed an increase in 
pro-inflammatory (TNF-α, IL-2) and decrease in anti-inflammatory (IL-4, IL-8, Il-10) 
cytokines (Üçeyler et al., 2007a). Another study of normal subjects, and those with 
painful versus painless neuropathies, found an increase in TNF-α and IL-2 in the 
serum of subjects with painful neuropathy, and an increase in IL-10 in those with 
painless neuropathy. These findings were independent of whether the underlying 
pathology was inflammatory or not (Üçeyler et al., 2007c).  The findings in this latter 
paper may not be completely valid, as diabetic neuropathy was included in the 
‘noninflammatory’ subgroup, and diabetic neuropathy is known to be associated 
with activation of inflammatory pathways (Vincent et al., 2011). Elevated cutaneous 
mRNA levels of inflammatory cytokine have been reported in patients with small 
fibre neuropathy (SFN), with IL-6 and IL-8 elevated in painful idiopathic SFN. In a 
subset of subjects with a length dependent idiopathic SFN (proximal intraepidermal 
nerve fibre density (IENFD)/distal IENFD > 5), distal levels of TNF-α, IL-8, IL-1β and 
IL-6 were much greater than in the proximal skin of the same individual (Üçeyler et 
al., 2010). 
Whilst these findings are of interest, it remains unclear whether the immune 
changes are causal in pain pathogenesis, due to a common underlying inflammatory 
pathology, or a response to nerve damage. The potential modulatory role of 
immune changes in the skin neighbouring the terminal receptive field of cutaneous 
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nociceptors in the generation of neuropathic pain is explored further in Chapter 5 of 
this thesis. The following section summarises some of the key features of the 
cytokines studied, focussing on their potential role in pain and neurocutaneous 
interactions. Figure 9 shows a summary of key pathways of T cell differentiation, 
effector molecules and immunological functions. Figure 10 summarises some of the 
key cutaneous neuroimmune interactions that may be relevant factors in possible 
mechanisms of initiation and maintenance of neuropathic pain. 
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Cytokines implicated in modulation of neuropathic pain: 
IL-1β 
Interleukin 1β (IL-1β) is a key pluripotent pro-inflammatory cytokine produced by 
macrophages, monocytes, dendritic cells, natural killer cells, microglia and Schwann 
cells (Thacker et al., 2007, Kiguchi et al., 2010, Dinarello, 2009). IL-1β increases 
synthesis of inflammatory mediators, including COX-2, phospholipase A, inducible 
nitric oxide synthetase (iNOS), adhesion molecules, chemokines and angiogenic 
factor (Dinarello, 2009). These increase PGE2, NO, IL-6, immune cell recruitment, 
vasodilatation, angiogenesis and pain sensitivity, and act systemically to produce 
fever and hypotension. IL-1β acts as a growth factor for B cell production, a 
costimulator of T-cells, and a key initiator of Th17 responses (Dinarello, 2009). 
IL-1β mRNA is rapidly upregulated in the DRG following chronic constriction injury 
(CCI) of the sciatic nerve (Üçeyler et al., 2007d) and Schwann cells also produce IL-
1β in response to nerve injury, augmenting myelin phagocytosis by macrophages 
(Shamash et al., 2002). Intraneural, intraplantar or systemic IL-1β induces thermal 
hyperalgesia and mechanical allodynia (Zelenka et al., 2005, Follenfant et al., 1989, 
Fukuoka et al., 1994, Ferreira et al., 1988). Blockade of IL-1β signalling reduces pain 
behaviour and DRG spontaneous activity following nerve injury (Wolf et al., 2006). 
IL-1β also potentiates TRPV1 activation in a heterologous expression system and 
induces CGRP release by sensory ganglion cells (Camprubí-Robles et al., 2009, Neeb 
et al., 2011, Hou et al., 2003).  
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TNF-α 
TNF-α is a complex cytokine that can exist as a free soluble or membrane-bound 
form. It is secreted by monocytes, macrophages, mast cells, fibroblasts, smooth 
muscle cells, endothelial cells, keratinocytes, T-cells and NK cells (Bos, 2004). 
Schwann cells also secrete TNF-α through activation of the NF-κB pathway in 
response to injury or inflammation (Qin et al., 2012). This Schwann cell cytokine 
response initiates an early immune response to injury, which is then augmented by 
recruited immune cells, particularly macrophages (Shamash et al., 2002). TNF-α can 
exert both pro- and anti-inflammatory actions, as well as acting as a growth factor. 
TNF-α synthesis is primarily regulated by IFN-γ, but modulated by TGF-β, IL-6, PGE2 
and vitamin D3. TNF-α can also be stimulated by IL-1, substance P, and bradykinin 
and can act in an autocrine fashion to further increase its own release (Bos, 2004). 
TNF-α promotes fever, cachexia, macrophage and neutrophil chemotaxis, 
phagocytosis and cytotoxicity, and is an important regulator of Langerhans cell 
maturation (Bos, 2004).  
Intraneural or subcutaneous injection of TNF-α evokes hyperalgesia and allodynia 
and increases ectopic firing of nociceptors, which is blocked by a TNF-receptor 
antagonist (Sorkin and Doom, 2000, Wagner and Myers, 1996, Sorkin et al., 1997). 
Pretreatment with the TNF-α antagonist etanercept prevented development of 
allodynia in a rat spinal nerve ligation model of neuropathic pain (Schafers et al., 
2003). TRPV1 is sensitised by TNF-α via a PKC-dependent mechanism (Russell et al., 
2009). Tetrodotoxin-resistant voltage-gated sodium channels (TTX-R) in sensory 
neurons exhibit increased currents after exposure to TNF-α, contributing to 
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nociceptor sensitisation and pain behaviours (Czeschik et al., 2008, Jin and Gereau, 
2006).  
IL-6 
Interleukin 6 is an early pro-inflammatory cytokine generated primarily by 
monocytes, but also by bone marrow cells, fibroblasts, endothelial cells, 
lymphocytes, Langerhans’ cells and keratinocytes (Bos, 2004, Gallucci et al., 2000). 
It is important for regulation of B-, T- and NK- cell function, and hepatocyte 
generation of acute phase proteins. IL-6 also acts as an amplifier of the immune 
response, released in response to IL-1 and TNF-α stimulation. Several autoimmune 
diseases such as systemic lupus erythematosus, systemic scleroderma and 
pemphigus vulgaris are associated with elevated levels of IL-6 (Bos, 2004). 
The effect of IL-6 on sensory neurons is complex, and appears to depend on the site 
of administration as well as other soluble factors present. Skin perfused (by 
microdialysis) with IL-6 in conjunction with the soluble IL-6 receptor (sIL-6R) 
released more CGRP in response to heat than control or solely IL-6 perfused skin 
(Opree and Kress, 2000). Neuronal firing rate in response to stimulation of the 
receptive field in a skin-nerve preparation increased with low dose of IL-6, but 
decreased with higher doses, or a combination of IL-6 and sIL-6R (Flatters et al., 
2004). Heat hyperalgesia has been reported after intrathecal injection of IL-6 (Oka 
et al., 1995, Flatters et al., 2004), and an IL-6 knockout mouse exhibits delayed 
onset of mechanical allodynia following spinal nerve ligation compared to wild-type 
(Ramer et al., 1998). 
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IL-10 
IL-10 is an immunosuppressive cytokine primarily synthesised by monocytes, but 
also by Th1 and Th2 T-cells, cytotoxic T-cells, mast cells, B lymphocytes and 
keratinocytes. IL-10 has a number of actions, acting to reduce synthesis of 
inflammatory cytokines (including IFNγ, IL-1β, IL-6, IL-8, and TNFα), mast cell 
chemotaxis and inhibition of antigen presentation by dendritic cells (Bos, 2004, 
Pietrzak et al., 2009). IL-10 increases IgG production by B cells. The net effect of IL-
10 is to suppress cellular and allergic immune responses, whilst increasing humoral 
and cytotoxic ones (Bos, 2004). 
IL-10 mRNA is rapidly upregulated in the DRG following CCI (Sommer and Schäfers, 
2004, Üçeyler et al., 2007d). Intraplantar IL-10 reduces hyperalgesia evoked by 
intraplantar carrageenan or inflammatory cytokine injection, and from nerve injury 
(when administered at the site of injury) (Poole et al., 1995, Wagner et al., 1998). 
Intrathecal IL-10 reverses neuropathic pain associated with the chronic constriction 
and paclitaxel-induced neuropathic pain models in rodents (Milligan et al., 2006, 
Ledeboer et al., 2007). 
IFN-Υ 
IFN-γ is a key regulator of tissue inflammation and immune response, released 
primarily by Th1 cells. IFN-γ promotes the release of pro-inflammatory cytokines in 
the skin, including IP-10, IL-1, IL-6, IL-8, TNF-α and CCL5/RANTES (Bos, 2004). IFN-γ 
also facilitates antigen presentation, induces Th1 differentiation, increases NK cell 
and macrophage activity and leucocyte migration. IFN-γ has been implicated in 
autoimmune disease such as systemic lupus erythematosus (Bos, 2004). IFN-γ has 
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also been found to upregulate keratinocyte Th1 chemokines whilst downregulating 
Langerhans’ cell Th2 chemokines, suggesting it may act as a regulator of immune 
tone in the skin (Mori et al., 2008). 
IL-17 and Th17 cells 
Th17 cells are a subset of effector T-cells, important in clearance of pathogens 
resistant to initial Th1 and Th2 responses, particularly fungal pathogens. They are 
also in pathogenesis of autoimmune diseases, where they act to create persistent 
inflammation (Peck and Mellins, 2009).  Cytokines produced by Th17 cells (IL-17, IL-
21, IL-22, GM-CSF, G-CSF, IL-6 and TNF-α) are potent inducers of tissue 
inflammation. Th17 cells differentiate in response to TGF-β and IL-6 / IL-21 co-
stimulation. IL-17 is a proinflammatory cytokine, which acts to increase release of 
the inflammatory cytokines (TNF-α, IL-1β, IL-6), chemokines, and 
metalloproteinases, and is a potent neutrophil chemoattractant (Korn et al., 2009). 
Neural IL-17 increases within 8 days of nerve injury (Noma et al., 2011). IL-17 
sensitises nociceptors, with intraplantar or intraneural injection of IL-17 resulting in 
increased thermal hyperalgesia and mechanical allodynia. IL-17 null mice exhibit 
reduced allodynia and thermal hyperalgesia in response to partial sciatic nerve 
ligation than their wild type counterparts (Kim and Moalem-Taylor, 2011).  
MCP-1 
Monocyte chemoattractant protein (MCP-1, also known as CCL2) is a member of the 
CC family of chemokines and is a powerful chemoattractant for monocytes, 
memory T-cells and dendritic cells. It is primarily produced by monocytes and 
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macrophages, but also by epithelial, endothelial and smooth muscle cells, 
fibroblasts, astrocytes and microglia. Synthesis and release of MCP-1 is stimulated 
by IL-1β, TNF-α and endotoxin and regulated by IFN-γ, IL-4, IL-10 and IL-13. 
Keratinocytes and fibroblasts produce MCP-1 in response to IFN-γ and TNF-α 
respectively, promoting increased recruitment of dendritic (Langerhans’) cells 
(Giustizieri et al., 2001, Nakamura et al., 1995, Ouwehand et al., 2010). MCP-1 is an 
important chemokine in the early stages of cutaneous wound healing, and in some 
inflammatory skin conditions (Gillitzer and Goebeler, 2001, Bos, 2004). 
Hyperalgesia is reported in MCP-1 overexpressing mice (White et al., 2009). MCP-1 
induces elevation of intracellular calcium and CGRP release via PLC/PKC pathways in 
cultured DRG neurons, and evokes thermal and mechanical hyperalgesia when 
injected into the plantar skin of mice (Qin et al., 2005). Focal demyelination 
increases expression of MCP-1, RANTES and IP-10, as well as their receptors, on 
sensory neurons that also exhibit transient elevation of intracellular calcium in 
response to MCP-1. Hyperalgesia following nerve injury may be reversed by the 
administration of a MCP-1 receptor antagonist (Bhangoo et al., 2007). 
IP-10 
IFN-induced protein of 10 kDa (IP-10, also known as CXCL10) is a chemokine of the 
CXC family, which binds to the G-protein coupled receptors CXCR3 and CCR3. CCR3 
is highly expressed on Th2 cells and cytotoxic T-cells, whilst Th1 cells express CXCR3. 
Other cells expressing CXCR3 include B cells, natural killer cells, dendritic cells and 
macrophages. Stimulation of CXCR3 promotes chemotaxis of cells bearing CXCR3 
(Bos, 2004, Liu et al., 2011). IFN-γ stimulates IP-10 release from leukocytes, 
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neutrophils, eosinophils, monocytes, epithelial and endothelial cells. A positive 
feedback loop exists, as IP-10 recruits IFN-γ producing Th1 cells, which then acts to 
further promote IP-10 release (Liu et al., 2011). IP-10, with MCP-1 and IL-8 are the 
most abundant chemokines produced by keratinocytes in response to activation by 
inflammatory cytokines. In particular, IFN-γ, with or without TNF-α, promotes 
production of IP-10 and MCP-1 in both keratinocytes and dendritic cells (Liu et al., 
2011, Bos, 2004).  
RANTES 
Regulated (increased) upon activation, expressed by normal T-cells and secreted 
(RANTES, also known as CCL5) is a chemokine which binds to the receptor CCR5. 
RANTES is produced by platelets, macrophages, eosinophils, fibroblasts, endothelial 
cells, keratinocytes and Langerhans’ cells (Levy, 2009, Fujita et al., 2004, Sanmiguel 
et al., 2009). RANTES acts to recruit T-cells, dendritic cells, eosinophils, natural killer 
cells, mast cells and basophils to the site of inflammation, and to induce migration 
of activated Langerhans’ cells from the epidermis, as well as activating 
macrophages. RANTES has been linked with several inflammatory diseases 
(arthritis, atopic dermatitis, colitis), atherosclerosis and development of breast and 
prostate cancer (Levy, 2009). Schwann-cell derived RANTES is a mediator of HIV-
neurotoxicity through activation of an autocrine TNF-α release and binding pathway 
through TNFR1 in DRG cells (Keswani et al., 2003). RANTES and its receptor are also 
upregulated in sensory neurons following focal demyelination, but there are no 
reports of the effects of direct application of RANTES to nerves (Bhangoo et al., 
2007). 
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NGF-β 
Nerve growth factor (NGF) is a neurotrophic factor important for developmental 
survival and appropriate target-tissue innervation of trkA positive nociceptors 
(Albers et al., 1994, Diamond et al., 1992, Goodness et al., 1997). The TrkA-NGF 
responsive population of nociceptors has extensive overlap with the CGRP/SP 
positive and TRPV1 positive population, whilst the IB4 population loses TrkA 
sensitivity in later development (Averill et al., 1995, Bennett et al., 1996, Bennett, 
2001). In the adult, target production of NGF is an important regulator of sprouting 
and reinnervation of target tissue (Pertens et al., 1999).   
Systemic administration of NGF results in thermal hyperalgesia, as does local 
inflammation-induced elevation in NGF (Lewin et al., 1994). NGF application to 
murine cultured DRG neurons also increases response to noxious heat, in both the 
IB4-positive and IB4-negative populations (Stucky and Lewin, 1999). A monoclonal 
antibody against NGF, tanezumab, has recently been developed and shown some 
benefit in osteoarthritic pain, although some concerns have been raised about side 
effects (Lane et al., 2010). 
NGF enhances TRPV1 currents (Shu and Mendell, 1999, Zhu et al., 2004) through 
phosphorylation, increased expression and membrane insertion (Xue et al., 2007, 
Zhu and Oxford, 2011, Zhang et al., 2005). NGF also sensitises nociceptors through 
activation of neutrophils, stimulating their production of leukotriene B4 which 
activates TRPV1 (Bennett et al., 1998, Vigna et al., 2011); and through 
degranulation of mast cells, inducing the release of various sensitising mediators 
including bradykinin, histamine and 5-hydroxytryptamine (Lewin et al., 1994, 
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Štempelj and Ferjan, 2005). NGF stimulates cytokine release from dendritic cells, 
depending on existing skin conditions (IL-6 in allergic subjects, IL-10 in healthy 
controls) (Noga et al., 2007). NGF increases DRG synthesis of CGRP and SP (Lindsay 
and Harmar, 1989, Park et al., 2010), and increases evoked release of CGRP from 
peripheral terminals (Bowles et al., 2006). NGF induces keratinocyte proliferation 
(Pincelli et al., 1994), and keratinocyte NGF overexpression induces epidermal 
hyperinnervation (Albers et al., 1994).
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Cellular Components of the Cutaneous Immune System 
In addition to the potential effect of the cytokines discussed above, the skin 
contains a complex array of immune cells to maintain integrity and respond to 
threats, which may also play a role in modulation of pain perception, as they 
comprise the cellular environment in which nerve endings exist. In the 
epidermis, the primary immune cell is the epidermal dendritic, or Langerhans’ 
cell, however the keratinocytes also have immune functions, and sparse T cells 
are present (Torvin Möller et al., 2009, Shipton, 2013, Metz and Maurer, 2009). 
In the deeper dermis, there are two populations of dendritic cells, Langerin 
positive and negative, as well as T- cells (most are memory T-cells), mast cells 
and macrophages.  Additional cells are recruited to the dermis in inflammatory 
states, including granulocytes, monocytes, additional dendritic cells, and T-cells 
(Shipton, 2013). 
Langerhans cells 
Close contacts have been observed between Langerhans’ cells and 
intraepidermal nerve fibres (Hosoi et al., 1993, Gaudillere et al., 1996). In 
addition there is considerable overlap in the signalling molecules to which both 
cell types are responsive, making them of interest in understanding potential 
neuroimmune interactions in neuropathic pain associated with neuropathy. A 
recent study also found that targeted depletion in Langerhans’ cells in mice 
reduced cutaneous innervation, as well as inducing mechanical (but not 
thermal) hyperalgesia (Doss and Smith, 2014). Conversely, denervation has 
been associated with increased Langerhans’ cell numbers (Hsieh et al., 1996, 
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Lauria et al., 2005). This provides further support to the presence of a degree of 
interdependence and influence between nerve cells and Langerhans’ cells. 
Langerhans’ cells are a subset of dendritic cells (DCs), which form one of the key 
groups of cellular elements in the skin immune system. These cells are spread 
throughout the epidermis and dermis and form a continuous network of 
professional antigen presenting cells (APC). They are located in the epidermis, 
primarily in the suprabasal region and form a regular, near-interconnected 
network throughout the epidermis with their protrusions. Langerhans cells 
make up between 3-5% of the nucleated cells of the human epidermis (Merad, 
Ginhoux, & Collin 2008). Their function and cell marker expression profile 
varies, with the two major groups being the epidermally situated Langerhans 
cells, and the deeper dermal dendritic cells, with further subtypes existing in 
inflammatory skin pathology. Langerhans cells express CD1a, which may also be 
seen in a small number (~10%) of dermal dendritic cells, thought to be largely 
migrating Langerhans cells (Shipton, 2013). Dendritic cells can initiate an 
adaptive immune response through their ability to stimulate naive T-cells, 
generating specific immune responses. They also participate in the innate 
immune response through the release of pro-inflammatory or modulatory 
cytokines. Langerhans cells also play an important role in the maintenance of 
tolerance and induction of regulatory T-cells (Lutz and Kurts, 2009, Merad et al., 
2008).  
They originate from a population of radioresistant haematopoetic precursor 
cells resident in the skin from embryonic development, although they may also 
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derive from circulating cells in certain inflammatory skin diseases (Shipton, 
2013, Merad et al., 2008). The Langerhans cell is an immature dendritic cell, 
which undergoes phenotypic and functional differentiation (maturation) upon 
exposure to antigen, and it is in the mature state that it initiates a T-cell 
response. There is a continuous low level of Langerhans cell migration to 
draining lymph nodes, which is thought to play a role in immune tolerance. This 
migration is increased on exposure to antigen, a process that is regulated, in 
part, by TNF-α and IL-1β (Shipton, 2013). They express a variety of surface 
markers, which vary over the lifetime of the cell dependent upon its 
maturational state. These include CD45, MHC class II, CD1a, CD11c, CCR6, 
Langerin and CD205 (Teunissen, 2004). They contain a characteristic, but poorly 
understood intracellular organelle, the Birbeck granule, thought to play a role in 
endocytosis and specific to epidermally located Langerhans cells (Merad, 
Ginhoux, & Collin 2008;Teunissen 2004).  
Modulation of Langerhans cell responses: 
Langerhans cells have the capacity to modulate the local immune milieu via 
their ability to express either a Th1 or Th2 cytokine profile. Immature dendritic 
cells may express a tolerogenic profile, while mature dendritic cells produce 
either Th1 polarizing cytokines (IL-1β, IL-12, IL-18 and TNF-α) or Th2 polarising 
cytokines (IL-10 and CCL 17) (Toebak et al., 2008).  A variety of compounds act 
on Langerhans cells to modulate their functional interactions with T-cells to 
drive either a Th1 (T cells produce high levels of IFN) or Th2 dominant response 
(T cells produce high levels of IL-4). Compounds which act to promote an 
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inflammatory, cell-mediated immunity Th1 response include ATP, BK, SP, TRPV1 
and IFN-. Substances which inhibit the Th1 and promote an anti-inflammatory, 
antibody-dominant Th2 response include histamine, CGRP, α-MSH, cAMP, 
Vitamin D and UVB irradiation (Teunissen, 2004). Please refer to Figure 11 for a 
summary of key factors and their proposed effect on Langerhans cells. 
Pro-Th1 stimulating factors acting on Langerhans cells 
Langerhans cells have also been shown to express functional P2X7, indicating 
the capacity to respond to ATP (Tran et al., 2010). ATP has been shown to 
promote IL-1β and TNF-α release by Langerhans cells (Ferrari et al., 2000, 
Pizzirani et al., 2007, Burnstock, 2012), and to increase their antigen presenting 
capacity, inducing contact hypersensitivity in mice (Boulais and Misery, 2008, 
Yamamoto et al., 1996). Damaged cells release a range of damage-associated 
molecular pattern molecules (DAMP), which drive inflammatory responses, one 
of which is ATP. It is proposed that activation of P2X7 by ATP may be one of the 
mediators of the pro-inflammatory Langerhans cell response to DAMPs 
(Fukuhara et al., 1975).  
Substance P also has immunomodulatory effects. The high-affinity neurokinin-1 
receptor NK1R is expressed on murine CD11c positive skin Langerhans and 
dermal dendritic cells. Stimulation of NK1R increases nuclear translocation of 
NF-κB and pushes the LC to generate an immunostimulatory, Th1 response 
(Mathers et al., 2007). 
In addition to its role in cutaneous sensory transduction, the TRPV1 receptor 
may be present on Langerhans cells. There is one positive (Bodo et al., 2004) 
   74 
and one negative (Ständer et al., 2004) report of TRPV1 expression in in situ 
Langerhans cells.  Blood derived dendritic cells express functional TRPV1, and in 
culture, incubation with capsaicin did not induce cell death, but did inhibit 
differentiation, maturation and phagocytosis, as well as shifting the cytokine 
profile of these cells to an anti-inflammatory, rather than pro-inflammatory one 
(Toth et al., 2009). 
Pro-Th2 stimulating factors acting on Langerhans cells 
CGRP positive fibres are often observed in close apposition to the cell body of 
Langerhans cells in the epidermis (Hosoi et al. 1993). Recent murine in vitro 
studies of the effect of CGRP stimulation on the behaviour of Langerhans cells 
support the idea that CGRP contacts may regulate immune functioning of these 
cells. Ding et al found that exposure of Langerhans cells to CGRP increased their 
ability to present antigen to Th2 cells, whilst decreasing their ability to present 
antigen to Th1 cells. They also found that CGRP inhibited Langerhans cell 
production of Th1 chemokines CXCL9 and CXCL10 in response to IFN-gamma 
stimulation (Ding et al. 2008). Overall, this suggests that CGRP positive nerve 
contacts with Langerhans cells may act to suppress Th1 inflammatory immune 
processes in the normal, resting epidermis, and that loss of these contacts may 
result in an increase in Th2, inflammatory behaviour of Langerhans cells.  
Increased intracellular levels of cAMP in Langerhans cells are the result of the 
action of a number of effector molecules, including catecholamines, CGRP, VIP 
and histamine (Shepherd et al., 2005). Raised levels of cAMP act to inhibit 
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activation of the NFκB pathway, pushing the cell towards a Th2 response (Peters 
et al. 2006). 
The active metabolite of vitamin D is 1,25-dihydroxyvitamin D3 (VD3), which acts 
via its nuclear receptor (VDR). Vitamin D3 is produced in the skin following 
exposure to sunlight, then metabolised in the kidney to 1,25-dihydroxyvitamin-
D3. Keratinocytes and melanocytes are also able to produce 1,25 (OH)2D3 
following UVB exposure (Gorman et al., 2010a). The Vitamin D3 receptor, VDR is 
expressed in immune cells, including dendritic cells, mast cells and T-cells. 
Topical 1,25(OH)2D3 suppresses dendritic cell maturation and Th1 cytokine 
expression. It also reduces dendritic cell arborisation and prompts migration to 
lymph nodes in murine skin, with induction of regulatory T-cells and reduced 
skin contact hypersensitivity responses (Gorman et al., 2010b). 
Histamine acts via H4 receptors in LC to downregulate CCL-2 expression in 
isolated cultured Langerhans cells, and increases in vivo migration of 
Langerhans cells from the epidermis (Gschwandtner et al., 2010). Degranulating 
mast cells in vitro polarise dendritic cell response to Th2 rather than Th1 
(Mazzoni et al., 2006). The effect of histamine stimulation on other skin cells, 
particularly mast cells and the release of mediators which in turn may alter 
Langerhans cell behaviour must be taken into account when considering the 
effect of histamine stimulation on intact skin.   
Hydrocortisone and dexamethasone also suppress dendritic cell maturation and 
Th1 cytokine expression. Glucocorticoids induce apoptosis in immature 
dendritic cells, but suppress activation of dendritic cells after antigen uptake 
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through reduction of MHCII, co-stimulatory molecule and cytokine expression. 
Glucocorticoids inhibit DC migration and induce a tolerogenic phenotype, with 
increased phagocytic activity and IL-10 expression (Baschant and Tuckermann, 
2010). 
Ultraviolet B radiation induces a number of immune changes in the skin, with 
effects on Langerhans cells, keratinocytes and melanocytes. UVB irradiation 
induces apoptosis and reduction in number of Langerhans cells in murine skin, 
and upregulates keratinocyte production of RANKL, which induces Langerhans 
expression of IL-10 through binding to RANK expressed on their surface. UVB-
induced cutaneous immunosuppression does not occur in Langerhan cell-
depleted mice, nor in the case of blockade of RANK, OX-40 ligand or IL-10 
(Yoshiki et al., 2010). 
Other modulatory influences of Langerhans cell maturation 
The neurotrophins NGF and BDNF have been reported to effect changes in 
cytokine secretion from dendritic cells, acting via RhoA and RacA GTPases. 
However the net balance between pro- and anti-inflammatory cytokines 
appears to be dependent upon underlying skin pathology (Noga et al. 2007). 
Non-neural adrenergic signalling also modulates dendritic cell immune 
responses. Beta-adrenergic signalling impairs the ability of Langerghans cells to 
present antigen in vitro, as well as downregulating cytokine production via the 
induction of cAMP which inhibits NFκB (Goyarts et al., 2008). Norepinepherine 
also reduces TNF alpha and increases Langerhans cell migration (Goyarts et al., 
2008).  
   77 
Adenosine may be released by a variety of cells and modulates dendritic cell 
function through interaction with adenosine receptors on dendritic cells. 
Adenosine promotes chemotaxis of immature dendritic cells and inhibits IL-12 
production in mature dendritic cells. 
TNF-α induces dose-dependent migration of human Langerhans cells from the 
epidermis (Cumberbatch et al., 1999). Thalidomide inhibits TNF-α production by 
Langerhans cells as well as their capacity to present antigen to Th1 clones (Deng 
et al., 2003). 
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Langerhans cell interaction with sensory nerves 
1. Effect of denervation 
There are varying reports of the effect of denervation on Langerhans cells. One 
recent study found an increase in Langerhans cells in the denervated skin, but 
not neighbouring skin or the spared nerve injury model in rats (Dauch et al., 
2013). However, Langerhans cells were identified using PGP 9.5, rather than a 
specific Langerhans cell stain. It is known that a variable proportion of 
Langerhans cells express PGP 9.5, and that this number increases after nerve 
injury (Hsieh et al., 1996), so this may simply reflect a functional change in 
immunoreactivity, rather than a true change in cell numbers. Similar findings 
and limitations are presented in a study of chemotherapy-induced neuropathy 
in rats (Siau et al., 2006). Increased Langerhans cells, identified by S-100, were 
seen in the skin of a group of 5 patients with complex regional pain syndrome, 
with the greatest numbers seen in the patient with the lowest innervation 
density (Saporta, 2014). Another study, using the Langerhans cell specific CD1a 
marker, found no change in Langerhans cell numbers in patients with post 
herpetic neuralgia, despite marked denervation (Oaklander et al., 2003). 
Langerhans cells were found to be increased in the cornea in early diabetic 
corneal neuropathy (Tavakoli et al., 2011). Taken together, these studies may 
suggest that Langerhans cells are increased early in neuropathy, but decrease 
later. This is reflected by Tavakoli’s findings that the Langerhans cell numbers, 
whilst higher in diabetic neuropathy patients than in controls, were relatively 
lower in more severe neuropathy. More recently, increased numbers of 
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Langerhans cells have been observed in small fibre neuropathy, but no 
correlation with pain assessed by VAS score was identified (Casanova-Molla et 
al., 2012). The increase in Langerhans cells was particularly marked in a diabetic 
subgroup, who also showed a more profound loss of IENFD. 
Possible effect of Langerhans cells and neuropathic pain 
A recent study in a diabetic mouse model found an increase in epidermal and 
subepidermal Langerhans cell numbers during the period of mechanical 
allodynia. This change was proposed to be mediated by epidermal nerve fibre 
derived NGF-TrkA signaling to epidermal Langerhans cells, and from TNF-α 
positive subepidermal fibres to subepidermal immature Langerhans cells. The 
increase was abolished with an intrathecal p38-MAPK inhibitor, which also 
reduced mechanical allodynia and TNF-α expression in subepidermal fibres. No 
changes were seen in the non-diabetic control mice (Bertelsen et al., 2013). 
These findings, in conjunction with the anatomical studies above, support a role 
for Langerhans cell modulation of neuropathic pain, although the pathways 
require further study.  
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Objectives of this study 
Neuroimmune interactions in the skin are an area of interest in particular 
considering the possibility of identifying new therapeutic targets for 
neuropathic pain which could be modulated topically, potentially with less 
systemic side effects than many currently used agents. Cutaneous nerves also 
offer a potentially more accessible window on neurobiology of neuropathy and 
neuropathic pain in human subjects. If results from animal models can be 
reliably explored using skin biopsies, either of glabrous or hairy skin, rather than 
sural nerve biopsies, it would allow far easier exploration of pathogenic 
mechanisms, natural history of disease and possible responses to therapies. 
1. c-Jun expression in demyelinating neuropathies. 
This section of the thesis aims to determine whether: 
A. Schwann cell c-Jun upregulation demonstrated in animal models of 
neuropathy is also seen in human disease, using a cohort of patients 
with both axonal and demyelinating neuropathies, with the latter 
split between genetic and inflammatory forms; and 
B. Whether it is possible to use glabrous skin biopsy to examine these 
same pathways in dermal myelinated nerve fibres. 
2. Dermal microdialysis evaluation of the immune effect of acute 
nociceptor activation. 
This section of the thesis aims to determine: 
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A. Whether acute nociceptor activation by the application of topical 
capsaicin is sufficient to induce an acute inflammatory response in 
the absence of nerve damage; and 
B. To establish the ELISA cytokine assay in dermal microdialysis fluid in 
our laboratory, prior to the last section of this project 
3. Small fibre function, immune changes and pain in Anderson-Fabry 
disease. 
This section of the thesis aims to determine whether pain in a single 
neuropathy type (Anderson-Fabry disease) is determined by the 
presence of a pro-inflammatory cytokine profile in the skin, or is 




Chapter 3: c-Jun expression in human neuropathies: using skin 
nerves to study pathologic mechanisms. 
Abstract: 
Introduction: 
Cutaneous nerves have potential to provide an accessible window on pathogenic 
mechanisms in human neuropathies. Animal research and cell models continue to 
identify new pathways involved in neuropathies, as well as potential ways of 
modifying those pathways for therapeutic gain. A key limit to the translation of 
these findings into human disease is the ability to demonstrate that the 
mechanisms identified in these models exist and behave in similar ways in human 
nerves. Studying human nerves has traditionally been limited to sural nerve biopsy, 
which is both invasive, and limited to examination at a single time point, thus 
precluding studies of pathological evolution and of any therapeutic response. The 
development of skin biopsy demonstrating cutaneous nerves in the study of 
neuropathy over the last ten to fifteen years offers a new alternative to study 
pathogenic mechanisms and their response to modulation in human subjects, with 
minimal patient discomfort and potential for longitudinal studies.  
Hypothesis and aims: 
I postulated that c-Jun may be upregulated in human neuropathies, either as an 
aetiological factor, or as a modulator of outcome, and that these changes could be 
observed in both sural and cutaneous nerve samples.  This aim of this study was to 
demonstrate that skin biopsy could be used to establish whether recently identified 
changes in transcription factor signalling pathways in demyelinating neuropathies 
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could be shown to have altered function in human dermal nerve fibres, and how 
these changes correlated with disease states.  
Methods: 
This pilot study used semi-quantitative immunohistochemical techniques to assess 
c-Jun in human neuropathies, by comparing human sural nerve samples taken from 
normal controls and from patients with variety of neuropathies, both axonal and 
demyelinating.  The data from these human nerve samples were then compared 
with the same immunohistochemical techniques applied to cutaneous nerves in 
glabrous skin biopsies taken from normal controls and patients with the same 
diseases as the nerve samples.  
Subjects: 
Nerve tissue was obtained, after prospective or retrospective informed consent,  
from 28 patients with a variety of axonal and demyelinating neuropathies (diagnosis 
based on neurophysiology) and from 2 normal controls (normal control nerve tissue 
is very difficult to obtain). Skin biopsy tissue was obtained, after informed consent, 
from 4 normal subjects (normal was defined by the absence of any symptoms 
related to neuropathy), 5 patients with chronic inflammatory demyelinating 
polyneuropathy, 3 patients with genetically confirmed CMT1A and one patient with 
Guillain-Barré syndrome. 
Results: 
c-Jun immunoreactivity was identified in diseased, but not healthy nerve tissue in 
both the sural nerve and glabrous skin samples.  c-Jun-IR was upregulated in the 
Schwann cell nuclei of axonal neuropathies. Upregulation was more varied in 
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demyelinating neuropathies, with Schwann cell nuclei, and axons both exhibiting 
immunoreactivity. 
Conclusion:  
c-Jun immunoreactivity is increased in diseased, but not healthy nerves, and this 
can be demonstrated in both sural nerve tissue and in myelinated nerve fibres in 
glabrous skin. 
 
Note: This section of the thesis has been published: Hutton, E.J. et al (2011) c-Jun 







Schwann cell dedifferentiation following nerve injury is important to permit neural 
survival and axonal regrowth. Animal studies have shown that the transcription 
factor c-Jun is upregulated in Schwann cells of injured and pathological nerves 
where it acts as an important regulator of Schwann cell plasticity, promoting 
dedifferentiation and demyelination. This pilot immunohistochemical study 
investigates whether c-Jun is upregulated in nerves available from skin and nerve 
biopsies in human neuropathies.  We examined c-Jun expression in normal and 
diseased human nerves, as well as in dermal myelinated nerve fibres. Our findings 
show that although as predicted c-Jun is rarely expressed in normal nerves, it is 
expressed in Schwann cell nuclei of pathological nerves as predicted by animal 
studies. Pathological dermal myelinated nerve fibres also show clear nuclear c-Jun 
expression.  Further studies of c-Jun expression will help clarify its role in human 
neuropathies. 
Neuropathies may be divided into two subgroups: those that primarily affect the 
myelin sheath (demyelinating neuropathies) and those that primarily affect the 
axon (axonal neuropathies), and may be genetic or acquired. Charcot-Marie-Tooth 
disease (CMT) is the most frequent inherited neuropathy in humans affecting 1 in 
2,500 of the population and can be primarily demyelinating (CMT1) or axonal 
(CMT2). To date there are over 40 causative genes associated with CMT(Jerath and 
Shy, 2015). Therapies are currently limited for many neuropathies, especially the 
genetic neuropathies where there are no effective treatments. Better 
 87 
understanding of human Schwann cell biology may identify new therapeutic 
targets.  
c-Jun was initially shown to be a key transcription factor in the governance of 
Schwann cell phenotype in a study of its expression in cultured Schwann cells, as 
well as in rat sciatic nerve crush and transection models (Macedo et al., 2012). Shy 
et al demonstrated that increased c-Jun expression was seen in nonmyelinating and 
denervated Schwann cells, but not in myelinating Schwann cells (Shy et al., 1996).  
Recent animal studies have further defined pathways in the developmental 
regulation of myelination, as well as dedifferentiation of Schwann cells following 
nerve injury (Jessen and Mirsky, 2008). Myelinating Schwann cells dedifferentiate 
when they are removed from axonal contact in injured nerves or in culture. 
Dedifferentiated cells can remyelinate under appropriate conditions (Parkinson et 
al., 2008). Regulatory factors control the phenotypic switch in myelinating Schwann 
cells between myelination and dedifferentiation / demyelination. Positive 
regulators which drive Schwann cells towards myelination include (among others) 
the transcription factors Krox-20, Sox-10 and NF-κB and the cytoplasmic messenger 
cAMP whilst negative regulators include c-Jun, Notch, Sox-2 and the trophic factor 
NT3 (Jessen and Mirsky, 2008).  
c-Jun is a basic leucine zipper protein which forms homo- or heterodimers with Fos, 
Jun and ATF proteins to form the AP-1 complex (Jochum et al., 2001).  AP-1 
modulates a variety of processes, including cell differentiation, proliferation, 
apoptosis and oncogenic transformation. AP-1 activity is induced by growth factors, 
cytokines and extracellular stresses and is modulated by other transcriptional 
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regulators, as well as by upstream kinases. One effect of AP-1 induction is further 
upregulation of c-Jun (O'Reilly et al., 2011). While the action of c-Jun in the AP-1 
complex is regulated through phosphorylation by Jun-NH2-terminal kinase (JNK), 
other actions of c-Jun, particularly its role in myelin regulation, are independent of 
its phosphorylation status (Parkinson et al., 2008). 
Following nerve injury in rodents, c-Jun, phospho-c-Jun, JNK 1 & 2 and phospho-JNK 
1 & 2 are all rapidly upregulated, particularly phospho-JNK 1 & 2 (Parkinson et al., 
2008). Myelin degeneration following nerve injury in a Schwann cell specific c-Jun 
knockout mouse is delayed, and myelin phagocytosis impaired, as was expression of 
other markers of Schwann cell dedifferentiation including L1, N-cadherin and p75NTR 
(Arthur-Farraj et al., 2007, Jessen and Mirsky, 2008, Parkinson et al., 2008).  
Regeneration and functional recovery was also impaired in these mice. Activation of 
the p38 MAPK pathway also appears to be important, with p38 MAPK increasing c-
Jun levels, inducing myelin breakdown and change to an immature Schwann cell 
phenotype (Pereira et al., 2013). Schwann cell c-Jun expression also appears to 
modulate neuronal survival through upregulation of growth factors such as artemin 
and GDNF (De Francesco et al., 2013). 
Activation on JNK is modulated by two primary pathways, which may be modulated 
by several factors. Activation of MAP kinases (MAPK) by molecules such as TGF-β, 
TNF-α and ligation of the TCR phosphorylates and activates JNK, Conversely, 
activation of MAP kinase phopshpholipases (MKP) by molecules such as TNF-α 
dephosphorylates and suppresses JNK activity (Kamata et al., 2004). TNF-α has a 
complex modulatory effect on JNK, which is regulated by the balance of several 
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intracellular mechanisms. Apoptosis is augmented by NF-κB, concomitant activation 
of TNFR2 and prolonged, high concentration exposure to TNF-α, all of which act to 
potentiate JNK activation. Conversely, activation of the IKK-NF-κB pathway or low 
level, transient exposure to TNF-α act as a negative regulator of apoptosis. Overall, 
prolonged and robust JNK activation promotes apoptosis, whilst transient activation 
promotes cellular proliferation (Kamata et al., 2004). Figure 1 below summarises 







Materials and Methods: 
Subjects: 
Ethical approval for this project was obtained from the Joint National Hospital for 
Neurology and Neurosurgery and Institute of Neurology Research Ethics 
Committee.  
Consent was obtained from 28 patients either prior to routine nerve biopsy for 
diagnostic purposes or retrospectively (see table 1 for subject details).  Nerve 
biopsies were taken according to standard clinical procedures at the National 
Hospital for Neurology and Neurosurgery, with all biopsies being from the sural 
nerve apart from 2 patients (dorsal ulnar nerve in cases 13 and 14). Although the 
availability of normal nerve biopsy tissue is limited, 2 archival nerves were identified 
and used in this study (cases 29 and 30). Case 29 was taken from a 20 month-old 
male with a suspected mitochondrial disease, and was pathologically normal for 
age. Case 30 was taken from a 53 year-old female with neuropathic pain in the legs 
and normal neurophysiological studies. Her nerve was reported as ‘within normal 
limits’ but did have some epineurial perivascular T-lymphocytes. 
For the skin biopsies, informed consent was obtained from 9 patients with 
neuropathies and 4 normal controls (see table 2 for subject details). Subjects were 
defined as ‘normal’ on the basis of an absence of any symptoms of neuropathy, 
however they were not examined and did not undergo neurophysiology. A 3-mm 
punch biopsy was taken from the glabrous skin at the lateral border of the non-
dominant index finger of each subject after anaesthesia with 2% intradermal 
lignocaine. The skin biopsies were performed according to the techniques described 
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by McCarthy et al, but without adrenaline in the local anaesthetic due to the end 
circulation in the fingers (McCarthy et al., 1995). 
Nerve and dermal myelinated nerve biopsies for this study were from patients with 
a variety of diagnoses including axonal neuropathies (vasculitic neuropathy, 
sensorimotor axonal neuropathy, idiopathic axonal neuropathy, motor neuron 
disease, carcinomatous radiculopathy, preganglionic sensory neuropathy), inherited 
demyelinating neuropathies (CMT1A), acquired inflammatory demyelinating 
neuropathies (GBS, CIDP) and a group with mixed axonal and demyelinating 
neuropathies (CMT-X, POEMS, amyloid neuropathy). The diagnoses of CIDP, GBS 
and POEMS syndrome were made using established criteria (Hadden et al., 2006, 
Hughes and Cornblath, 2005, Lunn and Willison, 2009). The cases of CMT1A and 
CMTX1 all had a genetically confirmed diagnosis. 
Methods: 
1. Tissue collection: 
Nerve tissue was obtained from spare tissue sections remaining after diagnostic 
nerve biopsies had been performed.  
Skin biopsies were taken from the lateral palmar surface of the second finger of the 
non-dominant hand in patients and normal controls after informed consent had 
been obtained. The area was cleaned with Chorhexidine Acetate 0.015% + 
Cetrimide 0.15% (Travasept 100), and the skin anaesthetised with a bleb of 2% 
lignocaine introduced with a 27G syringe, taking care not to introduce the needle 
directly into the planned biopsy site. A 3 mm punch biopsy was then taken from the 
lateral palmar aspect of the forefinger and the core carefully removed with fine-
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toothed forceps. Tissue was placed immediately in 10% neutral buffered 
formaldehyde and pressure applied to the biopsy site to achieve homeostasis. A 
steristrip and waterproof dressing was then applied. 
2. Nerve tissue processing: 
Tissue was immediately immersed in 3% glutaraldehyde in 0.05M/Sodium 
cacodylate buffer, pH 7.4 for 5 minutes, followed by immersion in 10% neutral 
buffered formalin (Sigma-Aldrich, UK) for 24 hours at room temperature and 
paraffin embedding. Four micron sections were cut for immunohistochemistry. 
3. Skin tissue processing: 
Tissue was fixed in 10% neutral buffered formalin (Sigma-Aldrich, UK) overnight, 
prior to embedding in paraffin and sectioning at 4μm. 
4. Immunohistochemistry Methods: 
Sections for Myelin Basic Protein (MBP) were processed using standard protocols 
on a Leica Bond Max Immunostainer, using 1:1000 mouse anti-mammal MBP 
(Convance, California, SMI-94). For the other antibodies, sections were rehydrated 
to water through successive xylene and alcohol baths. Sections were then blocked 
with 0.9% hydrogen peroxide in water to quench endogenous peroxidase activity, 
followed by 4 x 5 minute washes in PBS. For c-Jun and p-JNK staining, sections were 
treated with a citrate antigen unmasking step prior to the PBS washes, by 
incubating in a microwave for 20 minutes in 700mL of water containing 7mL antigen 
unmasking solution (Vector Laboratories, UK), followed by another 4 x 5 minute PBS 
washes.  
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Sections were then incubated for 1 hour with 2.5% horse serum (Vector 
Laboratories, UK) in PBS (with 0.1% Tween to improve permeabilisation). Protein 
gene product 9.5 (PGP 9.5) sections had 5% powdered non-fat milk added to the 
blocker.  Sections were incubated in primary antibody diluted in 2.5% horse serum / 
PBS overnight at 4°C. Antibodies used were 1:1000 rabbit anti-PGP 9.5 (Ultraclone 
Ltd, Isle of Wight), 1:50 rabbit anti-human c-Jun (Santa Cruz Biotechnology Ltd, USA 
sc-1694) and 1:50 mouse anti-human p-JNK (Santa Cruz Biotechnology Ltd., USA, sc-
6254). Following 4 x 5 minute PBS washes, sections were incubated with 
appropriate biotinylated secondary antibodies (Vector Laboratories, UK) for 1 hour 
at room temperature, then washed with PBS 4 x 5 minutes, before antigen 
visualisation using the VECTASTAIN® Elite ABC kit and 3,3' Diaminobenzidine (DAB) 
with haematoxylin counterstaining. Glioblastoma tissue was used as a positive 
control for c-Jun staining.  
Protein gene product 9.5 (PGP 9.5) is an ubiquitin C-terminal hydroxylase expressed 
by all neurons of the peripheral nervous system, and is an established marker for 
dermal and intraepidermal nerve fibres (Lauria, 2005). 
 Analysis 
1. Nerve Analysis: 
Slides were examined and photographed using a Zeiss Axioscope 2 microscope and 
imaging system. The images were analysed and location and intensity of c-Jun 
immunoreactivity (IR) recorded for each subject, after coding the sections to allow 
for blinded analysis. Immunoreactivity was graded as follows: 0 – absent; 1 – faint 
staining; 2 – moderate staining; 3 – intense staining.  
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MBP staining was graded as follows: 0 – no positive myelinated fibres; 1 – 
occasional positive myelinated fibres; 2 – moderate numbers of myelinated fibres; 3 
– full complement of myelinated fibres.  
Assessment of inflammation and numbers of inflammatory cells was made on the 
existing diagnostic sections stained for CD4+ T-cells, CD8+ T-cells and CD68+ 
macrophages. Grading of inflammatory cell numbers was taken from the diagnostic 
reports issued by the reporting Neuropathologist. 
2. Skin Analysis: 
Sections were photographed and immunostaining intensity graded, after coding the 
sections to allow for blinded analysis. Dermal nerve c-Jun intensity was graded as 
follows: 0 – no intraneural staining; 1 – faint nuclear IR in some nerves; 2 – definite 
IR in a few nuclei within the dermal nerve; 3 – strong IR in several nuclei within the 
dermal nerve. Dermal MBP was graded in comparison to the pattern and intensity 
of staining observed in dermal nerves taken from normal controls. Grading was as 
follows: 0 – no IR; 1 – some faint IR; 2 – definite, but reduced IR either due to 
reduced numbers of positive fibres or by thinned myelin; 3 – full, ‘normal’ MBP IR. 
PGP 9.5 IR was graded in comparison to the pattern and intensity of staining 
observed in dermal nerves taken from normal controls. Grading was as follows: 0 – 
no IR; 1 – some faint IR; 2 – definite, but reduced IR, either due to reduced numbers 
of positive fibres or reduced intensity of staining; 3 – full, ‘normal’ PGP 9.5-IR.  
An epidermal thickness was recorded for each subject, defined as the maximal 
width of the cellular epidermis, and as measured between the basement membrane 
and the junction of the stratum lucidem and stratum granulosum (where nuclei are 
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lost from the keratinocytes). Meissner’s corpuscles were defined morphologically as 
dermal papillae containing PGP 9.5 positive fibres. The maximal width of these 
structures was recorded for each subject. 
Slides were imaged using a Zeiss Axioscope 2 microscope and imaging system using 
automatic exposure correction. Composite micrographs were compiled using 
Adobe Photoshop CS4. The original micrographs were corrected for brightness 
and contrast and sharpened, then resized to create the composite figure.  
3. Statistical Analysis: 
Graphs and statistical analysis were undertaken using SPSS Statistics 17. Kendall’s 
tau-c coefficient was used to evaluate the strength of associations between ordinal 
data sets. Skin morphology data was analysed using an unpaired t-test. 
Materials: 
3% glutaraldehyde solution in 0.05M Cacodylate buffer: 
 Solution A: Cacodylate Stock (0.2M): 42.8g sodium cacodylate in 1L distilled 
water 
 Solution B: 25% glutaradhyde in water (Sigma Aldrich) 
50mL Solution A plus 24mL of Solution B plus 2.7 mL of 0.2M hydrochloric acid, 




8% Paraformaldehyde stock 
 Heat 80mL distilled water to 55°C 
 Add 3-4 drops of 5M NaOH 
 Add 8 grams paraformaldehyde and stir continuously 
 When clear, vacuum filter 
 Top off to 100mL and store at 4°C for up to 1 month. 
 
Phosphate Buffered Saline (5X concentrate stock solution) 
 40g NaCl 
 1g KCl 
 5.75g Na2HPO4.7H2O 
 1g KH2PO4 
 Made up to 1L with distilled water, pH 7.4 (corrected with HCl / NaOH) 
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Results: 
The clinical and pathological details of the subjects studied are given in Table 1.  
 
1. Nerve biopsy tissue: 
c-Jun immunoreactivity in nerve biopsy tissue: 
c-Jun was not seen in normal nerve biopsy specimens (please refer to Figure 1 (A)). 
Figure 4 illustrates the dominant patterns of c-Jun-IR in each neuropathy subtype. 
Axonal Neuropathies:  
A variety of axonal neuropathy pathologies were studied, including vasculitic 
neuropathy, idiopathic axonal neuropathy, motor neuron disease, carcinomatous 
radiculopathy and preganglionic sensory neuropathy. c-Jun immunoreactivity (c-
Jun-IR) was upregulated in the majority (86%) of axonal neuropathies examined. c-
Jun-IR was localised to the Schwann cell nuclei in 42% of positive cases (Figure 1B) 
and to axonal cytoplasm in 50%, with faint myelin staining seen in the remaining 
case. At high magnification in both longitudinal and transverse sections, the 
identified nuclei were characteristic of Schwann cells, with elongated nuclear 
structures closely apposed to the nerve fibre they myelinate and orientated 
longitudinally to the nerve fibre (Castaneda et al., 2008). Immunoreactivity was also 
seen in axonal cytoplasm in this group (in 43% of the c-Jun positive axonal 
neuropathy cases), however the significance of this is unclear. There was no specific 
subtype of axonal pathology associated with either axonal or Schwann cell nuclear 
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staining in the axonal neuropathy group, although there were only small numbers 
of different types of axonal neuropathy studied (please refer to Table 1).
 100 
Table 1: Nerve Biopsy Data. 
Macrophage activity/density:  scant +; moderate ++; frequent +++. T-cell activity: scant +; moderate ++; frequent+++. Axonal loss: none 0; mild 
+; moderate ++; severe +++. 
Abbreviations:  DM-demyelination; SM-sensorimotor; NP-neuropathy; CIDP-chronic inflammatory demyelinating polyradiculoneuropathy; GBS-
Guillain-Barré syndrome; SFN-small fibre neuropathy; POEMS-polyneuropathy with organomegaly, endocrinopathy, M-protein and skin 
changes; TTR-transthyretin; CMT-X-Charcot-Marie-Tooth, X-linked; CMT1A – Charcot-Marie-Tooth type 1A; EMG-electromyography; SC-
Schwann cell; Mφ -macrophages; OB-onion bulbs. 
Case Age Diagnosis Neurophysiology Pathology   
Mφ T-cells Axonal loss Myelin 
1 47 Vasculitic NP Axonal +++ +++ ++ No DM 
2 71 Vasculitic NP Axonal ++ +++ + No DM 
3 74 SM NP, ?inflammatory Axonal ++ + ++ - +++ No DM 
4 74 Idiopathic axonal NP Axonal ++ 0 ++ No DM 
5 74 MND (LMN) with sensory 
involvement 
Axonal + 0 + No DM 
6 56 Idiopathic axonal NP, 
?inflammatory 
Axonal ++ 0 ++ - +++ No DM 
7 60 Axonal NP, impaired glucose 
tolerance 
Axonal + + + DM 
8 82 SM NP Axonal ++ + +++ No DM 
9 73 Idiopathic axonal NP Axonal + + + No DM 
10 61 Axonal NP (Sjogrens) Axonal + 0 ++ - +++ No DM 
11 50 SM NP Axonal + 0 ++ - +++ No DM 
12 46 Acute SFN, Inflammatory Axonal +++ + ++ - +++ No DM 
13 42 Preganglioinic Sensory NP Axonal + 0 ++ No DM 
14 73 Carcinomatous radiculopathy Axonal +++ 0 + No DM 
15 40 POEMS Mixed ++ 0 ++ No DM 





Table 1 continued: 
Case Age Diagnosis Neurophysiology Pathology   
Mφ T-cells Axonal loss Myelin 
17 67 Amyloid neuropathy (TTR) Mixed ++ 0 +++ No DM 
18 74 CIDP Mixed 0 ++ +++ De- & re-
myelination 
19 68 CIDP Demyelinating + + + De- & re-
myelination 
20 73 CIDP Demyelinating + 0 + Frequent 
demyelination 
21 58 CIDP Mixed +++ ++ + De- & re-
myelination 
22 33 GBS Inexcitable nerves.  ++ + ++ - +++ DM, Mφ 
associated DM 
23 22 CMT-X (Connexin-32) Mixed 0 0 ++ DM, OB 
24 60 CMT1A Demyelinating + + ++ - +++ DM, OB 
25 42 CMT1A Not available 0 0 +++ OB 
26 41 CMT1A Not available 0 0 +++ OB 
27 27 CMT1A Demyelinating + + ++ OB 
28 55 CMT1A Not available 0 0 ++ OB 
29 20 
mth 
Normal Not available 0 0 0 No DM 





Charcot-Marie-Tooth type 1A: 
In the CMT1A patients Schwann cell nuclear c-Jun immunopositivity was seen in half 
of the cases studied. c-Jun IR in the CMT-1A nerves was less intense than in the 
acquired neuropathies, perhaps reflecting a more chronic disease process with 
slower, more protracted biologic mechanisms (Figure 2B(C))). Figure 3 shows the 
cellular localisation (by morphology) of c-Jun in the different demyelinating 
neuropathies studied. 
Acquired demyelinating neuropathies: 
In the five cases of acquired demyelinating neuropathies, clear nuclear c-Jun-IR was 
seen in only one case of CIDP. c-Jun-IR was, however, seen in myelin sheaths in 
several subjects with CIDP and GBS (Figure 2B(A) and 2B(B)); the significance of this is 
unclear, and animal data is not available for comparison. Further evaluation of this 









p-JNK-IR in nerve biopsy tissue: 
p-JNK activity was less clearly defined, but tended to occur primarily in a 
distribution and morphology consistent with cytoplasmic macrophage and 
fibroblast immunoreactivity (figure 3). The intensity of p-JNK-IR also correlated 
most strongly with macrophage activity in the biopsy (Kendall’s tau-c 0.367, 
p=0.005). The nerve from the subject with CIDP (figure 3(C)) shows the clearest 









Skin biopsy tissue: 
Skin Morphology: 
All subjects tolerated the skin biopsy well, with no complications reported. The details of 
the subjects studied are given in Table 2.
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Several changes in skin morphology were observed in the patients with chronic 
neuropathies. These included reduced epidermal thickness (mean difference 49.3 m 
(95% CI: 10.5 – 88.12, p=0.017), which has been previously observed in patients with 
neuropathies (Atherton et al., 2007). Reductions in the width and numbers of Meissner’s 
corpuscles were also observed in the subjects with CMT1A, CIDP and GBS in comparison 
to normal controls (see Figure 5B-D, mean difference in width between neuropathy 
subjects and controls 17.6 m (95% CI: 6.4 – 28.8, p=0.005)). Figure 5a, panel A shows a 
section of typical skin demonstrating the epidermal thickness, a healthy Meissner’s 
corpuscle and the location of the dermal nerve bundles. Meissner’s corpuscles have been 
previously reported to decrease in density with increasing age (Bolton, Winkelmann, & 
Dyck 1966), as well as in neuropathies (Dickens, Mulker, & Winkelmann 1963;Dyck, 
Winkelmann, & Bolton 1966). In our study the correlation between age and numbers of 
Meissner’s corpuscles was not significant (Kendall’s tau-c -0.28, p=0.2), however the 
numbers are too small to analyse the effect of age in subgroups divided by diagnosis.
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Table 2: Skin biopsy data 
c-Jun intensity: 0 no intraneural staining; + faint nuclear c-Jun-IR in some nerves; ++ definite c-Jun-IR in a few intraneural nuclei; +++ strong c-Jun-IR in several intraneural 
nuclei. PGP 9.5 intensity (compared to pattern and intensity seen in normal dermal nerves): 0 no PGP 9.5-IR; + some faint PGP 9.5-IR; ++ definite, but reduced PGP 9.5-IR 
(reduction in density or intensity of positive fibres); +++ full pattern of PGP 9.5-IR.  MBP intensity (compared to normal dermal myelinated nerve bundles): 0 no MBP-IR; + 
some faint MBP-IR; ++ definite, but reduced MBP-IR (reduced numbers of positive fibres or reduced intensity (myelin thinning); +++ full, normal-equivalent MBP-IR. 
Abbreviations:   CIDP-chronic inflammatory demyelinating polyradiculoneuropathy; GBS-Guillain-Barré syndrome; CMT1A-Charcot-Marie-Tooth type 1A. 
 











1 36 Normal 0 +++ +++ 230 64 
2 48 Normal 0 +++ ++ 290 38 
3 46 Normal 0 + + 300 47 
4 28 Normal ++ +++ +++ 212 28 
5 63 CIDP ++ + ++ 187 25 
6 67 CIDP +++ + ++ 190 26 
7 77 CIDP ++ + 0 191 30 
8 51 CIDP +++ ++ ++ 228 26 
9 68 CIDP +++ ++ ++ 196 26 
10 74 CMT1A + + ++ 211 20 
11 34 CMT1A +++ ++ ++ 219 29 
12 47 CMT1A +++ ++ + 203 27 





Skin innervation and c-Jun-IR: 
c-Jun-IR was absent in 75% of the control nerves (Figure 6A), whilst moderate 
immunoreactivity was seen in one subject. Markers of dermal innervation density 
(PGP 9.5) and of myelinated fibres (MBP) were reduced in the pathological subjects 
compared with the controls (Figure 6). c-Jun-IR was increased in all 9 of the 
pathological biopsy specimens (Figure 6B-D). 
Characteristic dermal nerve staining patterns in each of the diagnostic subgroups 
examined are shown in Figure 6. As expected, PGP 9.5 and MBP staining was 
reduced, although not completely absent in the dermal nerves of subjects with GBS, 
CIDP and CMT1A compared with the normal subjects. c-Jun-IR was absent within the 
nerve in the normal subjects, but normal staining of endothelial cells was seen. In 
the subjects with neuropathies, increased c-Jun-IR was clearly seen in nuclei within 
the dermal nerve. On the basis of morphology these are likely to be Schwann cell 
nuclei, with the most intense c-Jun staining of individual Schwann cell nuclei seen in 
the subject with GBS (figure 6C). Figure 7 highlights the differences in innervation 








This small pilot study of c-Jun immunoreactivity demonstrates that c-Jun is 
expressed in pathological, but not in normal nerves, both in nerve biopsy 
specimens and in dermal nerve bundles. Faint c-Jun-IR was detected in one 
normal myelinated dermal nerve specimen, however the significance of this is 
unclear given that ‘normality’ was based on history, and not neurophysiologically 
confirmed. Of note, this subject also had the thinnest epidermis and narrowest 
Meissner’s corpuscles of the normal volunteers. A detailed history was not taken 
from normal controls, just a screening one to exclude neuropathy symptoms. In 
addition, it is not known whether factors such as minor trauma (which may not 
exhibit any obvious signs) may have any effect on distal innervation. 
Axonal neuropathies show upregulation of c-Jun in Schwann cell nuclei, 
but also in axonal profiles 
Axonal neuropathies are probably the closest human correlate to animal models 
using nerve transaction as a model for a neuropathy. We found c-Jun-IR was 
markedly upregulated in human axonal neuropathies. Schwann cell nuclear c-Jun-
IR in this group mimics the findings of upregulation of c-Jun expression following 
nerve transection observed in animal studies of (Arthur-Farraj et al., 2007, Jessen 
and Mirsky, 2008, Macedo et al., 2012). Immunoreactivity was also seen in some 
of the remaining axons in this group. The significance of this is uncertain, but may 
perhaps reflect an alternate role for c-Jun, such as activation of apoptotic 
pathways after a failure of regeneration. c-Jun regulation is complex, and 
modulated by several phosphorylation pathways, including JNK 1-3, ERK 1 and 2 
and p38 MAPK. Each of these pathways has its own activating factors, such as loss 
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of trophic factor signalling (e.g. NGF), excitotoxicity, hypoxic / ischaemic insult and 
inflammation (Raivich, 2008). Whilst brief activation is associated with repair and 
regeneration, prolonged activation and / or high levels of c-Jun are thought to be 
linked to activation of apoptotic pathways (Raivich, 2008, Ferraris et al., 2012). It 
is tempting to speculate that the variation is pathological localisation noted in this 
study may reflect nerves at different stages of disease, differing severity of the 
initial insult, or other factors such as stronger concurrent inflammation or 
ischemia. 
c-Jun is upregulated in Schwan cell nuclei in demyelinating neuropathies, 
with additional expression in axons in the more chronic, less inflammatory 
CMT1a, and in myelin in the more acute, inflammatory CIDP and GBS 
c-Jun was also clearly upregulated in the nuclei of Schwann cells in demyelinating 
diseases, judging from our observations on nerves and skin biopsies tissue. This 
was seen in a number of different demyelinating pathologies including CMT1A, 
CIDP and GBS. Observations on nerve biopsies confirmed c-Jun upregulation in 
about 50% of CMT1A nerves. Of note, the positive Schwann cell nuclei in the CMT-
1A group were seen in the younger two subjects, which is in keeping with the idea 
the Schwann cell nuclear upregulation is c-Jun occurs earlier in the neuropathy in 
an attempt to promote repair, and that this response is lost later in the disease, 
with axonal and fibroblast expression correlating with a later phase of cell death.  
c-Jun biology is complex, which is aptly demonstrated by a recent study examining 
the response of an isolated Schwann cell c-Jun knockout mouse to nerve injury 
(Arthur-Farraj et al., 2012). This showed marked alteration in the nerve expression 
of over 172 molecules, including growth factors, adhesion molecules, growth-
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associated proteins and transcription factors (Arthur-Farraj et al., 2012). The 
expression of c-Jun itself is regulated by many factors, including the AP-1 
transcription complex, of which c-Jun is often one of the dimerising components. 
AP-1 is regulated by several signals, including the MAPK pathways (Erk1/2, JNK 
and p38). Inflammatory mediators, particularly TNF-α, are dose-dependent 
modulators of the activity of JNK and p38 MAPK, and through them of AP-1. 
Inflammation may therefore contribute to further upregulation of c-Jun beyond 
that induced by nerve injury (Kamata et al., 2004, Myers et al., 2003). Given that 
both c-Jun and TNF-α can promote repair at transient, lower levels, and apoptosis 
and more sustained, higher levels, this balance may have a role in shifting 
between repair and apoptosis. This may be particularly relevant in understanding 
the differences in the cellular distribution of expression of c-Jun in the more 
acute, inflammatory demyelinating neuropathies (CIDP and GBS) in comparison to 
the more protracted, less inflammatory course of CMT1A. 
It would be interesting to conduct a larger study to explore further whether there 
are age- or duration-related changes in c-Jun-IR in the demyelinating 
neuropathies. One may hypothesise an evolution of the primary pathology in 
CMT1A from a demyelinating, Schwann cell dominated process in which ongoing 
attempts at regeneration are made, to a later phase of more prominent 
secondary axonal loss. Likewise, correlation with duration of disease and vigour of 
immune response in CIDP and GBS may help us better understand the unexpected 
myelin-based upregulation of c-Jun seen in this group. Longitudinal dermal nerve 
biopsy may be of help in such studies, given its relatively non-invasive nature 
compared with traditional sural nerve biopsy. 
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p-JNK-IR appears to be independent of c-Jun-IR in human neuropathies. 
Whilst p-JNK immunoreactivity was commonly observed in the nerves of both 
neuropathy patients and normal controls, and the distribution was more variable, 
with most prominent expression in macrophages and fibroblasts. This would 
suggest that nerve damage and the type of that damage is less of a determinant 
of p-JNK expression than it is on c-Jun expression. The independence of p-JNK and 
c-Jun immunoreactivity, and its distribution primarily in macrophages and 
fibroblasts suggests that p-JNK may be more responsive to ‘housekeeping’ 
activities of the nerve. The lack of dependence of c-Jun-IR on p-JNK levels in in 
keeping with the findings of animal studies, which show that the activation of c-
Jun following nerve injury is independent of phosphorylation by JNK (Parkinson et 
al., 2008). As TNF-α also promotes JNK activation (Kamata et al., 2004), this may 
explain the more defined macrophage p-JNK-IR seen in the inflammatory 
demyelinating neuropathies (GBS and CIDP) compared to the other patient 
groups. 
Dermal myelinated nerve fibres were useful for studying c-Jun expression in 
human neuropathies. In dermal myelinated nerves from patients with 
demyelinating neuropathies, c-Jun-IR was seen in Schwann cell nuclei. c-Jun-IR is 
largely absent from dermal nerves in healthy controls. Epidermal nerves have 
previously been described to show frequent degenerating and regenerating 
axons, thought to be attributable to continuous nerve fibre remodelling in 
response to injuries induced by minor daily skin trauma (Arthur and Shelley, 
1959). Such remodelling could involve dermal nerve plasticity and prompt local 
cycles of demyelination and remyelination in response. This process may explain 
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the moderate c-Jun-IR seen in one of our normal controls, although no obvious 
trauma was observed. A recent study of dermal innervation in CMT, whilst 
showing reduced innervation density of Meissner’s corpuscles and intrapapillary 
myelinated fibres in CMT1A compared to normal controls, did demonstrate some 
overlap in innervation density between the patient group (n=10) and the normal 
controls (n=45), but did not discuss factors in the normal group which may be 
linked to denser of lesser innervation density (Manganelli et al., 2015). The 
numbers in our cohort were small, and larger normal numbers of normal subjects 
would be helpful to explore the range of normal variation in both morphology and 
c-Jun expression in this relatively new technique. 
Limitations and further directions 
There are several difficulties encountered in translating findings from 
experimental models of neuropathy to human studies. By their nature, animal and 
cell models allow for a monogenic population (or controlled alteration of an 
isolated gene), with homogenicity of age, sex, time of nerve injury and severity of 
the injury. In contrast, studies of human neuropathology, even in a single 
pathology, will have variation in disease duration and severity. There are then the 
added factors of variability in host response, including age, comorbidities, and 
genetics, which may influence factors such as the immune and inflammatory 
response to nerve damage. 
The complexity of c-Jun biology, with multiple factors that can modify both its 
expression, and shift the net effect between proliferation / repair and apoptosis, 
make it difficult to conduct a patient-based study. In addition to the subjects 
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being enrolled at varying points in the time-course of their neuropathy, they will 
exhibit wide inter-individual variability in factors modulating these pathways, such 
as immune function, the net effect of which means that they may have varying 
degrees of activation of these competing pathways. 
Despite the above concerns, there were clear differences seen in glabrous skin 
myelinated nerve fibres between the neuropathy patients and normal controls. 
The relatively non-invasive nature of the technique, coupled with ability to 
examine 5 five micron wax-embedded sections which are considerably easier to 
process in a conventional neuropathology laboratory than the protracted, 
technically more demanding floating 50 micron sections used to determine 
intraepidermal nerve fibre density make glabrous skin biopsy a potentially useful 
tool in understanding neuropathology in human neuropathies. This technique 
would also lend itself to following a patient cohort over time, allowing better 
understanding of the evolution of neuropathy, and its response to treatment. 
Conclusions: 
c-Jun immunoreactivity is increased in diseased, but not healthy nerves, and may 
be semi-quantitatively studied in both nerve biopsies and dermal nerves in 
glabrous skin biopsies. Findings in human neuropathy mimic those reported in 
animal models, suggesting that c-Jun activation plays a similar role in human 
Schwann cell biology, inducing dedifferentiation and demyelination in response to 
loss of axonal integrity. The additional c-Jun-IR seen in axons and myelin requires 
further study, in order to determine the role other factors, such as immune 
activation and apoptosis play in the evolution of human neuropathies. A similar 
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study undertaken in a larger cohort, with staining for other markers such as TNF-
α, AP-1 and markers of apoptosis would help to clarify this. Longitudinal 
evaluation of glabrous skin evolution, particularly in CMT1A could help define 
whether the dominant role of c-Jun does indeed shift over time from one of 
Schwann cell proliferation and promotion of repair to one of apoptosis and axonal 
loss. This small pilot study confirms the utility of skin nerve examination in the 






Chapter 4: Use of dermal microdialysis to determine the 
immune effect of acute nociceptor activation 
Abstract 
Introduction: 
Recent studies suggest changes in the local immune profile of the skin (with a 
higher level of pro-inflammatory and a lower level of anti-inflammatory cytokines) 
may be a relevant aetiological factor in development and maintenance of 
neuropathic pain. However it remains unclear whether these changes are a 
response to nerve damage, nociceptor activity or a reflection of the underlying 
pathology in painful neuropathy. 
Hypothesis: 
I proposed that neurogenic inflammation induced by acute activation of nociceptors 
by topical application of capsaicin would not be sufficient stimulus to induce any 
immediate changes in immune profile in the innervated skin. This was important to 
determine prior to the next phase of my project, which examines whether ongoing, 
proinflammatory immune activation is a necessary addition to nerve damage in the 
development of neuropathic pain in Anderson-Fabry neuropathy.  
Methods: 
A dermal microdialysis catheter was inserted in the bilateral volar forearms of 
healthy subjects and a one-hour baseline collection of dermal microdialysis fluid 
was made. Topical capsaicin  (1% in methylcellulose gel) was then applied to the 
forearm in a methylcellulose gel matrix, and three further hourly aliquots of dermal 
microdialysis fluid were collected and cytokine levels analysed using a multiplex 
ELISA assay. The nine cytokines assayed were selected according to those pro- and 
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anti-inflammatory cytokines postulated to modulate pain behaviour and nociceptor 
activity. Neurogenic activation in the capsaicin treated skin was confirmed by laser 
Doppler imaging measurement of the flare response. 
Subjects: 
Ten healthy volunteers were recruited and the study performed over a single 4-
hour collection period. All subjects were studied starting at 9am to eliminate any 
diurnal variation in skin cytokine levels. The contralateral, untreated arm of each 
subject acted as his or her own control. 
Results: 
No significant difference for any of the cytokines measured was observed between 
the capsaicin-treated and control arms at any timepoint during the study. Neither 
was there any correlation observed between cytokine levels and pain scores or flare 
response. MCP-1 and IL-6 increased over the duration of the study in both treated 
and untreated arms. 
Conclusion: 
Capsaicin-evoked neurogenic inflammation was not sufficient to alter cytokine 
profile. Progressive elevation in MCP-1 and IL-6 was observed, and is likely to 







Neuroimmune interactions in the skin are an area of interest for pain and 
neuroscience research because of developments in detection of low level analytes 
now allows the exploration of possible new therapeutic targets for neuropathic 
pain. Local agents might be applied topically, with fewer systemic side effects than 
many currently used agents. In order to pursue this line of enquiry, we first need to 
understand the bidirectional effects of nerve-immune interaction in the skin, and 
how resident skin cells may modulate these. Some of the possible key mechanisms 
in understanding these links are summarised in figure 10 in the background chapter. 
1. Effects of nociceptor activation: 
Direct TRPV1 activation induces a local inflammatory cytokine and NGF release 
from keratinocytes. However, neuropeptide release in response to nociceptor 
activation induces a much larger number of cascades, including mast cell 
degranulation, keratinocyte activation and Langerhans’ cell modulation, 
potentially far more effective inflammatory mechanisms. Mast cell 
degranulation and keratinocyte activation increase levels of the inflammatory 
mediators IL-1β, TNF-α, IL-8, NGF, ATP and histamine, whilst the effect of 
Langerhan’s cell modulation may depend on the relative levels of CGRP and SP 
release. ATP release may also induce local calcium signalling through 
keratinocyte purinergic receptors, potentially augmenting the response 
(Koizumi et al., 2004). 
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Neuropeptides may also increase local synthesis of chemotactic cytokines, such 
as MCP-1, IP-10, IL-17 and TNF-α, augmenting an initial inflammatory immune 
response. 
2. Effects of immune mediators on nociceptors: 
A number of cytokines are known to modulate nociceptor excitability and pain 
behaviours. Inflammatory cytokines such as IL-1β, TNF-α, IL-6, IL-17, MCP-1 and 
NGFβ are known to sensitise nociceptors directly. IFN-γ may be considered an 
indirect sensitiser, as although there are no reports of direct effects, it is a key 
initiator of inflammatory immune response, and increases the levels of the 
other cytokine molecules. IL-10 is an anti-inflammatory cytokine known to have 
algesic effects. Other chemotactic cytokines may indirectly augment 
sensitisation through recruitment of cells to the skin that release inflammatory, 
sensitising mediators, augmenting an initial response. 
In neuropathy, it may be that an initial inflammatory response driven by nociceptor 
damage or increased firing generates local inflammatory changes in the skin. In 
subjects with persistent neuropathic pain, it may be that either their initial 
inflammatory response is stronger, the counter-regulatory anti-inflammatory 
resolution phase weaker, or the tendency to establish persistent inflammation 
through a shift to Th17 activity may be stronger. There are two aspects of this 
question that need to be resolved: 
1. Does acute activation of nociceptors alone induce inflammatory changes in the 
skin (addressed below); and 
 125 
2. Is there a difference in immune profile in subjects with chronic neuropathic pain 
than those purely with neuropathy, where the damage to the nerves is similar 
and from the same cause? (addressed in next section of thesis) 
This study sought to determine whether acute activation of cutaneous nociceptors 
by topical capsaicin would alter the skin’s immune profile. The aim of this section of 
the project was three-fold. Firstly, I wished to establish a new low volume and 
highly sensitive analytical system or dermal microdialysis. Next I wished to establish 
that dermal microdialysis in normal controls was able to detect the cytokines of 
interest, and to establish the operating range of the assay. Lastly, I wished to 
determine whether acute activation of nociceptors altered the levels of cutaneous 
cytokines, as this has not previously been established. 
Background to Methods: 
1. Dermal Microdialysis 
Dermal microdialysis is an in vivo sampling technique used to measure hydrophilic 
molecules in the dermal extracellular fluid. The technique utilises a hollow, fluid-
containing semiporous membrane, which permits the diffusion of molecules of a 
certain size, limited by the membrane pores, along a concentration gradient 
(Ungerstedt, 1984). Microdialysis can be used to either extract compounds of 
interest from the skin, or to introduce bioactive agents into the skin, as the 
direction of flux depends on the relative concentration gradient of the substance 
between the tissue and the dialysate. It may also be used in combination to study 
real-time effects of an agent on its surrounding tissue. Early studies used 
membranes with small pores, which limited the diffusion of proteins. The 
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introduction of larger pore (3000kDa) membranes in the 1990s enabled the study of 
bioactive proteins such as cytokines and growth factors (Schmelz et al., 1997, 
Schmelz et al., 1999).  Combined with refinement of the multiplex ELISA technique 
with better dynamic range, it is now possible to measure very low concentrations of 
cytokines and growth factors in the skin in very small volumes of dialysate. 
The extraction efficiency, or relative recovery of molecules from the surrounding 
tissue by microdialysis, is complex and influenced by a number of factors. These 
include perfusion flow rate and duration, membrane surface area, molecular size 
and hydrophilicity of the analyte, matrix properties of the surrounding media (e.g. 
viscosity) and temperature. Larger protein molecules have a diffusion coefficient 
around an order of magnitude lower than that for neurotransmitters such as 
dopamine, with extraction efficiency of 1-5% for proteins 10kDa or larger across a 
100kDa membrane perfused at 0.5-1 μL/min (Ao and Stenken, 2006). In addition to 
reduced recovery due to their increased size, proteins may be adsorbed onto the 
microdialysis membrane (Schnetz and Fartasch, 2001). The relative recovery of a 
solute is given by the concentration in the dialysate divided by the concentration in 
the tissue, and is proportional to the flow rate.  For example the relative recovery of 
glucose is nearly 100% at flow rates of 1 μL/min, but drops logarithmically to 
around 20% at 15 μL/min (Petersen et al., 1992). Total protein extraction also falls 
over time, with initial yields of 0.6 mg/mL in the first 20 minutes of dialysis to 0.2 
mg/mL 100 minutes later (perfusion with Ringer’s lactate at 4 μL/min) (Schmelz et 
al., 1997). A microdialysis study using a concentric microdialysis catheter found 
recovery rates: ~20% for IL-1β, 12-18% for IL-5, IL-6, IFN-γ and ~5% for IL-2, IL-4 and 
TNF-α (Sjögren and Anderson, 2009). This variability indicates that the technique is 
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most useful for establishing relative changes, rather than absolute tissue 
concentrations. 
Another key variable in the technique is the depth of catheter insertion. The depth 
of catheter insertion measured by ultrasound, ranges from 0.4 – 1mm (Groth and 
Serup, 1998, Fartasch et al., 1997). As epidermal thickness ranges from 
approximately 70 μm in the arm to around 370 μm in the fingertip, this places the 
catheter within the dermis (Whitton and Everall, 1973). Microdialysis insertion 
produces a degree of local skin trauma, neural activation and immune reaction to 
the presence of a foreign body. Neurogenic activation induces a cutaneous flare 
response, which has been assessed by laser Doppler imaging. Initially distributed 
along the intradermal length of the catheter, it becomes more intense at the points 
of entry and exit from the skin. The increased blood flow begins to resolve by 15 
minutes after insertion and returns to resting levels by 60 minutes (Anderson et al., 
1994, Schmelz et al., 1997). An earlier study found longer lasting changes in blood 
flow (90-120 minutes), however this study used a larger cannula (21G) through 
which the microdialysis membrane was threaded, making direct comparison 
difficult (Groth and Serup, 1998). The magnitude, but not recovery duration, is 
reduced with the prior administration of local anaesthetic (Groth and Serup, 1998). 
Cytokine levels are elevated by catheter insertion, with elevation of IL-6, IL-8, TNF-α 
and IL-1β returning to baseline over 24 hours (Averbeck et al., 2006).  Another 
group found levels of IL-1β, IL-6 and IL-8 were detectable after one hour, peaked at 
5-8 hours and returned to baseline by 24 hours after catheter insertion (Sjögren and 
Anderson, 2009). 
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Responsiveness of the technique to topical agents has been previously 
demonstrated for examination of total protein content, with a 300% increase in 
protein extravasation in the area of histamine-induced wheal, but no change in the 
area of histamine-induced flare. In contrast, capsaicin did not induce any plasma 
extravasation either at the site of stimulation or in the region of the flare response.  
The histamine flare area also exhibited elevation of CGRP, but not SP (Schmelz et 
al., 1997). 
2. Laser Doppler Imaging measurement of Flare 
Laser Doppler Imaging is a method of measuring relative changes in capillary flow in 
the upper layers of the skin, developed in the 1990’s (Essex and Byrne, 1991). The 
technique uses a narrow beam single wavelength laser (633nm, 1mm diameter 
beam) shone in a raster pattern over a region of skin (approximately 10cm2 in our 
study). The beam passes into the upper layers of the skin, to a depth of 
approximately 1 mm, and is reflected off moving blood cells in capillary beds. The 
moving cells induce a frequency shift in the reflected beam, which is received by 
photodiodes. The magnitude of the shift correlates with the blood volume and 
velocity. The imaging device builds up a 256 x 256 pixel image of the scanned 
region, in which each pixel is a point measurement of flux, thereby building a 2 
dimensional map of relative blood flow in the skin. As absolute velocities cannot be 
calculated, the relative changes in flux are reported as arbitrary flux units (Essex and 
Byrne, 1991, Moor Instruments, 2012). The equipment is regularly calibrated 
against the Brownian motion detected in a vial of polystyrene microspheres (Moor 
Instruments, 2012). A series of scans can be taken over the same region, with 
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subtraction of a resting baseline scan possible to distinguish changes in perfusion 
from baseline blood flow. Neurogenic inflammation induced by activation of C-
mechano-insensitive, heat-insensitive (CMiHi) and C-mechano- and heat-sensitive 
(CMH) fibres releases neuropeptides within the receptive fields of these neurons, 
inducing vasodilatation and increased perfusion of capillary beds, allowing Laser 
Doppler Imaging to map the extent of the induced flare response. This method thus 
provides one method to investigate functional integrity of C-fibres in the skin. 
3. Multiplex enzyme-linked immunoabsorbant assay (ELISA) 
Cytokine production is tightly regulated, and cytokines are usually only detectable 
in body fluids in the context of an immune response, and then at low levels 
(picomole per litre) (Ao and Stenken, 2006). As cytokines tend to work in groups of 
molecules with related effects, a panel of cytokines and chemokines was selected 
for this study, which included key components of inflammatory and counter-
regulatory anti-inflammatory cytokine and chemokine networks, as well as those 
implicated in modulation of nociceptor function and neuropathic pain states. A 
variety of analytical techniques are available to detect and quantitate cytokine 
production, including PCR (for mRNA), radio-immunolinked assays (RIA) and 
enzyme-linked immunoabsorbent assays (ELISA) (for protein). Some cytokines, such 
as IL-1β undergo considerable regulation between mRNA synthesis and protein 
release. As it is the secreted proteins that are biologically active, these were felt to 
be the more pertinent focus for this study. Multiplex ELISA was therefore selected 
due to the need to balance a sensitive and specific assay with the ability to detect 
multiple analytes within a small sample volume. 
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Multiplex ELISA techniques have developed to capture and quantitate a variety of 
analytes simultaneously within a small sample volume. A set of microspheres 
(beads of 5-7μm diameter) is labelled with a primary fluorophore at specific 
concentrations. The intensity of the fluorophore detected gives the bead a unique 
‘address’. Each bead with the same concentration of fluorophore (address) is 
coated with an antibody specific to a single cytokine analyte. The set of beads 
coated with the individual antibodies are mixed to produce a set of beads that bind 
the range of cytokines of interest. These are incubated with the sample, then with a 
second detection antibody that binds to the cytokines. The intensity of the second 
antibody allows detection of the amount of bound cytokine attached to each bead 
subset by flow cytometry. The final concentration of each analyte is obtained by 
plotting internal bead density (denoting each cytokine) against the concentration of 
the detection antibody fluorophore to obtain the concentration of each cytokine in 
the sample. One hundred beads are sampled for each address and the intensities of 
the second fluorophore averaged to produce the final value used to calculate the 
concentration. Figure 1 summarises the multiplex ELISA method (Ao and Stenken, 
2006). Multiplex bead-based assays have been found to have good correlation 




The data obtained in immunoassays is not linearly distributed, so a straight line-of-
best fit is inappropriate (Findlay et al., 2000). Whilst logarithmic plots improve the 
fit, the data is usually also not symmetrically distributed, meaning that the upper 
and lower asymptotes do not mirror each other. In order to incorporate this, and 
thereby reduce error from lack-of-fit, modelling of calibration curves for this 
technique have been progressively refined, resulting in the 5PL (five-parameter 
 132 
logistic) curve-fitting method used in this study (Gottschalk and Dunn, 2005, Findlay 
and Dillard, 2007). 
Modelling of the calibration is derived from the equation below (Findlay and Dillard, 
2007), with the points illustrated on one of the calibration graphs from the study - a 
10-point calibration curve for IL-6: 
    
   






Where:   
y = assay signal 
 x = analyte concentration 
a = estimated response as concentration approaches zero (lower asymptote) 
b = slope factor of linear section of curve 
c = mid-range concentration / point of inflection / C50 
 d = estimated response as concentration approaches infinity (upper 
asymptote) 
g = the degree of asymmetry of the curve around the C50. If m = 1, there is 





1. Dermal Microdialysis Method 
Microdialysis catheters were kindly supplied by the laboratory of Professor Martin 
Schmelz, Department of Anesthesiology, Mannheim, University of Heidelberg, 
Germany. These are 0.4mm diameter microdialysis membranes with a pore cutoff 
for proteins above 3000kDa (cytokines are 8-80kDa (Ao and Stenken, 2006)). The 
membrane is attached to a 26G introducing needle at one end and a length of 
Tygon tubing at the other, which connects to a 27G needle attached to a saline-
filled syringe. The microdialysis catheter is perfused at a rate of 0.2 mL per hour (3.3 
μL/min), regulated by a syringe pump. 
All subjects were pretreated by the application of 5% EMLA local anaesthetic cream 
(2.5% lidocaine / 2.5% prilocaine eutectic mixture) for 45-75 minutes (until 
analgesia to pinprick was obtained). The microdialysis catheter was primed with 
saline, and the 26G introducing needle held with a needle holder and inserted at a 
30° angle to the skin surface, then flattened off immediately on piercing the skin. 
The needle was advanced parallel to the skin surface, as superficially as possible 
without breaking the skin surface. The needle was advanced for 1.5cm, then pushed 
through the skin surface and the microdialysis membrane gently drawn through, 
keeping straight alignment with the intracutaneous path. Once the membrane was 
drawn through to within 2 mm of the joint with the Tygon tubing, the needle was 
cut off, leaving a 3 cm distal length of membrane. The proximal Tygon tubing was 
connected to the syringe pump, and flushed to remove any air. A 1.5 mL Eppendorf 
tube containing 30 μL of Roche complete protease inhibitor was taped below the 
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cut end of the tubing to collect the fluid, and microdialysis commenced at a flow 
rate of 0.2 mL/hr (3.3 μL/min). Please see below for justification of inclusion of 
protease inhibitor based on the preliminary experiments. 
Despite the changes in cytokine yield over time discussed above, there is a 
precedent for the use of a 1 hour stabilisation period prior to stimulation 
experiments, using the same technique and catheters which this project employed 
& utilised in this study of the effect of topical capsaicin on cutaneous cytokine 





2. ELISA Method 
Note: All reagents and buffers were equilibrated to room temperature prior to use. 
Each wash was performed using 100 μL of wash buffer per well, then vacuum 
filtering the plate and returning it to the plate holder. After each wash on the 
vacuum manifold, blot the base of the plate on clean paper towel. The plate was 
kept on the plate holder at all other times to prevent contamination. The vacuum 
manifold was calibrated using a flat-bottomed 96 well plate. The pressure was set 
at -1 to -3 mmHg, such that 100 μL liquid was extracted over 3-4 seconds to clear 
the well. 
The standards were prepared for a 10-point calibration curve using the low PMT 
(RP1) settings. Standards were prepared according to the company instruction for a 
mixed assay, using Cytokine Group I Human Cytokine Standard (IL-1β, IL-6, IL-10, IL-
17, TNF-α, IFN-γ, IP-10, MCP-1 and RANTES) and Group II Human Cytokine Standard 
(NGFβ). Each vial of lyophilised standard was reconstituted using 250 μL of standard 
diluent, vortexed for 3 seconds, then incubated on ice for 30 minutes. After 
incubation, 64 μL of each reconstituted standard was added to a vial containing 72 
μL of standard diluent to make the S1 standard, which was vortexed for 3 seconds. 
Sequential 1:4 serial dilutions were prepared to make standards S2-S10. The 
standard diluent constituted the blank for the assay. The samples for the assay 
were thawed and kept on ice until just prior to use. Microdialysis samples were 
used undiluted. 
The coupled beads were prepared by adding 4,600 μL of assay buffer to a 6 mL vial. 
Coupled beads were vortexed for 30 seconds, then 575 μL of each of the coupled 
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beads (for Human Cytokine Group I and Group II) were added to the 6 mL vial, 
which was vortexed for 3 seconds. The prepared beads were wrapped in aluminium 
foil and equilibrated at room temperature for 20 minutes prior to use. Just prior to 
adding the beads to the assay well, they were vortexed for 30 seconds. 
The plate was pre-wetted by adding 100 μL of assay buffer per well, then vacuum 
filtering and blotting the base of the plate on paper towel. 50 μL of coupled beads 
were added per well, and then two washes were performed. Fifty microlitres of 
each of the standards and samples were added to the appropriate wells according 
to original assay plan, with each sample or standard run in duplicate. Each vial was 
vortexed for three seconds immediately prior to adding to the plate. The plate was 
then covered with sealing tape, wrapped in foil and incubated at room temperature 
for 30 minutes on the shaker (1,100 rpm for 30 seconds, then 300rpm). 
The detection antibodies were prepared by vortexing for 15-20 seconds, followed 
by a 30 second spin. Three hundred microlitres of each detection antibody was then 
added to a 6 mL vial containing 2,400 μL of detection antibody diluent, which was 
vortexed for three seconds immediately prior to use. 
The plate was removed from the shaker and three washes performed. Twenty-five 
microlitres of detection antibody were added to each well, and the plate then 
covered with sealing tape, wrapped in foil and incubated at room temperature for 
30 minutes on the shaker (1,100 rpm for 30 seconds, then 300rpm). 
The streptavidin-PE 100x was vortexed for 20 seconds, and then spun for 30 
seconds. Sixty microlitres of streptavidin-PE 100x was added to a 6 mL vial 
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containing 5,940 μL of assay buffer, vortexed for 3 seconds and protected from light 
until use. 
The plate was removed from the shaker and washed 3 times, then 50 μL of 
streptavidin-PE was added per well (after a 3 second vortex). The plate was covered 
with sealing tape, wrapped in foil and incubated at room temperature for 10 
minutes (with shaking at 1,100 rpm for 30 seconds, then 300rpm). After incubation, 
the plate was removed from the shaker and 3 washes performed. The beads were 
then resuspended using 125 μL of assay buffer per well. 
The Luminex reader was switched on and allowed to stabilise for at least 30 
minutes prior to use. The reader was calibrated, after confirming that the CAL1 and 
CAL2 settings were the same as those printed on the bottle of Bio-Plex calibration 
beads. The low PMT (RP1) target value was used. The plate protocol and the analyte 
details (bead regions and predicted concentrations for dilution curves) were 
entered. The data acquisition settings were confirmed as follows: 50 beads per 
region, bead map set to 100 region, sample size set to 50 μL, and DD gates set to 
5,000 (low) and 25,000 (high). The plate was shaken for 30 seconds at 1,100 rpm 
immediately prior to being placed in the reader and the analysis run was 
commenced. 
The reliable limit of the standard curve was determined by the region for which the 
observed / predicted concentrations x 100% fell in the 70 – 130% range. The level of 
fluorescence detected for the lowest point of the curve was also checked against 
the level recorded for the blank, and if the fluorescence for the lowest point of the 
curve within the 70-130% range fell beneath that of the blank, the next highest 
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point in the curve was selected as the lower limit of reliable quantification. The 
singular results for each pair of samples were compared, and if one sample was 
clearly greatly divergent across analytes, it was removed from the assay, and that 
point considered only from the reliable single sample point. This occurred very 
rarely.  
Validation of ELISA 
The reliability of an immunoassay is determined by a number of measures. The 2 
key measures are precision (SD/mean x 100%) and accuracy (Observed/Expected 
concentration x 100%). FDA guidelines for immunoassay evaluation published in 
2000 set a recommended acceptable level for accuracy of 75-125% but comment 
that this could be expanded, and indeed common practice is to accept the reliable 
region of the calibration curve as that in which accuracy is between 70-130%, which 
has been used in this study (Findlay et al., 2000, Urbanowska et al., 2006).  
The limit of blank (LOB) is the lowest limit at which an assay can reliably determine 
the difference between the presence and absence of an analyte, but not necessarily 
be able to reliably quantitate the amount of the analyte present. It is calculated 
using at least 20 repeated blank samples by the following:  
LOB = meanblank + 1.645(SDblank) 
This gives a LOB at which 95% of blanks will be true blanks, but will include some 
samples that are not true blanks. This means that the false positive (Type I error) 
and false negative (Type II error) rates are 5% at the LOB (Armbruster and Pry, 
2008). The limit of quantification (LOQ) is the level at which concentration, not just 
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presence, of the analyte may be reliably determined. It may be calculated based on 
the LOB by the following equation: 
LOQ = meanblank + 2(SDblank) 
Alternately, LOQ may be determined by repeated analysis of samples containing a 
known, low concentration of the analyte in order to empirically determine the level 
at which the signal : noise ratio permits accurate quantification. This method uses 
the formula: 
LOQ = meanblank + 1.645(SDlow concentration sample) 
The information on the assay limits provided by BioRad on the Precision Pro assay 
used for this study are presented below (Table 1) (Bio-Rad, 2012). They are based 
on an 8-point calibration curve, rather than the 10-point curve this study used to try 
to optimise the sensitivity of the assay for low concentrations. Using a 10-point 
calibration curve, I obtained lower reliable values for all cytokines (except NGF-β) 
than the published data provided by the company using an 8-point curve. The range 
between our lower limit of quantification (LLOQ) and that published by the 
company, should however, be interpreted with caution, as it is likely to be less 








Table 1: Company published dynamic range  
 
  Working Range Sensitivity Precision   
 

















IL-1β 3.2 3261.0 0.6 6 8 
 
IL-6 2.3 18880.0 2.6 7 11 
 
IL-10 2.2 8840.0 0.3 5 6 
 
IL-17 4.9 12235.0 3.3 8 6 
 
IFN-γ 92.8 52719.0 6.4 15 9 
 
IP-10 18.8 26867.0 6.1 11 9 
 
MCP-1 2.1 1820.0 1.1 9 7 
 
RANTES 2.2 8617.0 1.8 9 6 
 
TNF-α 5.8 95484.0 6.0 8 6 
 
NGF-β 1.0 4247.0 0.2 4 7 
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Table 2 presents the ranges of the assay which were within the acceptable ranges 
for precision and accuracy based on the analysis of 3 x 10-point standard curves run 





Table 2: Overall assay dynamic range in our laboratory 
 
















IL-1β 0.1 2903.7 5.6 11.3 
 
IL-6 1.6 23944.5 5.9 17.8 
 
IL-10 0.4 1793.3 3.9 10.6 
 
IL-17 1.6 23612.8 14.4 6.5 
 
IFN-γ 32.8 26525.0 6.2 9.9 
 
IP-10 11.7 36114.9 12.3 14.2 
 
MCP-1 1.5 1578.7 5.9 16.7 
 
RANTES 6.2 5386.9 6.3 18.3 
 
TNF-α 0.3 24177.7 8.6 7.5 
 
NGF-β 1.1 13256.0 6.6 11.1 
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Table 3 presents the values this study obtained for cutaneous cytokines using 
dermal microdialysis in the forearms of 10 healthy controls (5 male). Data is from 20 
forearms (2 per subject, collected simultaneously) over 1 hour at a flow rate of 0.2 
mL/hr. Values that are below our established LLOQ are highlighted in grey, and thus 
effectively not detectable (ND). Those that are between our LLOQ and that of the 
company are highlighted in pale blue, and must be interpreted with caution. 
Key to Table 3: ND: effectively not detected as outside real detection limits; SD: 
standard deviation. Relative standard deviation (RSD) is a measure of variability, 
calculated by SD/mean x 100%. Skewness indicates deviation from the normal 
distribution (skew = 0). Positive skew indicates a distribution with a right-sided tail 
and negative skew indicates a left-sided tail. All cytokines assayed are not normally 
distributed, with most demonstrated a right-sided tail to their distribution. 














IL-1β 0.5 0.7 135 0.4 0.0 1.0 2.11 
IL-6 5.9 6.1 103 3.2 1.6 10.3 1.02 
IL-10 1.0 (ND) 1.0 100 1.0 (ND) 0.3 (ND) 1.6 0.52 
IL-17 13.6 11.8 87 12.6 5.1 22.0 1.13 
IFN-γ 15118.7 6808.5 45 17164.4 10248.2 19989.2 -0.93 
IP-10 650.9 286.3 44 614.4 446.0 855.7 0.34 
MCP-1 63.2 174.9 277 8.5 -61.9 (ND) 188.3 3.16 
RANTES 54.8 45.5 83 37.9 -23.5 (ND) 259.7 0.87 
TNF-α 5.0 3.6 71 5.2 2.5 7.6 0.38 
NGF-β 6.2 7.9 128 5.4 0.5 (ND) 11.9 1.92 
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Effect of protease inhibitor on cytokine yields 
The effect of protease inhibitor on microdialysis cytokine yields was assessed by a 
preliminary experiment using single subject. Both arms were prepared as above, 
with microdialysis catheters inserted in the mid-volar forearm bilaterally. A 
simultaneous 2-hour collection from each arm was obtained using a flow rate of 0.2 
mL/hr. One collection vial contained 30 μL of Roche Complete Protease Inhibitor. 
The protease inhibitor was prepared by dissolving the tablet to make a x7 stock 
solution as per the company instructions, then taking an aliquot estimated to 
provide the appropriate final concentration based on the estimated microdialysis 
volume. The results of this experiment are presented in the graphs in figure 3, 
which shows the effect of protease inhibitor (purple) on cytokine yield compared to 
that in the untreated simultaneous collection in the contralateral arm (blue). The 
top graph presents data for all the cytokines tested, the second graph presents an 
expansion of the axis to better illustrate the effect on cytokines with low 
concentrations. Low concentration cytokines are presented in the second graph 
with an expanded y-axis for clarity. Use of protease inhibitor increased recovery of 






Ethical permission to conduct the study was obtained from the Great Ormond 
Street and Institute of Child Health Research Ethics Committee (REC) (now London – 
Bloomsbury REC). Ten healthy normal volunteers (5 male, 24-49 years) were 
recruited. Subjects were excluded if they had any pre-existing dermatological or 
neurological disease, or were on any regular medication (other than the oral 
contraceptive). Subjects were asked to avoid heavy exercise for 3 days prior to the 
study, not to eat in the hour prior to the study, and to consume no alcohol for the 
day prior to the study, in order to minimize sources of potential variability in 
cytokine levels. 
Experimental design: 
The study was commenced at 9am for all subjects to minimize diurnal variation in 
cytokine levels. Subjects were seated comfortably in a room maintained at a 
comfortable ambient temperature (21-23°C) with their arms supported by pillows. 
EMLA cream was applied to the midpoint of each volar forearm for 45 – 90 minutes 
(until pinprick sensation was dulled). Skin was cleansed with chlorhexidine, then a 
single microdialysis catheter (0.4 mm diameter, 3000kDa cutoff) was inserted in 
each volar under sterile conditions (method detailed below). Hourly aliquots of 
microdialysis fluid were collected in separate protease inhibitor-containing 
Eppendorf tubes from each arm over a 4-hour period, with each aliquot placed on 
dry ice immediately after removal from the patient. Fluid volume collected in each 
Eppendorf tube was recorded by weight (post – pre collection weight). After one 
hour, the area over the left microdialysis catheter was covered with 1% topical 
 146 
capsaicin gel, applied over a 0.79cm2 area directly over the catheter. The area of gel 
in contact with the skin was controlled using a 1cm internal diameter ring of 
Comfeel® (Coloplast) adherent to the skin, and contained within a 1cm internal 
diameter lidded O-ring held to the Comfeel ring using a steristrip. The control arm 
was covered with the same mechanism, but using plain KY® Jelly. Capsaicin gel was 
prepared using 50 mg of capsaicin powder (Sigma Aldrich, M2028) dissolved in 0.5 
mL 100% ethanol then mixed with 4.5 mL KY® Jelly to make a final 1% w/v capsaicin 
gel. The gel remained in situ for the remaining 3 hours of the protocol. Vials were 
stored on dry ice at the end of each 1 hour collection and then transferred to an -
80°C freezer until analysis by multiplex ELISA.  
Time and peak intensity of pain / itch was recorded using a 0-10 numerical rating 
scale. Residual flare at the end of the 3 hours of capsaicin stimulation was recorded 
over the treated and control arms using Laser Doppler Imaging as a surrogate 









Summary of Protocol: 
 Right arm Left arm (control) 
Start 
Microdialysis catheter inserted 
under EMLA analgesia. 
Microdialysis catheter inserted 
under EMLA analgesia. 
0-60 min Collect first hour fluid (Baseline). Collect first hour fluid (Baseline). 
60 min 
Application of 1% topical 
capsaicin 
Application of KY jelly (control) 
60-120 min Collect first stimulated hour fluid Collect first stimulated hour fluid 
120-180 
min 
Collect second stimulated hour 
fluid. 




Collect third stimulated hour 
fluid. 
Collect third stimulated hour 
fluid. 
240 min 
Remove capsaicin and dialysis 
catheter. 
Remove KY Jelly and dialysis 
catheter. 
240 min LDI Flare LDI Flare 
Note: all microdialysis collections taken over 1 hour with a flow rate of 0.2 mL/hr 
into a collection vial containing 30 μL of Roche complete protease inhibitor. 
 
 
Photograph showing experimental design
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Cytokine data collection: 
IL-17, IFN-γ and IP-10 were robustly quantifiable in all subjects. IL-1β concentrations 
are all within the range of reliable detection, but uncertain concentration, as are 
most subjects TNF-α and some subjects with low levels of IL-6. Nearly all levels of IL-
10 fell in the undetectable range, as did some subjects with the lowest levels of 
MCP-1 and RANTES.  
In the following experiments, individual assay results were included or excluded 
from analysis dependent on whether they were within the accuracy range for the 
standard curve run with the assay. If below the accuracy range for the curve run 
simultaneously with the assay, they were allocated a value of 0. 
Analysis: 
Samples were analysed using Bio-Rad Bio-Plex Precision Pro™ multiplex ELISA as 
described in the Methods section. Changes in cytokine levels in the treated and 
non-treated arms were evaluated using two-way repeated measures ANOVA 
(timepoint and treatment) with Bonferroni correction for repeated measures (time) 
to evaluate whether there were significant changes between the treated and 
untreated groups at any timepoint, as well as whether there were changes over 
time. All samples were corrected for volume of collection prior to analysis. 
Significance was assumed at 0.05 and analysis was performed using SPSS 20.0. Data 
are presented as mean ± SD unless otherwise noted. 
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Results: 
The peak VAS score was recorded at 49 ± 25 minutes, with an intensity of 2.4 ± 0.8 
on a 0-10 scale. Subjects reported the sensation uniformly as a burning / stinging 
pain. Doppler flare response in the treated arm was 8.6 ± 3.7 cm with an intensity of 
38.5 ± 12 units. Flare in the control arm was 1.2 ± 0.9 cm. Please see Table 4 for 
details of capsaicin response and flare characteristics. Microdialysis fluid collected 
per hour was 174 ± 3 μL. Figure 15 shows some typical flare recordings and the 
experimental setup for the treated and untreated limbs. 
 
Typical laser Doppler flare response 
Cytokine values for IL-1β, IL-10, IL-17, TNF-α and NGF-β remained below the LLOQ 
throughout the study. Results for IP-10, MCP-1, RANTES, IL-6 and IFN-γ were all 
above the LLOQ and are presented in the graphs below. Significance calculated 
using two-way ANOVA with Bonferroni correction for repeated measures. The limits 
of detection for the assay based on the concurrently run standard curves are shown 




Table 4: Subject demographics, pain response and flare characteristics. 
 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7 Subject 8 Subject 9 Subject 10 Mean SD 
Gender M F F F F M M M M F -  -  
Age 34 36 49 39 30 30 31 25 24 29 32.7 7.3 
Time to onset of 
capsaicin effect 
(mins) 
10 15 10 15 15 20 10 10 5 20 13 4.8 
Time to peak 
capsaicin effect 
(mins) 
60 60 90 70 60 60 30 20 10 30 49 25.1 
Max. VAS 3 3 1 2 3 3 3 1 2 3 2.4 0.8 
Max. Flare Intensity 
(Capsaicin arm) 
(units) 
48.2 43.1 19.9 27.3 29 31.4 46.9 58.8 41.6 39.1 38.5 11.7 
Max. Flare Area 
(Capsaicin arm) (cm2) 
15.7 7.8 3.3 6.2 8.4 6.5 12.2 4.6 9.8 11.0 8.6 3.7 
Max. Flare Area 
(Control arm) (cm2) 








Table 5: Cytokine limits of detection for capsaicin study assay (ρg/mL) 









0.11 0.24 0.14 0.11 1.57 6.18 0.27 35 6 1.13 
Upper limit 
of detection 






No significant changes (at p<0.05 or below) between the treated and untreated 
limb at a single timepoint were observed for any cytokines. Significant changes 
(at p<0.01 to p<0.001 level) were only seen over time for MCP-1 and IL-6. No 
significant correlations were seen between pain scores, time to peak onset of 




The effect of acute nociceptor activation on nine cytokines thought to be of key 
interest in skin immune regulation and genesis of pain, as well as NGF-β were 
assessed by dermal microdialysis and multiplex ELISA at hourly intervals in 10 
subjects who each acted as their own control. The only significant changes in 
cytokine levels seen were increases over time in MCP-1 and IL-6, which is not 
unexpected, as inflammatory cytokines which are known to increase following 
insertional trauma (Averbeck et al., 2006, Sjögren and Anderson, 2009). No 
changes were seen between the treated and untreated arms in any of the 
cytokines measured at any time point. The presence of a capsaicin-induced flare 
remaining in the treated, but not in the untreated arm after 3 hours suggests 
nociceptors were activated appropriately by the topical capsaicin, although the 
low VAS score suggests that nociceptors were relatively mildly activated.  
These findings indicate that acute activation of the capsaicin-sensitive 
polymodal nociceptors that mediate flare response and neurogenic 
inflammation is insufficient to evoke acute changes in key cutaneous cytokines. 
This suggests that the inflammatory changes observed in patients with painful 
small fibre neuropathy are not mediated purely by nociceptor activation, but 
either require additional stimulus, or a longer duration of activation to evolve.  
Acute nociceptor activation may induce inflammatory changes in the skin that 
this study did not detect in its 3-hour examination, perhaps through initiation of 
cellular changes in cells such as Langerhans’ cells and keratinocytes. SP, and 
particularly CGRP, have been found to regulate immune tone in Langerhans’ 
 156 
cells through regulation of NF-κB activation. Modulation of cellular machinery, 
production and secretion of effector cytokines and chemokines may take longer 
than the 3-hour window of this study. Similarly, recruitment of other immune 
cells such as macrophages and lymphocytes would take longer than processes 
dependent on immediate cytokine release. Other possible explanations for the 
lack of inflammatory change include the need for a more intense stimulus (only 
low-levels of pain were induced); the combination of neuropeptide release and 
activation of cellular stress and injury pathways relating to the underlying 
pathology of the neuropathy; or changes in skin biology (particularly that of 
keratinocytes and Langerhans’ cells) induced by loss of nerve fibre contact. 
A further consideration is that the peptidergic population represents only 
around 15% of epidermal fibres (Wallengren and Sundler, 2004, Chao et al., 
2007). Other fibre types, such as the IB4 / P2X3 positive population may be of 
interest in this context, as P2X3 mediated ATP signalling has been implicated in 
pain, and ATP activates a number of inflammatory pathways in the skin.  P2X3 
knockout mice have normal acute nociceptive responses, but less increase in 
pain behaviour with chronic, but not acute, inflammation models. Of note, the 
knockout mice also do not exhibit any change in response to capsaicin (Souslova 
et al., 2000). P2X3 antagonist or antisense treatments have also been found to 
reduce hyperalgesia in models of neuropathic and inflammatory pain, but not 
response to acute pain (Jarvis et al., 2002, Barclay et al., 2002, Honore et al., 
2002). It is interesting that selective depletion of IB4 neurons in the rat sciatic 
nerve results in severe tissue ulceration without changes in nociception 
(Vulchanova et al., 2001), while neonatal capsaicin reduces peptidergic 
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innervation in rats, with no histological epidermal changes (Martínez-Martínez 
et al., 2011). Additionally, capsaicin is used topically to reduce peptidergic 
innervation therapeutically for human pain without causing damage to skin 
integrity (Anand and Bley, 2011). It is tempting to speculate that the relative 
loss of peptidergic and non-peptidergic fibres may be an important factor in 
skin inflammation. Inflammatory mediators could then sensitise remaining 
nociceptors.  
To answer these questions, an extended study with stronger nociceptor 
activation would be ideal. However it is difficult for subjects to remain immobile 
for prolonged periods, making such an examination by microdialysis difficult. 
Conclusion and future work: 
This study shows that chemical activation of the TRPV1+ve subpopulation of 
nociceptors does not alter the levels of key pro- or anti-inflammatory cytokines 
in the skin acutely (within hours). This suggests that changes in cytokine levels 
associated with neuropathic pain either require a longer period of activation, or 
that immune changes in the skin in the context of neuropathy are dependent on 
a combination of nociceptor activation and nerve damage, or perhaps are 
dependent on the subtypes of fibres involved. A third possibility is simply that 
certain neuropathy pathologies both induce pain and induce cytokine changes, 
with immune changes being dependent on the nerve pathology rather than a 
causal agent in the development of pain.  
To further address this issue, the final part of my study examines a population 
of patients with a single neuropathy subtype, Anderson-Fabry disease, which is 
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frequently, but not invariably, associated with neuropathic pain, as well as a 
group of normal controls. These subjects will undergo a detailed clinical and 
neurophysiological characterisation of their neuropathy (including IENFD), 
evaluation of their pain levels, and a detailed cutaneous immune profile using 
dermal microdialysis and assessment of Langerhans’ cell density on skin biopsy. 
By correlating the levels of pain with the immune profiles in these subjects, and 
comparing them with healthy controls, I hope to establish which immune 
changes occur in painless neuropathy compared to those that occur in 
neuropathy with pain. The fact that they all have the same, non-immune 
mediated neuropathology should limit confounding effects of variable 
neuropathology in evaluating immune changes.  
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Chapter 5: Small fibre function, immune changes and pain in 
Anderson-Fabry neuropathy  
Abstract 
Introduction: 
Several studies have linked pain in neuropathy with systemic or local immune 
changes, but have included a variety of pathologies, leading to conflicting 
results. I sought to identify whether inflammatory changes in skin cytokines or 
intrinsic immune cells corresponded with the painfulness of neuropathy in a 
single neuropathy subtype, Anderson-Fabry disease with a high incidence of 
neuropathic pain. By comparing the presence or absence of pain with a variety 
of neurophysiological, histological and immunological measures, I hoped to 
obtain a clearer understanding of the role of inflammation in the painfulness of 
a neuropathy. 
Hypothesis: 
I postulated that Anderson-Fabry patients with a painful neuropathy would 
exhibit a higher level of proinflammatory cytokines and / or lower levels of anti-
inflammatory cytokines in the skin than those with a painless neuropathy. A 
secondary aim was to explore whether changes in Langerhans cell density or 
morphology correlated with the painfulness of the neuropathy.  
Methods: 
Detailed neurophysiology, including quantitative sensory testing, pain and 
mood questionnaires, dermal microdialysis collection of interstitial fluid for 
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multiplex ELISA analysis of cytokines and skin biopsy at the proximal and distal 
leg for intraepidermal nerve fibre density (IENFD) and Langerhans cell numbers 
and morphology were performed at a single visit on each subject. Blood 
samples were also taken to exclude other causes for neuropathy and to 
measure systemic cytokine levels. Cytokines included IL-1β, IL-6, IL-10, IL-17, 
TNF-α, IP-10, MCP-1, RANTES and the growth factor NGF-β. 
Subjects: 
Fourteen patients with Anderson-Fabry disease (age 47 ± 12.7y, 5 men) with 
varying amounts of neuropathic pain and 14 healthy volunteers (age 33 ± 10.1y, 
7 men) were studied. Seven of the Anderson-Fabry patients had significant pain 
on a composite VAS score. 
Results: 
IENFD displayed a proximal-distal gradient in all Anderson-Fabry subjects, and 
was significantly lower than control subjects at both sites in Anderson-Fabry. 
Proximal and distal IENFD correlated with the sum of the three pain-defining 
VAS scores, and proximal IENFD with current VAS score. Quantitative sensory 
testing showed significant differences in several modalities between patients 
and controls in the lower limb, but only in warm detection threshold in the 
upper limb. Only upper limb paroxysmal heat sensation correlated with the 
presence of pain. Several pain measures correlated with proximal MCP-1 and 
proximal IL-6, as well as serum TNF-α and RANTES. Linear density of Langerhans 
cells was significantly reduced at the calf in Anderson-Fabry patients compared 
to controls (p=0.035) with a non-significant trend to reduced density at the 
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thigh. Langerhans cells were also morphologically abnormal in the Anderson-
Fabry patients. 
Conclusion: 
Anderson-Fabry patients have a small fibre neuropathy confirmed on 
morphological and functional studies. Whilst overall cytokine levels between 
groups did not show marked differences, some interesting correlations between 
pain scores and inflammatory cytokine levels were observed. The altered 
density and morphology of Langerhans cells in Anderson-Fabry patients 
warrants more detailed study. 
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Background: Anderson-Fabry disease 
Anderson-Fabry disease is an X-linked lysosomal storage disease characterized 
by a mutation on the GLA gene causing deficiency of the enzyme α-
galactosidase A and leading to accumulation of the glycosphingolipid enzyme 
substrate, globotriaosylceramide (Gb3, or GL-3) in various tissues (Biegstraaten 
et al., 2012, Zarate and Hopkin, 2008).  Symptom onset is usually in childhood in 
men, with a more severe phenotype, but later in affected female heterozygotes, 
who exhibit milder symptoms. Life expectancy in untreated Anderson-Fabry 
disease is reduced by 20 years in men and 15 years in women (Zarate and 
Hopkin, 2008). Enzyme deficiency (less than 5-10% residual activity) leads to 
deposition of glycosphingolipids (globotriaosylceramide and 
galactosylceramide) in tissues and cells leading to organ dysfunction and clinical 
expression of the disease. Organ damage is mediated by impaired tissue 
perfusion and diffusion due to glycosphingolipid deposition in the vascular 
endothelium, particularly in the kidneys, heart, skin and nervous system, but 
fibrosis and inflammation may also be involved, as well as deposition in other 
cell types such as renal podocytes (Zarate and Hopkin, 2008). 
Symptoms worsen with age. Some patients may have disease activity focused 
on one organ system more than others. The clinical picture has not been found 
to correlate closely with the genotype, and considerable variation in age of 
onset, severity and pattern of organ involvement is seen within single families. 
Renal dysfunction is more frequent and severe in men, but both women and 
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men can develop cardiac and cerebrovascular disease. The spectrum of organ 
involvement and subsequent disease may include: 
 Neurological:  neuropathic pain, MRI white/grey matter and posterior 
circulation lesions, TIA, stroke, hearing impairment 
 Gastrointestinal: gastrointestinal symptoms,  
 Skin and eyes: hypohidrosis, skin angiokeratomas, corneal opacities,  
 Renal: proteinuria and hyperfiltration, end-stage renal disease,  
 Cardiac: hypertrophic cardiomyopathy, left-ventricular hypertrophy, 
systolic and diastolic dysfunction, arrhythmia 
The natural progression of Anderson-Fabry disease has been slowed by the 
introduction of enzyme replacement therapy (ERT) with alpha agalsidase 
(Fabrazyme®, Genzyme Corporation, Cambridge, MA, USA) or beta agalsidase 
(Replagal®, Shire Human Genetic Therapies, Boston, MA, USA). Clinical 
improvement across several organ systems has been shown in treatment trials, 
including renal and cardiac function, thermal detection thresholds, evoked 
sweating and reduction in pain severity (Schiffmann et al., 2003, Wilcox et al., 
2008). Despite functional improvements in small fibre function, no increase in 
intraepidermal nerve fibre density at the lower lateral thigh was found after 18 
months of ERT, suggesting any improvement in neuropathic pain and sensation 
with ERT may be mediated by metabolic and functional changes, rather than 
nerve fibre regeneration (Schiffmann et al., 2006).  
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Small fibre neuropathy in Anderson-Fabry disease 
Small fibre neuropathy manifests through the involvement of both sensory and 
autonomic small fibre populations. Pain is often one of the earliest 
manifestations of Anderson-Fabry disease, starting in childhood and 
contributing significantly to morbidity throughout life. There are two primary 
types of pain experienced in Anderson-Fabry disease: chronic pain and Fabry 
crisis pain. Symptoms typically begin in the hands and feet with chronic burning 
and shooting pains and dysaesthesias, thermal sensory loss (particularly cold 
perception) and paraesthesias. Symptoms of autonomic involvement include 
hypohidrosis, impaired pupillary constriction, saliva and tear production and 
gastrointestinal dysmotility (Burlina et al., 2011). The median age of onset at 9 
years in males and 16 years in females (Wilcox et al., 2008). Early in the disease 
course, males experience more severe pain, although this tends to equalize 
later in life (Wilcox et al., 2008).  
Provoked crises of extreme pain may be precipitated by a number of stimuli. 
Crises occur more frequently in early life, tending to decrease in frequency with 
age. They may be precipitated by a number of triggers including heat, stress, 
common illnesses, fatigue and exercise. These episodes of pain typically start in 
the hands and feet and radiate proximally.  
Proposed pathophysiology of sensory dysfunction in Anderson-Fabry disease: 
Sensory dysfunction in Anderson-Fabry disease is thought to be due primarily to 
impairment of peripheral neuronal function secondary to Gb3 accumulation in 
blood vessels, neurons, Schwann cells and skin cells surrounding cutaneous 
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sensory receptors. These factors are thought to combine to impair key neuronal 
functions, with clinical effect mediated through a combination of axonal 
hyperexcitability, ectopic spontaneous firing and central sensitisation (Burlina et 
al., 2011). 
Deposition of Gb3 in vascular smooth muscle and endothelial cells of epineurial 
and endoneurial blood vessels results in ischaemic damage to nerve fibres due 
to reduced blood flow and associated thrombotic complications. Accumulation 
of Gb3 within dorsal root ganglion cells is also reported (Kaye et al., 1988). They 
are thought to be particularly vulnerable due to the fenestrated epithelium of 
their supplying blood vessels. Length-dependent loss of small myelinated and 
unmyelinated fibers has been demonstrated in sural nerve biopsies and through 
intraepidermal nerve fiber analysis (Scott et al., 1999). Ultrastructural studies 
confirm degeneration of dermal axons, with remaining axons showing swollen 
segments filled with inclusions, presumably of lipid, and loss of intracellular 
organelles (Cable et al., 1982b, Vital et al., 1984). Pain and paraesthesias are 
attributed to a combination of poor perfusion of peripheral nerves, and / or 
glycosphingolipid accumulation in axons and dorsal root ganglia cells, leading to 
atrophy of small fibres (Zarate and Hopkin, 2008). 
Neurophysiology and histology of neuropathy in Anderson-Fabry: 
Nerve conduction studies in Anderson-Fabry patients find that large fibre 
function is largely normal in patients who do not have concomitant renal 
impairment, but a higher than expected incidence of carpal tunnel syndrome 
(around 25% of patients) is noted in several studies (Luciano et al., 2002, 
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Laaksonen et al., 2008). When large fibre nerve involvement occurs, amplitude 
is more affected than velocity, suggesting an axonal neuropathy (Lakomá et al., 
2014). Alterations in ion channel function and excitability of sensory nerves 
have been linked to Anderson-Fabry disease, and may contribute to pain. The 
mechanism underlying these changes in some cases may be elevated levels of 
glycolipid directly (Choi et al., 2015), whilst in others the cause is not as clearly 
defined (Geevasinga et al., 2012). Nerve excitability testing in Fabry patients has 
revealed lower thresholds and increased hyperpolarizing current/threshold 
gradients in Fabry patients compared with controls, suggestive of upregulation 
of inward rectifying currents in Fabry disease. ‘Fanning-in’ of threshold 
electrotonus, suggestive of membrane depolarization, has been demonstrated 
in large myelinated fibres in Fabry’s disease (Tan et al., 2005). Sensory axons 
have also been found to have a reduced threshold and increased 
hyperpolarizing current/threshold gradient (I/V), suggestive of changes in ion 
channels involved in the inward rectifying current, Ih (Matafora et al., 2015, Tan 
et al., 2005, Geevasinga et al., 2012). These changes correlated with disease 
severity and pain scores (Geevasinga et al., 2012). Unlike in motor axons, 
sensory axons did not demonstrate membrane depolarization, suggesting that 
ischaemia, previously postulated as the cause of altered Fabry neuron 
neurophysiology in motor axons (Tan et al., 2005), is unlikely to be the sole 
explanation of altered function. 
In a DRG cell culture model, application of clinically relevant concentrations of 
lyso-Gb3 resulted in increased calcium influx in capsaicin-sensitive peptidergic 
DRG neurons, which were predominantly IB4 negative. This was mediated by 
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increased voltage-activated Ca2+ currents (Choi et al., 2015). Thus, the 
improvement in pain with enzyme replacement therapy (Schiffmann et al., 
2001) may be at least partially mediated by the effect of lowering levels of Gb3 
on ion channel function.  
Length-dependent loss of intraepidermal nerve fibre density, altered thermal 
and vibration perception, and reduced autonomic innervation of cutaneous 
structures have been found in some asymptomatic women in addition to 
affected patients with Anderson-Fabry (Mauhin et al., 2015, De Francesco et 
al.). This suggests that small fibre neuropathy may be an early manifestation of 
the disease, evident on testing prior to the development of clinical symptoms or 
involvement of other organ systems. Structural loss of small fibres has been 
reported in nearly all males and up to 50% of women with Anderson-Fabry’s 






Power calculations for planning of study cohort size: 
A number of power calculations were performed prior to the study, based on 
reported cytokine values in serum and interstitial fluid. These were based to 
determine the number of subjects needed in the Anderson-Fabry patients 
groups with and without pain which would be required to yield 80% power 
(alpha = 0.05, two-tailed) for the study to be able to reject the null hypothesis of 
zero correlation between pain and variation in cytokine levels. 
Based on a 50% higher level of pro-inflammatory cytokines in the subgroup of 
Anderson-Fabry patients with significant pain, this returned an estimated 
required subgroup sample size of 28 per group. Based on a 100% higher level of 
proinflammatory cytokines in the subgroup of Anderson-Fabry patients with 
significant pain, this returned an estimated subgroup sample size of 12 per 
group. 
Inclusion and exclusion criteria and baseline screening tests: 
Subjects were recruited from the Metabolic Clinic at the National Hospital for 
Neurology and Neurosurgery (Queens Square) and from the Lysosomal Storage 
Disorders Unit at the Royal Free Hospital. Potential subjects were identified by 
the treating clinicians (Dr. Robin Lachman, Prof. Atul Mehta and Dr. Derralynn 
Hughes) and sent information about the study and a form to return if they were 
interested in being contacted to discuss the study further. Clinicians did not 
send letters to patients known to have significant co-morbidities (please refer to 
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exclusion criteria). Patients interested in participating then returned a response 
form and were followed up by telephone. If no exclusion criteria were identified 
and they remained willing to participate, they were recruited into the study.  
The combined group of Anderson-Fabry patients being treated at the two sites 
was estimated to be around 400. Clinicians sent letters of invitation to patients 
without significant comorbidities, but unfortunately a record of the number of 
letters sent out was not kept. Of the patients that were returned the form and 
were contacted by phone, the majority agreed to take part in the study, with 
only a few declining due largely to difficulties in spending an entire day in 
testing.   
Normal controls were drawn from volunteers responding to a university-wide 
email to all staff and students. Respondents were selected to try to maintain as 
closely as possible an age and gender matched population for comparison with 
the Anderson-Fabry patients. 
Each subject was studied over a single day. Inclusion criteria for all subjects 
included: Age 18-75 years; ability to undergo the testing in the study protocol; 
and signed informed consent. For the Anderson-Fabry patients inclusion criteria 
also included: Clinical diagnosis of Anderson-Fabry disease, confirmed by low 
alpha-Gal A activity in leukocytes or plasma, or of glycolipid deposits on skin 
biopsy, or by genetic testing. Exclusion criteria for all participants included: 
intercurrent illness; immunodeficiency (HIV, lymphoma, malignancy, 
immunosuppressive therapy (greater than 7.5mg prednisolone/day, TNF-alpha 
inhibitors, chemotherapy)); diabetes: significant peripheral vascular disease: 
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significant renal failure (GFR <60mL/min): substance abuse or psychiatric illness; 
pregnancy; neurological disorder: connective tissue disease and insufficient 
command of English for informed consent to be obtained. 
After obtaining written informed consent and screening for inclusion and 
exclusion criteria, each subject underwent an initial assessment, to evaluate 
suitability for inclusion in the study and to exclude other causes of neuropathy. 
This included medical and medication history and baseline blood tests (Urea, 
electrolytes, creatinine, liver function tests, vitamin B12, folate, homocysteine, 
calcium, magnesium, fasting blood glucose level, thyroid function, full blood 
count, erythrocyte sedimentation rate, C-reactive protein, serum protein 
electrophoresis and immunofixation and autoantibodies (ANA, ENA, dsDNA, 
RF). If the patient had not been tested for hepatitis B, C and HIV in the last 6 
months, this was also performed, if appropriate after appropriate counselling as 
per routine clinical practice. 
Scores and Scales 
A number of scores and scales were assessed to determine pain intensity, 
profile and the possible coexistence of anxiety and depression, as these are 
known to alter cytokine profiles. Scales included the following: 
1. Visual Analogue Pain Scale (VAS): Pain intensity was evaluated using visual 
analogue scales to assess limb pain at different time points. The study 
protocol did not specifically record the pain distribution of the patients 
involved, however the descriptions given were primarily that of the 
distribution seen in a length-dependent neuropathy. The Neuropathic Pain 
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Symptom Inventory (see below) was included to try to obtain a more 
detailed characterisation of the patient’s pain, particularly the neuropathic 
features. Participants were asked to place a mark on a linear scale for their 
current level of pain, worst pain in the last month, least pain in the last 
month, average pain in the last month and inconvenience due to pain (how 
much pain interfered with their daily life). For each parameter, a mark was 
made on a 10-cm long line, scoring 0 cm = no pain, and 10 cm = the most 
intense pain one can imagine. The distance in cm is measured from the start 
of the scale to the patient’s mark, and provides the score. A subject was 
classified as having significant pain if their rating fell ≥ 3 cm for 2 out of 3 of 
the following: pain at time of assessment, average pain in the last 4 weeks, 
and inconvenience due to pain. This method has been utilised by other 
authors for similar studies (Üçeyler et al., 2007b).  Please refer to appendix 
for study VAS forms. 
 
2. Neuropathic Pain Symptom Inventory (NPSI): Spontaneous versus evoked 
pain was characterised using the Neuropathic Pain Symptom Inventory 
(NPSI) (Bouhassira et al., 2004). The NPSI was developed to characterise 
clinical subgroups of patients with neuropathic pain, as patients with 
different patterns of neuropathic pain, for example variable levels of 
spontaneous versus evoked pain, may reflect differences in underlying 
pathologic mechanisms and responsiveness to treatment. It is a reliable 
psychometric tool for evaluation of the different dimensions of neuropathic 
pain syndromes. It uses 12 questions with graded responses (0-10) which 
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produces a summary showing the degree of burning and deep spontaneous 
pains, paroxysmal pain, evoked pain and paraesthesia / dysaesthesia 
experienced by the subject.  Please refer to appendix for study NPSI form. 
 
3. Hospital Anxiety and Depression Scale (HADS); this scale was developed in 
1983 (Zigmond and Snaith, 1983) to screen hospital patients for significant 
levels of anxiety and depression. It is a 14-question scale, with seven 
questions, each scoring zero to three, pertaining to depression and seven to 
anxiety.  These result in a score out of 21 for each, with scores over 8 
correlating with significant mood disturbance. Please refer to appendix for 
study HADS form. 
Histamine Flare 
Histamine flare response was evaluated on the mid anterolateral shin and mid 
volar forearm of the non-dominant limb in each subject. In each study, a 
baseline skin perfusion scan was performed using laser Doppler imaging (LDI2-
IR, Moor Instruments, UK). One percent histamine in a methylcellulose gel 
matrix (see below) was then iontophoresed into the skin for 1 minute using 250 
Amp passed through an iontophoresis chamber of 22mm diameter (MIC2 
Iontophoresis controller with ION6 chamber, Moor Instruments, UK). 
Further laser Doppler scans were taken at 3, 9 and 15 minutes after baseline. 
Prior to analysis, baseline blood flow was digitally subtracted from the 
subsequent images. The maximum flare area and intensity were calculated 
using digital imaging software (ImageJ). This was done by taking a ratio of the 
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outline of the flare image (traced manually to include all points above 
background signal) to the total imaged area and multiplying this result to the 
total imaged area (recorded by the laser Doppler software). The included area 
included the area covered by the histamine reservoir in all calculations. 
 
 
Method for Histamine Gel (1% histamine in 1.5% methylcellulose) 
1. 1.5 % Methylcellulose Gel (Sigma-Aldrich, UK, 4000cps): 
1. 1.5 grams of methylcellulose was dispersed slowly (usually over 20-30 
minutes) in 50 ml of boiling water and mixed well; 
2. When dispersed, 50 ml ice cold water was added and the beaker 
immersed in a larger container of crushed ice; 
3. The mixture was stirred continuously until clear (generally 10-15 
minutes).  
 2. 1% Histamine Gel (makes 50mls): 
1. 0.5 grams of histamine dihydrochloride powder (Sigma-Aldrich, UK) was 
added to 1mL deionized water and agitated to disperse;   
2. One mL of histamine solution was combined with 49ml (49.735g) of 
methylcellulose gel at room temperature and mixed using a plastic 
stirring rod; 
3. The gel was allowed to settle overnight, then refrigerated until required. 
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Quantitative Sensory Testing 
Quantitative sensory testing was performed according to the standardised 
protocol developed by the German Research Network on Neuropathic Pain 
(DFNS) (Rolke et al., 2006). Thermal thresholds (cold and warm detection 
thresholds, heat pain and cold pain thresholds) were tested using the method of 
limits on the non-dominant dorsal radial hand and dorsum of foot. Patients 
were asked to respond to changes in warming and cooling by pressing a button 
at the first detection of a temperature change. There were four trials for 
warming and four for cooling.  Paradoxical heat sensation was tested using 
thermal sensory limits and alternating hot and cold stimuli. Subjects were asked 
to press a button as soon as they detected a change in temperature, and to 
state whether the change was towards warm or cool. Warm and cool sensations 
were presented three times each. Paradoxical heating sensations to cool stimuli 
were noted. Mechanical detection thresholds were measured using the method 
of limits and a standardised set of von Frey hairs, which exert graded forces on 
the skin. Five threshold measurements were made, and the geometric mean of 
these used as the final result. Mechanical pain thresholds were determined 
using a set of weighted pinprick of graded stimulus intensity, with the first 
percept of sharpness defining the response. Five threshold measurements were 
made, and a geometric mean of these used as the final result. Mechanical pain 
sensitivity was assessed using the graded intensity pinprick stimuli, with 
subjects asked to rate each stimulus from 0 to 100 (“no pain” to “most intense 
pain imaginable”) to obtain a stimulus response curve to detect pinprick 
hyperalgesia. Dynamic mechanical allodynia was assessed as part of this test, 
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using three light tactile stimuli as moving innocuous stimuli at standardised 
force (e.g. cotton wisp, brush, cotton wool tip), applied over a 2cm length of 
skin. Wind-up ratio (WUR) was measured as the intensity of a single pinprick 
stimulus intensity (rated 0-100) and an estimated mean rating of 0-100 for a 
series of 10 repeated stimuli of the same intensity given at 1 second intervals. 
These were repeated 5 times, and the WUR taken as the ratio of the mean 
rating of the five series divided by the mean rating of the five single stimuli. 
Vibration detection threshold (VDT) was measured as a disappearance 
threshold performed using a graded (0-8) Rydel-Seiffer 64 Hz tuning fork placed 
over a bony prominence (ulnar styloid or medial malleolus). The VDT is the 
mean of three readings of the point on the scale at which the subject can no 
longer feel vibration. The pressure pain threshold (PPT) is performed over a 
muscle (thenar eminence, instep) using a pressure gauge with a 1cm2 probe 
that exerts a force up to 20kg/cm2 (corresponding to ~2000kPa). The PPT was 
determined by the mean of the threshold from 3 series of ascending stimulus 
intensities (slowly increasing ramps of 50kPa/s (~0.5kg/cm2s). 
Neurophysiology 
Three motor nerves (median, ulnar, and peroneal nerves) and four sensory 
nerves (ulnar, median, radial and sural nerves) were examined. The following 
parameters were assessed: motor conduction velocity (MCV), distal motor 
latencies (DML), compound muscle action potential (CMAP) amplitudes, sensory 
conduction velocity (SCV), and sensory action potential (SAP) amplitude. All 
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nerve conduction studies will be performed on the non-dominant upper and 
lower limb.  
Surface electrodes were used for bipolar stimulation, with the following 
stimulation sites for motor studies: median nerve (stimulation at elbow and 
wrist); ulnar nerve (stimulation above and below the elbow, and at wrist); and 
peroneal (stimulation at head of the fibula and dorsum of the ankle). A pair of 
surface electrodes with belly-tendon arrangement was used to record the 
compound motor action potentials (CMAPs) from abductor pollicis brevis, 
abductor digiti minimi, extensor digitorum brevis (EBD).  
Distal latency was measured from the stimulus artefact to the onset of negative 
response. Proximal and distal CMAP amplitude was measured from peak to 
peak and from the baseline to the negative peak. The motor terminal latency 
index (TLI) was calculated for all subjects according to the formula: distal 
conduction distance (mm) / (CV (ms-1) x DML (ms)). The values in normal 
controls in our cohort were consistent with those of healthy controls reported 
by other authors (Trojaborg et al., 1995). 
Sensory conduction velocity was measured using surface electrodes and 
orthodromic technique along the ulnar nerve from the fifth finger to the wrist 
and the median nerve from the second finger to the wrist. Radial sensory 
studies were performed antidromically, stimulating over the radial border of 
the forearm and recording from the anatomical snuff box. Sural sensory studies 
were also performed antidromically, recording from the lateral ankle and 
stimulating from the posterior calf. SCV was measured between the onset and 
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peak latency, and SAP amplitudes were measured between the negative and 
positive peaks.  
Foot and hand skin temperature were controlled to 32-340 C and recorded; 
when necessary limbs were warmed by immersion in warm water until a 
temperature of at least 32 degrees Celsius was reached. 
Cytokine Analysis of Dermal Microdialysis Fluid 
Dermal microdialysis and analysis by multiplex ELISA were carried out as 
described in the previous chapter. Dialysis catheters were inserted over the 
proximal thigh and distal calf, within 10cm of the site from which biopsies were 
taken. Dialysate was collected over 1 hour with the subject supine. 
Histology: IENFD, Langerhan’s cells 
Punch skin biopsies for intraepidermal nerve fibre density and Langerhan’s cell 
quantification were taken from the non-dominant limb, 10 cm proximal to the 
lateral malleolus and 20 cm distal to the anterior superior iliac spine, according 
to the method described by the Johns Hopkins group (McCarthy et al., 1995, 
McArthur et al., 1998).  
Sterile technique was used. The skin was cleaned with chlorhexidine acetate 
0.015% + cetrimide 0.15% (Travasept 100). Half to one millilitre of 2% Xylocaine 
was then infiltrated to raise a small bleb, and allowed to take effect. Analgesia 
at the margins of the anaesthetised area was confirmed, taking care to leave 
the biopsy site free from all needle intrusion. A 3mm punch biopsy was then 
taken (Stiefel 3mm disposable biopsy punch), and carefully removed using fine-
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toothed forceps, taking care not to exert any compressive or stretching force on 
the tissue. The biopsy was immediately placed in chilled 2% PLP fixative and 
stored at 4°C for 22 hours. Pressure was exerted over the biopsy site to achieve 
haemostasis, and then the site was covered with a steristrip and waterproof 
dressing. The subject was instructed to leave the dressing intact for 24 hours, 
and then change it daily until no longer oozing and scabbed over. 
Following immersion fixation, the biopsy was washed in 3x20 minute washes of 
0.1M Sorrenson’s phosphate buffer, then immersed in cryoprotectant at 4°C 
overnight. Tissue at this stage was stored for no more than 1 week before 
further processing. Tissue was embedded in OCT mounting medium and then 
50μm thickness sections were cut on a freezing microtome. Each section was 
placed in TBS-filled compartments of a 96-well plate, with two sections per well. 
Tissue sections were taken such that for each antibody, tissue from a range of 
sites within the biopsy was examined. The initial few sections from each side of 
the block were discarded.  
Two 10-minute TBS washes were performed, by aspirating the fluid using a 
200μL pipette, then refilling the wells. Sections were then incubated with 
blocker for 4 hours on a shaker table at room temperature, followed by 
incubation with the primary antibody for 36 hours at 4°C on a shaker table. PGP 
9.5 (rabbit) (Chemicon) was used at 1:1250, CD1a (mouse) Dako, Clone 010) was 
used at 1:50. Sections were then rinsed in 3 x 15-minute TBS washes and then 
incubated with the biotinylated secondary antibody (Vector) at 1:500 for 1 hour 
at room temperature. After 2 x 15-minute TBS washes, the sections were 
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incubated in 30% methanol in PBS with 1 % hydrogen peroxide to quench 
endogenous peroxidase for 30 minutes, then washed in PBS 2 x 10-minutes. 
Sections were then incubated in avidin-biotin complex (Vectastain Elite ABC kit, 
Vector Laboratories, UK) for 1 hour at room temperature. After 2 x 15-minute 
washes in PBS, sections were incubated in SG substrate (Vector Laboratories, 
UK), 3 drops in 5mL PBS with 3 drops hydrogen peroxide to visualise antibody 
binding. After a further 2 x 15 minute PBS washes, sections were mounted on 
microscope slides and air-dried. Slides were then washed in tap water for 1 
minute, then dipped in 0.5% eosin for 4 seconds, dehydrated through graded 






Fourteen normal controls (7 male, age range 23 – 61 years (mean 33 years)) and 
fourteen patients (5 males, with age range 27 – 69 years (mean 47 years)) were 
recruited. Table 1 shows the demographic characteristics of the normal 
volunteers and Table 2 that of the Anderson-Fabry group. 
 
Table 1: Demographic characteristics of normal control group 
 
Notes on Table 1: None of the normal subjects had significant pain or were 
taking pain medications. HAD – A: Hospital Anxiety and Depression Scale 
(Anxiety component); HAD – D: Hospital Anxiety and Depression Scale 
(Depression component); BMI: Body Mass Index. 
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Table 2: Demographic and pain characteristics of Anderson-Fabry patient 
group 
 
Notes on Table 2: Pain is defined as a VAS score of >3/10 on two or more of the 
following: Current pain, Average pain over the last month, and Inconvenience 
due to pain. HAD – A: Hospital Anxiety and Depression Scale (Anxiety 
component); HAD – D: Hospital Anxiety and Depression Scale (Depression 
component); BMI: Body Mass Index. 
Blood tests 
A number of blood tests were conducted on participants, including fasting 
blood glucose level, full blood count, erythrocyte sedimentation rate, C-reactive 
protein, liver function, urea, creatinine, calcium, magnesium, Vitamin D, Vitamin 
B12, folate, homocysteine, thyroid function tests, serum protein 
electrophoresis, ANA, ANCA, RF, Hepatitis B and C serology, HIV. There were no 
significant differences found between normal volunteers and Anderson-Fabry 
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patients, other than a slightly higher Hb level in normal controls (mean 
difference ± SEM, 1.1 ± 0.4 g/dL, p=0.014), and a slightly higher WCC in 
Anderson-Fabry patients (1.5 ± 0.5 x109/L, p=0.004). 
Pain Scores 
Normal controls had occasional positive VAS ratings over the last month due to 
injuries or headaches (Average pain over last month: VAS mean 0.1, S.D. 0.3; 
Worst pain in last month VAS mean 1.3, S.D. 1.5). None had any current pain, 
and none of the normal controls had ratings above 0 on any aspect of the 
Neuropathic Pain Symptom Inventory (NPSI). The ratings given by the 
Anderson-Fabry group are presented in Table 3 below. The total NPSI is scored 
out of 100, with each sub-component scored out of 10. Overall, Anderson-Fabry 
subjects scored more highly on the superficial spontaneous and paraesthesia 
subscores, with lowest ratings on the evoked pain score.  
The VAS scores have a maximum value of 10. The sum of three VAS scores is the 
total of the three scores used to divide the Anderson-Fabry patients into those 
with significant levels of pain, and those without significant pain. These three 
scores include current pain, average pain over the last month, and 
inconvenience due to pain. When used to define the presence or absence of 
pain as a binary function, pain was defined as a score of greater than or equal to 
3/10 in two of these three parameters. 
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Table 3: Pain scale ratings in Anderson-Fabry patients 
 
Notes on Table 3: VAS Sum of 3 measures includes Current pain, Average pain 
over the last month, and Inconvenience due to pain. 
Mood 
Table 1 and 2 include the results of the Hospital Anxiety and Depression score 
ratings in the normal and patient groups. The scale rates symptoms as normal if 
they fall between 0-7, borderline if they fall between 8-10 and abnormal if they 
are ≥ 11. In the normal population, two subjects had borderline ratings for 
anxiety, with no abnormal ratings for either anxiety or depression. In the 
Anderson-Fabry group, four patients had abnormal anxiety ratings, with one in 
the borderline range. Four patients had borderline depression ratings, but none 
were in the abnormal range.  
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Strong (R>0.7, Pearson correlation) correlations were seen between HAD 
anxiety and depression ratings and intensity of chronic pain, particularly with 
VAS ratings for average pain over the last month, worst pain over the last 
month and inconvenience due to pain. No significant correlation was found with 
the current VAS rating. Moderate correlations were seen with mood scores and 
NPSI ratings for superficial spontaneous and paraesthesias, but not with the 
overall NPSI score. These findings would indicate that the overall intensity of 
pain in Anderson-Fabry is more closely linked to mood disturbance than the 
quality of unpleasant sensation experienced. 
Neurophysiology 
Routine nerve conduction studies were conducted on all patients and normal 
controls and compared to departmental normative values. Skin temperature 
was above 31 °C in all subjects at the time of study.  
A summary of the large fibre neurophysiological studies in normal controls and 
Anderson-Fabry patients is presented in Table 4 below. Intergroup differences 
were calculated using independent groups T-test. Anderson-Fabry patients had 
significantly lower motor and sensory amplitudes in the lower limbs compared 
with controls, supporting a degree of length-dependent axonal involvement. 
Differences in the upper limbs were of lower magnitude, with the main 
difference being slower ulnar conduction velocity. There were no significant 
differences seen in large fibre function between the group of Anderson-Fabry 
patients with significant levels of pain compared to those without pain 
(comparisons done using ANOVA with Bonferroni correction for multiple 
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comparisons). Figures 1 and 2 presented the neurophysiological data in 
graphical form.  
Table 4: Neurophysiological results in normal controls and Anderson-Fabry 
patients. 
 
Notes on Table 4: TLI = terminal latency index; CMAP = compound motor action 
potential amplitude (mV); SAP – sensory amplitude (μV); CV = conduction 
velocity (ms-1). Parameters that showed a significant difference between normal 
controls and patients are presented in bold. The TLI is presented instead of the 
distal motor latency to allow comparison between groups, as a fixed stimulating 







Histamine iontophoresis was used to induce a neurogenic flare response in the 
leg (anterior shin) and forearm (mid-volar surface) in all subjects. Figure 3 






Flare responses were larger in intensity and area in normal subjects than in 
patients with Anderson-Fabry. These differences only reached significance in 
the upper limb studies. 
Table 5 and Figure 4 present the data for flare area, intensity and VAS score 
recorded for the maximal itch / prickling caused by the histamine in Anderson-
Fabry patients and normal controls. Differences between groups were 
compared using independent t-tests. Flare responses and differences between 
groups were most marked in the upper limb, which may partially reflect less 
effective penetrance of iontophoresed histamine in the thicker skin of the leg 
compared to the volar forearm. 
As skin thickness and innervation may be affected by age and gender, linear 
regression analysis was carried out to determine the relative contribution of 
Anderson-Fabry, gender and age to the histamine flare response. In the upper 
limb, the strongest contributor to flare area, intensity and lowered VAS 
response was the presence of Anderson-Fabry, with age and gender not 
significant. In the lower limb, none of the parameters (age, Anderson-Fabry, 
gender) were significant in determining flare area or VAS, while male gender 





Table 5: Histamine flare results 
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Figure 4: Histamine flare responses in Anderson-Fabry patients and controls 
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Quantitative sensory testing 
The results of quantitative sensory testing are presented in Table 6. 
Temperature detection and pain thresholds are in degree centigrade. A baseline 
of 32°C is used for these tests, so a detection threshold is more sensitive the 
closer to 32°C it falls. In contrast, if a pain threshold lies closer to 32°C than in 
the normal population, it indicates thermal hyperalgesia. Figure 5 summarises 
the thermal threshold results for normal controls and Anderson-Fabry patients 
in the hand and the foot. Note the reduced sensitivity to thermal stimuli at both 
sites in the patient group, more marked at the foot than in the hand, in keeping 
with a length dependent process. There is reduced sensitivity to heat pain in the 
patient group overall, but a tendency towards cold hyperalgesia compared with 
the healthy control group. The statistical comparisons between groups are 
presented in Table 6. Significant differences were found in the cold and warm 
detection thresholds at both sites, and in the heat pain threshold in the foot. 
The thermal sensory limens indicates sensitivity to a continually changing 
temperature, and was also significantly increased in Anderson-Fabry patients at 
both sites, providing further functional evidence of a small fibre neuropathy 
affecting temperature perception in this group. There was also greater 
abnormal paradoxical heat perception with cool stimulation to the foot in the 
Anderson-Fabry group compared with control. This is thought to reflect block or 






Several parameters within the QST group of tests are known to have a skewed 
distribution (Rolke et al., 2006), whilst others are normally distributed. To 
correctly assess the significance of the variation in parameters between 
Anderson-Fabry patients and healthy controls, the Kolmogorov–Smirnov test 
was applied to each test within each population group to test for the normality 
of its distribution. Data found to be normally distributed are presented as mean 
and standard deviation, with comparison between groups made using the 
independent groups t-test. Data found not to adhere to a normal distribution 
are presented as median and interquartile range, and differences between 
groups compared using a Mann-Whitney U-test. Table 6 presents a summary of 
the overall QST data and highlights parameters that were significantly different 
in between normal and patients. Thermal thresholds and thermal pain 
sensitivity in Anderson-Fabry patients differed from controls at both sites 
tested, while vibration detection threshold and mechanical detection threshold, 
assessing larger myelinated fibre function (Aβ) was only significantly different at 
the foot. These findings support a length-dependent neuropathy, and suggest 
the neuropathy in Anderson-Fabry may affect smaller unmyelinated fibres 
earlier than larger, myelinated ones. 
A second analysis comparing the three subgroups (comprising: normal controls, 
Anderson-Fabry (no pain) and Anderson-Fabry (with pain)) was conducted using 
ANOVA with Bonferroni correction for multiple comparisons. This showed 
significant differences between normal and Anderson-Fabry (with pain) for the 
parameters in the table below, but not between normal and Anderson-Fabry 
(no pain) or between the subgroups of Anderson-Fabry with and without pain. 
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This suggests that although overall, Anderson-Fabry patients differ from 
controls in these parameters, the bulk of the effect is mediated by the subgroup 
with pain, suggesting that these patients have a more severe small fibre 
neuropathy. The only exception to the above was that a significant difference 
was found between normal and the painless subgroup of Anderson-Fabry 
patients in the warm detection threshold in the foot (p=0.003), and in 
paradoxical heat sensation in the hand in painful Anderson-Fabry patients 














Table 6: Summary of quantitative sensory testing results  
 
Notes on Table 6: Normally distributed parameters are presented as mean ± SD 
and are compared using independent-groups T-test. Non-normally distributed 
parameters (highlighted in red) are presented as median (interquartile range) 
and are compared using the Mann-Whitney U-test. Parameters that are 
significantly different between normal controls and Anderson-Fabry patients 
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are highlighted in bold. The mean difference is the amount by which Anderson-
Fabry patients differ compared with normal controls. 
Abbreviations: CDT – cold detection threshold; WDT – warm detection 
threshold; TSL – thermal sensory limens; PHS – paradoxical heat sensation; CPT 
– cold pain threshold; HPT – heat pain threshold; MDT – mechanical detection 
threshold; MPT – mechanical pain threshold; MPS – mechanical pain sensitivity; 
ALL – dynamic mechanical allodynia; WUR – wind-up ratio; VDT – vibration 
detection threshold; and PPT – pressure pain threshold.  
Normalisation of QST data. 
As the normal range for quantitative sensory testing parameters is known to 
vary with age and gender, it is useful to normalize the raw data to facilitate 
group comparisons of the type and degree of dysfunction, despite differences in 
the normal ranges within the groups dependent on age and gender. It also 
enables graphical representation of the group data, with the range -1.96 to 
+1.96 incorporating data falling within 95% confidence interval for age (ie: ± 2 
S.D. when converted to a normalized scale). Values above the grey zone in the 
graphs below indicate gain of function (hyperalgesia and allodynia), while those 
below the grey zone represent loss of function (hypoaesthesia). 
The raw data is initially converted to a z-score using published normative values 
for age and gender (Rolke et al., 2006) by the following equation: 
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I used the published normative data (Rolke et al., 2006) rather than that 
obtained in our group, as subdividing 14 normal subjects by age and gender 
would render the groups too small for valid statistical data to be obtained. For 
certain parameters (WDT, TSL, CPT, HPT, MDT, MPT and PPT), the polarity of 
the Z-score was then reversed, to enable consistent graphical representation of 
gain or loss of function. 
Figures 6A and 6B show the comparison of QST profile between the controls 
and Anderson-Fabry patients, in the hand (6A) and the foot (6B). The main 
deficits in the Anderson-Fabry patients are seen in warm and cold detection 
thresholds (and the associated thermal sensory limens) and in mechanical 
detection threshold, indicating loss of function in C, Aδ and Aβ fibre types. No 
significant gain of function was noted (for example, thermal or mechanical 
hyperalgesia), although more paradoxical heat sensation was seen in patients 
than controls, thought to correlate with dysfunction or loss of thinly myelinated 
Aδ cold afferents. Although the z-scores do not fall outside the normal range in 
these graphs, there was a statistically significant difference in vibration 
detection threshold at the foot in the patient group compared with controls, 
again supporting a length-dependent neuropathy. Men are more severely 








Patients with significant levels of pain in Anderson-Fabry also have more severe 
small fibre dysfunction. Figure 8A and 8B illustrate the relative differences in 
QST profile between the normal and two subgroups of Anderson-Fabry patients 
subdivided by the presence of significant pain. Those patients with significant 
pain tend to have a more severe neuropathy. This particularly severely affects 
cold and mechanical detection thresholds, suggesting more severe or earlier 
involvement of myelinated compared to unmyelinated afferents. Those with 
pain also exhibit increased mechanical pain sensitivity and increased 
paradoxical heat sensation, also consistent with loss of small myelinated fibres. 
Mechanical pain sensitivity is a stimulus-response measure, whereby elevation 
indicates a greater degree of pain experienced for a particular stimulus.  
In summary, several significant differences were found in Anderson-Fabry 
patients compared to our control population: in both the hand and foot, cold 
and warm detection thresholds, as well as the thermal sensory limens were 
increased. In addition, in the foot, mechanical detection threshold, vibration 
detection threshold and heat pain threshold were increased in the patient 
group. No significant differences were seen between patients and controls in 
parameters evaluating hyperalgesia or central sensitisation (mechanical pain 
sensitivity, dynamic mechanical allodynia or wind-up ratio). These findings are 
consistent with a length-dependent small fibre neuropathy, with greater effect 
on small myelinated (Aδ and Aβ) fibres, but also involving unmyelinated C-
fibres. The subgroup analyses suggest that the subgroup of Anderson-Fabry 
patients with significant pain tend to have more severe small fibre dysfunction 
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than those without pain, but one that is characterized more by loss than gain of 






Cytokine concentrations at the three sites studied (proximal and distal leg and 
serum) were compared between subgroups: Normal controls, Anderson-Fabry 
patients without significant pain and Anderson-Fabry patients with significant 
pain. Full data are available for all subjects with the exception of the proximal 
thigh site in one normal control, due to collection difficulties. Volumes of 
microdialysis fluid from each site were: 176 ± 40 μL at the proximal thigh and 
175 ± 72 μL at the distal calf (mean ± SD), giving a mean flow rate of 2.9 μL / 
min. There was no significant difference in the volume of fluid collected 
between healthy volunteers and patients, nor between the two patient 
subgroups. When both normal and patient groups were divided into equal 
subgroups according to the volume of dialysate collected (larger volume versus 
lesser volume), no significant differences were found in any of the cytokines 
measured dependent upon the volume. 
Statistical comparisons were made between subgroups (normal, Anderson-
Fabry (no pain) and Anderson-Fabry (with pain) using a one-way ANOVA with 
Bonferroni correction for multiple comparisons. Comparisons between the total 
normal and Anderson-Fabry groups were made using independent t-tests. 
Significant differences within each site between groups are shown in Figures 9A 
– 9I below. Comparisons were not made between sites within groups as the 
research question is the association between cytokines and the presence of 
neuropathy and the presence of neuropathic pain, rather than the difference 
between sites in an individual. β-NGF remained undetectable at all sites in all 
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subjects, so was excluded from further analysis. The only statistically significant 
differences between the subgroups were found for: 
 IFN-γ measured at the proximal thigh, which was higher in pain-free 
Anderson-Fabry than in either Anderson-Fabry patients with significant pain 
or normal controls, and 
 IL-1β at the distal calf between healthy volunteers and the total Anderson-
Fabry group.  
Across all groups, cytokines were distributed variably across compartments. IL-
1β and IFN-γ were found at lower concentrations in the serum than in tissue, 
whilst IL-6, IL-10, and particularly MCP-1, IP-10 and RANTES are higher in serum. 
IL-17 is fairly constant across compartments. This variability in relative 
concentration would argue against a simple equilibration of cytokine levels 


















The only significant differences seen between groups were in distal IL-1β and 
proximal IFN-γ. Distal IL-1β was higher in Anderson-Fabry patients than in 
controls, but not different in the presence of pain. Proximal IFN-γ was higher in 
painless Anderson-Fabry patients than those with pain, but this association was 
not seen distally or in the serum.  
In addition to the significant differences presented above, some other cytokines 
showed a trend to a difference between subgroups (0.1>p>0.05). These 
included distal and proximal IL17, which tended to be lower in normal controls 
than the painless Anderson-Fabry group, as well as lower levels of distal IL17 in 
normal controls compared to the total Anderson-Fabry group. Serum IP-10 also 
showed a trend to lower levels in serum in normal controls compared to the 
Anderson-Fabry group. Overall, the differences in cytokine levels detected in 
between group comparisons were mostly linked to the presence of neuropathy, 
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rather than with the presence of pain, with the only cytokine difference in the 
painful neuropathy group being lower levels of IFN-γ in microdialysis fluid from 
the thigh. 
Continuous cytokine – pain comparisons: correlations 
Although some significant differences between groups defined on the presence 
or absence of pain as a categorical variable, correlations were found between 
some cytokines (particularly IL-6 and MCP-1) and continuous pain measures. 
Pearson’s bivariate correlation was used to analyse normally distributed 
variables, and Spearman’s test for those pairs in which one or both pairs were 
not normally distributed. The cytokine – continuous pain measure correlations 











Table 7: Significant correlations found between key continuous measures of 
pain and cytokines (Note: only those which showed a significant correlation are 
presented) 
 
Mood and cytokines: 
As cytokine levels have been reported to be affected by mood, and vice versa 
(Raedler, 2011), all subjects were requested to complete the Hospital Anxiety 
and Depression Score screening tool for anxiety and depression. A correlation 
analysis was conducted in both the normal and patient groups between the 
HAD-A and HAD-D scores and measured cytokine levels. The only significant 
correlation found was in the normal group, with a moderate correlation 
between serum IP-10 and the HAD-Anxiety score, with an R value of -0.539, 
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p=0.047. Therefore it is unlikely that intercurrent mood disturbance had any 
significant influence on the study results. 
Histology 
Intraepidermal nerve fibre density (IENFD) 
Intraepidermal nerve fibre density was calculated at each biopsy site from the 
average of four random sections. Intraepidermal fibres were counted according 
to the rules defined by McCarthy et al (McCarthy et al., 1995), which are 
summarized in Figure 10. The number of fibres was divided by the epidermal 
length (in mm) to obtain a linear density of epidermal nerve fibres in each 
section. An average of the 4 sections counted was then recorded as the 
intraepidermal nerve fibre density at that site in each subject. Slides were 
coded to ensure blinded analysis. Some examples of typical epidermal nerve 











In addition to diminished intraepidermal nerve fibre density, reduced 
autonomic innervation density of dermal organs such as sweat glands and 
arrector pilae muscles was also prominent in the Anderson-Fabry patients. 
These changes were not quantitated, but correlated with the severity of small 
fibre neuropathy seen in IENFD and quantitative sensory testing. Figures 12 and 
13 illustrate the loss of innervation in these structures in the Anderson-Fabry 
patients.  
Abnormal morphology of nerve fibres was also observed in the Anderson-Fabry 
group, with dilatation of subepidermal nerve fibres within dermal nerves, 
beading of smaller dermal nerve fibres, and prominent large varicosities, 
particularly around the hair follicle. These large varicosities differ from the small 
varicosities that are occasionally seen in intraepidermal nerve fibres in both 
healthy controls and patient groups. The larger varicosities in the Anderson-
Fabry group are 2-3 times larger, and sometimes appear to contain intra-axonal 











The mean linear density of intraepidermal nerve fibres at the proximal and 
distal leg in healthy controls and Anderson-Fabry patients is presented in Table 
8, and shown graphically in Figure 15. While women and men in both groups 
show a significant difference in IENFD at both proximal and distal sites, the 
difference is greater in men, which is consistent with male Anderson-Fabry 
patients having a more significant neuropathy than females. There was no 
significant correlation between age and distal IENFD in either the Anderson-
Fabry patients or the normal controls, although there was a trend to a negative 
correlation in the normal group (Pearson’s correlation coefficient = -0.521, 
p=0.056). This was confirmed by linear regression, which showed the presence 
of Anderson-Fabry disease has a stronger effect on distal IENFD than age: 
R2=0.664, distal IENFD = 18 - 0.134(Age, p=0.022) - 6.152(Fabry, p=0.000). 
 






Figure 15: IENFD in healthy controls and Anderson-Fabry patients 
 
Differences in proximal and distal IENFD between subgroups of patients with 
and without pain are shown in Table 9, and graphically in Figure 16. The 
greatest difference between healthy controls and Anderson-Fabry patients in 
IENFD proximally is seen in subjects with pain, whilst distally, a significant 
difference was seen between healthy controls and both subgroups of Anderson-
Fabry patients, although of a greater magnitude in the subgroup with pain. 
There was no significant difference between Anderson-Fabry patients with and 






















A significant proximal to distal gradient was seen in all groups of Anderson-
Fabry patients, as well as in healthy controls (Table 10). The magnitude of the 




Table 10: Proximal-Distal gradient in IENFD in healthy controls and Anderson-
Fabry patients by subgroups 
 
These data suggest that: 
1. There is significant loss of IENFD proximally and distally in Anderson-Fabry 
patients compared with controls (Table 8); 
2.  Men have a more severe small fibre neuropathy than women (Table 8); 
3. There is a similar magnitude of distal fibre loss in Anderson-Fabry patients 
with and without pain (Table 9); 
4. There is a greater loss of proximal nerve fibres in Anderson-Fabry patients 
with pain than those without (Table 9 and 10). 
 
In order to investigate the association of epidermal nerve fibre loss and 
functional characteristics, correlations were examined between proximal and 
distal IENFD and measures of pain intensity (VAS scores), pain quality 
(Neuropathic pain symptom inventory) and small fibre function (quantitative 
sensory testing). Correlations used were either bivariate Pearson (for normally 
distributed variables) or Spearman (for non-normally distributed variables). 
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Current VAS is VAS score at the time of investigation; sum of three key VAS 
scores is the sum of current VAS, VAS score for average pain over the last 
month and VAS score for inconvenience due to pain; total VAS score is as above 
with the addition of VAS score for worst pain in the last month and VAS score 
for least pain in the last month. The transformed z-scores were used for the 
quantitative sensory testing parameter comparisons, to correct for the 
variability in normal ranges due to gender and age. Tests returning significant 
correlations in each group are presented in Table 11. It is interesting to note 
that correlations relating to pain measures were only significant for measures of 
pain intensity, not of pain quality. Significant correlations with QST parameters 
were more frequently seen for those functions subserved by small myelinated 
fibres (cold detection, vibration detection and pressure pain threshold) rather 
than unmyelinated fibres (warm detection threshold). Also of note, correlations 
were more frequently significant with proximal IENFD, which is in keeping with 
the above finding that there is a greater loss of proximal than distal innervation 
in Anderson-Fabry patients with significant pain. 
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Table 11: Correlations between IENFD and measures of pain intensity, pain 
quality and functional loss. 
 
Langerhans cell density and morphology 
Langerhans cell linear density was calculated at each biopsy site from the 
average of four random sections. Langerhans cells were counted according to 
predefined rules. A cell was counted only if a definite cell body with at least 2 
processes emerging from it was seen. Isolated fragments of CD1a positive 
material not fulfilling these criteria were not counted. Also, only cell bodies 
above the dermal-epidermal junction were counted. Superficial dermal CD1a+ 
cells were considered to be part of the CD1a+ dermal dendritic cell population, 
not the epidermal Langerhans cell population. The number of cell bodies within 
the epidermis was divided by the length of the epidermis (in mm) to obtain a 
linear density. Four sections were counted in this way and averaged to obtain 
the Langerhans cell density at each site.  
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Some examples of typical Langerhans cell distribution and morphology in the 
skin of healthy controls and Anderson-Fabry patients are shown in figures 17 
and 18. Note the densely stained, orderly rows of Langerhans cells in the 
normal controls, and the paler, smaller, less frequent and more disorderly 








There was a significant reduction in Langerhans cells density at the calf in 
Anderson-Fabry patients, with a trend to reduction at the thigh. The reduction 
was greater in women than men at both sites (see Table 12). The difference was 
also greater between healthy controls and Anderson-Fabry patients without 
pain, than between controls and those with pain (Table 13). Also, while a 
proximal to distal gradient exists in all groups for Langerhans cell density, there 
is a greater distal reduction in Anderson-Fabry patients without pain than in 
those with pain (Table 14). Finally, although no significant differences were 
found in the between groups comparisons of proximal and distal IENFD: 
Langerhans cell ratio (using ANOVA with Bonferroni correction for multiple 
comparisons), in Anderson-Fabry patients with pain, compared to those without 
there was a trend towards a increase in the density of Langerhans cells at the 
calf relative to the IENFD. This is illustrated in Figures 19 A-C below. 
Differences between groups, subgroups and biopsy sites were assessed using a 
combination of paired and independent T-tests and ANOVA with Bonferroni 







Table 12: Langerhans cell linear density in normal and Anderson-Fabry 
patients 
 



















Figure 19C: Langerhans cell linear density compared to IENFD by subgroup. 
 
Langerhans Cell morphological changes in Anderson-Fabry disease 
Morphological differences were noted in the Langerhans cells of Anderson-
Fabry patients compared with those of healthy controls when visualized with 
the Langerhans cell antibody CD1a (see figures 17 and 18 for examples). 
Normally, Langerhans cells have densely stained, rounded to stellate cell bodies, 
forming 2 parallel layers in the epidermis. The deeper layer is often slightly 
elongated parallel to the dermal-epidermal junction, whilst the more superficial 
layer, located roughly in the centre of the thickness of the epidermis, are often 
more rounded and stellate in morphology. Several processes are seen emerging 
from each cell body, forming a dense surveillance network of fibres throughout 
the epidermis. Just deep to the dermal epidermal junction several larger CD1a+ 
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cells are also often seen. If hair follicles or sweat gland ducts are present in the 
section, these are also densely lined with CD1a+ Langerhans cells. 
In the Anderson-Fabry patients, Langerhans cell bodies were often smaller and 
more irregular in morphology, and less frequently seen organized into two well-
ordered rows. The overall density of cell bodies along the epidermis was 
reduced, with lengths of epidermis in which no cell bodies were seen occurring 
frequently. Less frequent cells were seen lining hair follicles and sweat glands, 
and less subepidermal CD1a+ cells were seen. CD1a+ processes within the 
epidermis were still often frequent, but often appeared fragmented and 
disorganized. 
These morphological differences were confirmed by examination of the 
Langerhans cells in 6 normal and 6 Anderson-Fabry patients by a second, 
blinded examiner (Dr Michael Lunn), who correctly identified all of the patients 
as being abnormal, and 5/6 of the normal controls as being normal. The slides 
were presented twice, with 100% concordance of the categorization by the 







Summary of Key Results: 
 Neurophysiology: 
o Nerve conduction study parameters fell within normal limits for 
normal controls and Anderson-Fabry patients, although there 
was a slight reduction in lower limb sensory and motor 
amplitudes in patients compared to normal controls. 
o Histamine-induced flare responses were reduced in intensity and 
size in Anderson-Fabry patients compared to normal controls, 
although the difference was only statistically significant in the 
upper limb. 
o Quantitative sensory testing showed significant variation from 
normal control subjects in the Anderson-Fabry group, particularly 
in thermal detection thresholds at both the hand and the foot, 
with mechanical detection, vibration detection, heat pain and 
paradoxical heat sensation additionally involved in the lower 
limb. Compared with age and gender matched normative data, 
only cold and warm detection thresholds and mechanical 
detection thresholds fall outside of the normal range in 
Anderson-Fabry patients. Subgroup analysis found that men 
were affected more than women, and that Anderson-Fabry 





 Immune Profile: 
o The only significant differences between normal controls, Anderson-
Fabry patients with pain and Anderson-Fabry patients without pain 
were found in: 
 IFN-γ at the proximal thigh, which was elevated in pain-free 
Anderson-Fabry patients compared to those with pain and 
normal controls. 
 IL-1β at the distal calf, which was significantly higher in 
Anderson-Fabry patients than in normal controls, with no 
differences in the subgroups with and without pain 
o Trends to differences between groups (0.1<p<0.05) were seen in the 
following cytokines: 
 IL-17 (distal and proximal levels) tended to be higher in the 
painless Anderson-Fabry group compared to normal controls, 
with distal IL-17 also tending to be higher in the total 
Anderson-Fabry group than in normal controls. 
 Serum IP-10 tended to be higher in the Anderson-Fabry 
group than in normal controls. 
o Significant positive correlations were seen between several pain 
measures and several cytokines, including proximal thigh levels of IL-
6 and MCP-1 and serum levels of TNF-α and RANTES. 
 Histology 
o Intraepidermal nerve fibres: 
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 Intraepidermal nerve fibre density was significantly reduced 
at both proximal and distal sites in Anderson-Fabry patients 
compared to controls, with men more severely affected. 
 There is a trend to more severe intraepidermal nerve fibre 
loss in Anderson-Fabry patients with pain, with a larger 
difference between the pain and no-pain groups seen at the 
proximal thigh than at the distal calf. 
 Pain scores had a significant negative correlation with 
proximal intraepidermal nerve fibre density. 
 The strongest correlations between intraepidermal nerve 
fibre density and QST parameters was seen at the proximal 
thigh, particularly with cold detection thresholds. In the 
lower limb, vibration detection and pressure pain thresholds 
also correlated with proximal intraepidermal nerve fibre 
density, whilst in the upper limb warm detection and thermal 
sensory limens correlated with proximal intraepidermal nerve 
fibre density. 
o Langerhans cells: 
 Langerhans cell density was significantly reduced at the calf 
in Anderson-Fabry patients, with a trend to reduction at the 
thigh. There was a trend to a larger reduction compared to 
normal control subjects in the patient subgroup without pain. 
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 As with intraepidermal nerve fibre density, there was a 
proximal to distal gradient in Langerhans cell density in both 
normal subjects and the patient cohort. 
 The ratio of Langerhans cells to intraepidermal nerve fibre 
density was similar at both sites in normal controls, mildly 
increased distally in the pain-free Anderson-Fabry group, and 
markedly increased distally in the Anderson-Fabry subgroup 
with pain, although the result did not reach statistical 
significance. 
 In Anderson-Fabry patients, Langerhans cells lost their usual 
two-layered arrangement in the epidermis, and developed 
morphological changes, including smaller, more irregular 
morphology of the cell body, with processes that were 





Whilst there were some slight reductions in large fibre neurophysiology, 
particularly amplitude of responses compared with normal controls, the mean 
velocities and amplitudes in this cohort did not fall outside generally accepted 
normal ranges. The slight variation may in part reflect the slightly older age of 
the patients compared with controls, although Dütsch et al reported similar 
findings in Anderson-Fabry patients (Dütsch et al., 2002). There were significant 
differences in quantitative sensory testing, consistent with a length-dependent 
small fibre neuropathy, with greater effect on small myelinated (Aδ and Aβ) 
fibres, but also involving unmyelinated C-fibres. The quantitative sensory testing 
profile in Anderson-Fabry is characterized more by loss than gain of sensory 
function. The small fibre deficits were more profound in the male patients. A 
similar pattern of small fibre functional change was found in previous studies 
(Dütsch et al., 2002, Üçeyler et al., 2011, Biegstraaten et al., 2011). 
The subgroup analyses suggest that in our Anderson-Fabry cohort, the subgroup 
with pain have more severe small fibre impairment. Previous studies reporting 
the correlation between severity of neuropathy and pain have yielded mixed 
results, but involved all female cohorts (Laaksonen et al., 2008, Torvin Möller et 
al., 2009). A recent study, which included male patients, also found no 
association between severity of neuropathy and pain. There are some factors to 
be considered in this paper, as two-thirds of the cohort were female, and in 
contrast to our study, demonstrated no QST abnormalities, whilst males had 
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abnormal cold detection threshold and thermal sensory limens. In addition, only 
one third were on enzyme replacement therapy. These factors suggest that 
overall the group had a milder phenotype than our cohort, which may affect the 
correlation of severity and pain (Biegstraaten et al., 2011). 
The reductions in flare intensity and size in Anderson-Fabry patients were 
significant only in the upper, rather than lower limbs, in contrast to the other 
small fibre functional measures examined in this study. This may reflect relative 
sensitivity of the test at different sites, perhaps due to thicker skin in the lower 
limb blunting the iontophoresis of histamine.  
Overall, the neurophysiological data support the findings of previous studies 
(Burlina et al., 2011, Lakomá et al., 2014, Mauhin et al., 2015, Biegstraaten et 
al., 2012). The correlation between severity of neuropathy and pain needs 
further refining. The difficulties arise in the phenotypic variability not just 
between hemizygotes and heterozygotes, but also within each group in terms 
of organ involvement and severity. There is also the question of enzyme 
replacement therapy and its potential impact, particularly on measures of 
function. Pain medication also will diminish the strength of any correlation with 
pain, but clearly cannot be withdrawn ethically. Larger cohort studies with 
planned stratification of these factors may help to clarify their potential 
impacts.  
Cytokine Profile 
IFNγ at the proximal thigh was significantly higher in pain-free Anderson-Fabry 
patients than in either the group with pain, or the normal controls. Distal calf IL-
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1β was higher in Anderson-Fabry patients than normal controls, but showed no 
difference related to the presence of pain. IL-17 levels are difficult to interpret, 
as although they trended to be at higher levels in Anderson-Fabry patients, they 
were also around the lower limit of quantification for the assay. Despite the 
relative paucity of strong intergroup differences, there were significant 
correlations of moderate strength seen between proximal levels of IL-6 and 
MCP-1 and serum levels of TNF-α and RANTES. The association between 
proximal, rather than distal cytokine levels and pain is interesting, and may 
indicate a role for cytokines at a particular point in the evolution of painful 
neuropathy, as the distal site is more severely affected in terms of nerve fibre 
loss than the proximal one. Although there were correlations found between 
serum cytokine levels and measures of pain, which may indicate a link between 
a pro-inflammatory profile and pain, this must be considered in light of recent 
studies (see below) suggesting Anderson-Fabry disease may be linked to pro-
inflammatory immune changes.  
A recent study (Üçeyler et al., 2011) examined cytokine levels in Anderson-
Fabry patients by skin mRNA, and found no differences in mRNA expression of 
TNF-α, IL-1β, IL-8, IL-10 or TGF-β1 between proximal and distal sites, or 
between patients and controls. Neither did they find an association with pain. 
Aside from the potential difference in cytokine levels measured by whole skin 
mRNA extraction compared to protein detection by ELISA in dermal 
microdialysis fluid, there are a number of other potential factors to consider in 
comparing their results to this study. These include the low proportion of 
patients on ERT at baseline (27%), a significant proportion with renal 
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impairment  (50%), and less significant QST abnormalities in women than were 
found in our cohort. 
Previous studies have found associations with inflammatory cytokines and pain, 
such as Üçeyler et al (2010) who found strong elevation in cutaneous mRNA 
expression for IL-6 and IL-8, and smaller elevation of TNFα and IL-1β in patients 
with painful small fibre neuropathy compared to healthy controls (Üçeyler et 
al., 2010). This is discordant to my findings in Anderson-Fabry patients, which 
may be due to a combination of methodological factors, included variable 
discordant profiles between dermal protein sampling by microdialysis 
compared to epidermal mRNA expression, as well as possible variations 
between gene expression and functional cytokine release. A key example of this 
is the regulation of the synthesis of mature IL-1β from pro-IL1β by 
inflammasome-regulated activation of caspase 1 (Guarda and So, 2010).  
The lack of difference in serum cytokine levels in Anderson-Fabry patients is 
also contrary to previous findings of elevated proinflammatory cytokines (IL-2 
and TNF-α) and reduced anti-inflammatory cytokines (IL-10, IL-4) in serum of 
patients with painful versus painless neuropathy (Üçeyler et al., 2007b). This 
may be an effect of the relatively small numbers studied, as there was 
considerable overlap in the levels found in individuals in the two groups in 
Üceyler’s study. 
Anderson-Fabry may impact on immune function 
There have been a number of recent papers describing immune differences in 
immune function in Anderson-Fabry patients compared with healthy controls 
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that may impact on these results. These studies suggest that Anderson-Fabry 
disease may have a greater degree of disease and treatment related immune 
variance than was suspected when this study was originally conceived. These 
recent findings relate both to the disease process, and to treatment effects. 
The first issue involves changes in innate immunity in Anderson-Fabry disease 
mediated by altered function of invariant natural killer cells (iNKT). Invariant 
natural killer (iNKT) cells are a subgroup of cytotoxic T-cells that have important 
roles in microbial infection, reducing autoimmune responses and tumour 
surveillance. Lysosomal activity is important in the regulation of activity of 
invariant natural killer (iNKT) cells, which recognize self and bacterial glycolipid 
antigens associated with MHC class I-like CD1d molecules (Pereira et al., 2013). 
It has been found that in Anderson-Fabry patients, increased levels of Gb3 acts 
on dendritic cells via toll-like receptor 4 to increase CD1d signaling via the T-cell 
receptor on invariant natural killer (iNKT) subsets, which in turn modulates 
peripheral blood mononuclear cell cytokine release via IFN-γ. The net effect is a 
shift to a more proinflammatory profile, with increased secretion of IL-1β, TNF-
α and IL-6, and reduction in IL-4 (Mauhin et al., 2015, De Francesco et al., 2013). 
The second recent finding that impacts on this study is that enzyme 
replacement therapy in Anderson-Fabry disease induces upregulation of 
transcription in components of several immune and inflammatory pathways, 
such as those involved in the molecular pathways for T-cell receptors, IL-2, IL-6 
and innate and adaptive immunity (Ko et al., 2015). Increased serum levels of 
TNF-α and IL-6 have also been reported in Anderson-Fabry patients treated with 
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enzyme replacement therapy (Biancini et al., 2012). Whether these changes 
reflect a disease-induced derangement, or a response to a foreign product 
(enzyme replacement therapy), these findings may still be a serious confounder 
in this study.  
These findings have important implications for this study, as any small shifts in 
immune function related to pain mechanisms may be swamped by fluctuations 
related to disease or treatment. This is of particular import given the small 
sample size. 
Overall, the data suggests a link between inflammatory cytokines and pain in 
Anderson-Fabry neuropathy, but confirmation in a larger cohort would be 
desirable. Ideally, this would allow subgroup analysis of patients at different 
stages of the disease, and include groups receiving and not receiving enzyme 
replacement therapy. This would allow further exploration of the idea that 
inflammation may be important at particular stages in the development of 
neuropathy, as well as the effect of enzyme replacement therapy on Anderson-
Fabry. There were no correlations with cytokine levels and HAD score in the 
patient cohort, indicating mood-induced cytokine variation is unlikely to be a 
significant confounder.  
Histology: 
1. Intraepidermal innervation. 
Intraepidermal nerve fibre density was reduced overall in the patients 
compared with the controls, and exhibited a length-dependent gradient. 
Reduced autonomic innervation of arrector pilae muscles and sweat glands was 
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also observed in Anderson-Fabry patients. Sweat glands in Anderson-Fabry 
demonstrate atrophy and stromal inclusions (Fukuhara et al., 1975, Yamamoto 
et al., 1996), as well as reduced sympathetic skin response (Yamamoto et al., 
1996). Reports of autonomic innervation of sweat glands are varied. One study 
reported no change in autonomic innervation of sweat glands in Anderson-
Fabry disease, although the skin examined was taken from the proximal thigh, 
which may not be involved until later in the disease (Schiffmann and Scott, 
2002). Coupled with a report of relatively uniform loss of sweat glands in 
Anderson-Fabry (Cable et al., 1982a), it has been proposed by some authors 
that loss of sweating is more closely linked to glandular dysfunction than to 
autonomic neuropathy (Schiffmann and Scott, 2002). A more recent paper did 
demonstrate a reduction in sweat gland innervation in Anderson-Fabry patients 
compared with controls (Liguori et al., 2010). My findings confirm that there is 
reduced cutaneous autonomic innervation in Anderson-Fabry disease, 
suggesting that reduced sweat production is likely due to a combination of 
reduced innervation and direct damage to sweat glands.   
Proximal and distal IENFD inversely correlated with the sum of the three pain-
defining VAS scores, and proximal IENFD with current VAS score. Reports of the 
association between IENFD and pain are varied, and most have small sample 
sizes. In a larger, mixed cohort, no association between intraepidermal nerve 
fibre density and pain was reported (Biegstraaten et al., 2012), however the 
neuropathy in this group appears to be milder (particularly in the female 
patients) than in my cohort, as there is less marked abnormality in quantitative 
sensory testing parameters. Two studies in female heterozygotes did find an 
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association between the severity of intraepidermal nerve fibre loss and pain 
scores (Torvin Möller et al., 2009, Laaksonen et al., 2008).   
The effect of age of IENFD is hard to control in small studies, but may be a 
factor, as IENFD declines with age. The decline from the 3rd to the 7th decade at 
the ankle is from a median of 11.2 to 7.9 in women, and from 9.0 to 6.3 in men 
(Bakkers et al., 2009). This is a potential confounder given the Anderson-Fabry 
patients in this study were slightly older than the normal controls. However, in 
my cohort, the presence of Anderson-Fabry disease was a greater determinant 
of distal IENFD than age, although there was a trend to reduced distal IENFD in 
older subjects in the normal control group. 
In addition to reduced innervation, there were frequent morphological 
abnormalities seen in Anderson-Fabry patients, including focal swellings, 
general dilatation and beading. These would warrant further study, to 
determine if they arise from mechanical obstruction due to G3b deposition, or 
to failure of axonal transport due to an energy deficit, such as mitochondrial 
failure. Recent work has suggested that mitochondrial loss and morphological 
change may predate degeneration of epidermal fibres in small fibre neuropathy 
(Choi et al., 2015). It would be useful to investigate these further with specific 
markers for mitochondria, lysosomes and G3b to determine their significance. 
2. Langerhans’ cells. 
Linear density of Langerhans cells was significantly reduced at the calf in 
Anderson-Fabry patients compared to controls (p=0.035) with a non-significant 
trend to reduced density at the thigh. Langerhans cells were also 
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morphologically abnormal in the Anderson-Fabry patients. Of interest, there 
was a trend to higher numbers of Langerhans cells relative to remaining 
intraepidermal nerve fibres in Anderson-Fabry patients with pain compared to 
those without significant pain. This trend was present at both the proximal and 
distal sites, but separation was more pronounced distally. There is a slight 
increase in this ratio in the Anderson-Fabry patients compared with controls, 
but the increase in the ratio is far greater in those with pain. Whilst this may be 
partially explained by the trend to more severe neuropathy in those with pain, 
figures 19A and B indicate that this is not the only reason, as there are patients 
with elevated Langerhans cell numbers and relatively preserved IENFD in these 
plots. Langerhans cell changes in morphology and density would certainly bear 
further study in painful neuropathies, and the addition of markers of immune 
activation in Langerhans cells would be helpful to clarify the relevance of these 
preliminary findings. 
A recent study in a diabetic mouse model found an increase in epidermal and 
subepidermal Langerhans’ cells during the period in which the mice 
demonstrated allodynia, with Langerhans’ cell numbers falling later in the 
disease course when the mice no longer demonstrated allodynia. This change 
was thought to be mediated by NGF-TrkA signaling to epidermal Langerhans 
cells, and from TNF-α positive subepidermal fibres to subepidermal immature 
Langerhans cells. The increase was abolished with an intrathecal p38 inhibitor, 
which also reduced mechanical allodynia and TNF-α expression in subepidermal 
fibres. This lead the authors to postulate a role for nerve-Langerhans’ cell NGF 
signaling in the increase in Langerhans’ cell numbers. No changes were seen in 
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the non-diabetic control mice (Dauch et al., 2013). Taken in conjunction with my 
findings of a trend to increased Langerhans cell numbers in subjects with pain, 
these findings support a role for Langerhans cell modulation of neuropathic 
pain, although the pathways require further study. It would be particularly 
interesting to determine whether Langerhans cells play a role in pain generation 
at particular points in the time course of neuropathy progression, as well as 
whether there are changes in markers of Langerhans cell activation, such as the 
shift to a more pro-inflammatory profile. 
Limitations of the study: 
Although every effort was made to match the patient and control groups, this 
was not completely possible, as the final Anderson-Fabry patient group did have 
a higher mean age than the controls, as well as a slight female preponderance. 
Unfortunately these factors could not be overcome, despite drawing the study 
population from two large metabolic units, and the normal controls from the 
University College London population. The normal controls were limited by the 
protocol requiring an entire day, which did restrict participation of those in full 
time employment, skewing the age demographic. This, combined with the small 
numbers in the study, means that the results must be interpreted with a degree 
of caution. The impact of analgesic use on the results also could not be 
controlled, and there were insufficient numbers to perform a reliable subgroup 
analysis to determine the effect this may have had on the results. It would also 
be interesting to compare patients receiving enzyme replacement therapy with 




Anderson-Fabry patients have a small fibre neuropathy confirmed on 
morphological and functional studies, with a trend to a more severe neuropathy 
in those with pain. Cytokine profiles did not differ between patients and 
controls, with limited changes within the Anderson-Fabry population linked to 
pain, which were certainly insufficient to explain the painfulness of the 
neuropathy. The altered density and morphology of Langerhans cells in 
Anderson-Fabry patients is interesting, and warrants more detailed study, 
particularly with respect to the possible link between changes in Langerhans 
cells and the painfulness of the neuropathy. It would be useful to either study a 
larger patient cohort that could be stratified by disease stage, or to study a 
group of individuals at different time points to determine whether immune 
factors play a key role at particular points in the evolution of the neuropathy. It 
would appear that it may be more helpful to design a study correlating pain 
experience with morphological examination of nerve fibre and Langerhans cell 
density, as well as immunohistochemical evaluation of markers of Langerhans 
cell activation, as well as keratinocyte immune profile, as it appears that cell-cell 
interactions may be a more sensitive way of examining possible mechanisms 
than quantification of overall tissue cytokine levels. Finally, emerging data 
suggests that G3b levels may have a direct effect on immune function in 
addition to its effect on nerve function, which would need to be accounted for 
in any further study of immune factors in the painfulness of neuropathy in 
Anderson-Fabry disease. 
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Chapter 6: Conclusions 
1. The skin can be used to study pathogenic mechanisms 
The study of dermal nerve fibres in patients with neuropathy and healthy 
controls confirmed that they can be a useful tool in the study of pathogenic 
mechanisms of some diseases. The ability to identify changes in transcription 
factors and proteins at varying time-points in disease will be a useful tool for 
future use. There are, however, limitations inherent in the translation of animal 
research to human studies. These arise in part due to the fact that animal 
studies are done largely in a monogenic , gender- and age-controlled 
population, whilst human studies generally include individuals of variable ages, 
genders, and medical co-morbidities. They may also have neuropathies at 
varying stages of disease process, which as was explored in Chapter 3, may 
impact on the molecular neuropathology expressed. Some of these factors can 
be overcome by careful subject selection, others may be overcome through 
longitudinal studies, which certainly is something that dermal and epidermal 
nerve biopsy techniques allow. Indeed, better understanding of how molecular 
pathways may alter as a neuropathic disease (such as CMT1A) progresses may 




2. Acute activation of nociceptors is insufficient to provoke a specific 
inflammatory response within 3 hours. 
Acute activation of TRPV1 nociceptors did not result in significant changes in 
cutaneous cytokine profile. This may indicate that the pro-inflammatory profile 
in painful neuropathy observed in some studies of painful human neuropathy is 
dependent upon other factors, such as cellular damage signals (DAMPs), 
immune cell recruitment or activation, or the subtypes of nerve fibres involved 
in the disease process (eg non-peptidergic versus peptidergic fibres). The 
relative role of peptidergic and non-peptidergic fibres need further exploration 
in human neuropathy, as although the majority of epidermal nerve fibres are 
non-peptidergic, they appear to have been the focus of less specific research, 
possibly in part due to greater difficulties in identifying this subgroup 
immunohistochemically due to cross-reactivity with markers such as IB4 with 
keratinocytes. Longer duration studies of the immune effect of nociceptor 
activation on immune profile would be of interest. These would allow 
exploration of whether a neurogenic stimulus without nerve damage would, 
over time, be sufficient to alter skin immune cell function (such as Langerhans’ 
cells, keratinocyte activation and immune cell recruitment), and whether these 
changes altered perceived pain. Ideally a combination of assessment of soluble 
mediators and skin immunohistochemistry would help answer this question. 
The limitations would be on devising a model that would be tolerated by the 
research subjects. 
My findings suggest that models of neuropathic pain which utilise application of 
topical agents or electrical currents, but do not induce nerve damage may not 
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accurately reflect the tissue responses, and pathogenic mechanisms in painful 
neuropathies. This reflects the ongoing difficulties in developing human 
neuropathic pain models (Schmelz, 2009). 
3. Pain in Anderson-Fabry correlates with some pro-inflammatory 
cytokines, and may be associated with increased Langerhans cells 
relative to innervation density. 
There was a trend towards a more severe neuropathy in patients with pain in 
Anderson-Fabry disease. Despite the lack of statistically significant differences 
in cytokine profile between the subgroups of Anderson-Fabry patients with and 
without pain, there were moderate correlations seen between measures of pain 
and levels of the pro-inflammatory cytokines IL-6, MCP-1, RANTES and TNF-α. 
IL-6, MCP-1 and RANTES. It is likely that the small sample size may have been a 
factor in the lack of statistically significant outcomes, particularly given the 
range of ages and severity of denervation seen. The fact that the correlation 
analysis does consistently link inflammatory cytokines with pain, rather than a 
mix of pro- and anti-inflammatory cytokines as may be expected in a truly 
chance finding also suggests there may be a true link.   
The most interesting aspect of this part of the study was the clear trend to 
increased numbers of Langerhans cells relative to nerve fibres in patients with 
pain. As Langerhans cells are important immunomodulatory cells with close 
contacts to epidermal nerves, and studies have shown modulation of their 
function by these contacts, it would be reasonable to hypothesise that they may 
well play a role in regulation of nociceptor function also. The clear proximal-
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distal gradient seen in the patient, but not healthy control cohort supports 
other recent animal studies suggesting neuropathy may affect Langerhans’ cell 
density (Dauch et al., 2013, Siau et al., 2006, Bertelsen et al., 2013). The trend 
to higher LC numbers relative to remaining IENFD suggests that Langerhans’ 
cells may indeed play a role in the modulation of the painfulness of a 
neuropathy, and is an area that would be very interesting to explore further. 
Ideally, any further study would examine markers of activation rather than just 
morphology and linear density, as well as fibre subtypes, as the peptidergic 
fibres are the ones implicated in maintenance of their tolerogenic phenotype. 
Conclusion and future directions: 
 
In summary, this project has demonstrated the utility of the skin as a tool to 
examine neuropathic mechanisms in neuropathy, confirmed that acute 
nociceptor activation is insufficient to provoke immune changes in the skin, and 
opened a new and interesting area of study exploring potential interaction 
between immune cells and neurons in the skin, particularly the role of 
Langerhans’ cells. Utilising a combination of immunohistochemistry to explore 
intracellular molecular pathways, dermal microdialysis and ELISA to quantitate 
small amounts of extracellular proteins of interest and correlation with clinical 
and neurophysiological phenotype may be useful tools to better understand the 
complex interplay between disease and host factors in neuropathy, and how 
best to modulate these to optimize patient outcomes. Markers of inflammation, 
dedifferentiation, redifferentiation and apoptosis may be useful endpoints in 
clinical trials.  
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There are two main sets of limitations of these and possible future studies: 
1. The difficulties in controlling for a possibly wide range of interindividual 
variability across complex molecular pathways, many of which exhibit 
significant degrees of interaction and redundancy; and 
2.  The difficulties in standardizing the point of assessment along the 
continuum of neuropathy progression, as it is likely that pathogenic 
mechanisms are not constant over time. For example earlier in the 
disease there may be more evidence of attempts at regeneration, 
possibly with more inflammation (either as part of the pathogenesis or 
as part of the repair response), and later apoptosis and clearing of 
cellular debris as attempts at repair fail. Similarly, mechanisms in the 
generation of pain may alter between the earlier phases of a painful 
neuropathy, when molecular changes in the peripheral nerve leading to 
peripheral nociceptor hyperexcitability and sensitisation may be more 
important, and later stages when factors such as dorsal horn 
hyperexcitability leading to central sensitisation and indeed cortical 
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Appendix 1: Scores and Scales used in Anderson-Fabry study 
Neuropathic Pain Symptom Inventory (NPSI) 
Q1. Does your pain feel like burning? 
No burning           0     1     2     3     4     5     6     7     8     9     10     Worst  
burning imaginable 
 
Q2. Does your pain feel like squeezing? 
No squeezing        0     1     2     3     4     5     6     7     8     9     10    Worst  
       squeezing imaginable 
 
Q3. Does your pain feel like pressure? 
No pressure          0     1     2     3     4     5     6     7     8     9     10      
Worst pressure imaginable 
 
Q4. During the past 24 h, your spontaneous pain has been present: 
Select the response that best describes your case: 
Permanently      
Between 8 and 12 h   
Between 4 and 7 h    
Between 1 and 3 h    
Less than 1 h     
 
We wish to know if you have brief attacks of pain. For each of the 
following questions, please select the number that best describes the 
average severity of your painful attacks during the past 24 h. Select the 
number 0 if you have not felt such pain (circle one number only). 
 
Q5. Does your pain feel like electric shocks? 
No electric shocks       0     1     2     3     4     5     6     7     8     9     10         
     Worst electric shocks  
imaginable  
Q6. Does your pain feel like stabbing? 
No stabbing     0     1     2     3     4     5     6     7     8     9     10    Worst  




Q7. During the past 24 h, how many of these pain attacks have you had? 
Select the response that best describes your case 
More than 20    
Between 11 and 20    
Between 6 and 10    
Between 1 and 5   
No pain attack    
We wish to know if you feel pain provoked or increased by brushing, 
pressure, contact with cold or warmth on the painful area. For each of the 
following questions, please select the number that best describes the 
average severity of your provoked pain during the past 24 h. Select the 
number 0 if you have not felt such pain (circle one number only). 
 
Q8. Is your pain provoked or increased by brushing on the painful area? 
No pain       0     1     2     3     4     5     6     7     8     9     10    Worst pain  
imaginable 
 
Q9. Is your pain provoked or increased by pressure on the painful area? 
No pain       0     1     2     3     4     5     6     7     8     9     10    Worst pain  
imaginable 
 
Q10. Is your pain provoked or increased by contact with something cold 
on the painful area? 
No pain       0     1     2     3     4     5     6     7     8     9     10    Worst pain  
imaginable 
 
We wish to know if you feel abnormal sensations in the painful area. For 
each of the following  questions, please select the number that best 
describes the average severity of your abnormal sensations during the 
past 24 h. Select the number 0 if your have not felt such sensation (circle 
one number only). 
 
Q11. Do you feel pins and needles? 
No pins & needles      0     1     2     3     4     5     6     7     8     9     10       
      Worst pins & needles  
imaginable 
Q12. Do you feel tingling? 






Total intensity score    Subscores 
Burning (superficial) spontaneous pain: 
1. Q1 =     Q1 =       /10 
 
Pressing (deep) spontaneous pain: 
2. (Q2 + Q3) =     (Q2 + Q3)/2 =   
  /10 
 
Paroxysmal pain: 
3. (Q5 + Q6) =    (Q5 + Q6)/2 =   
  /10 
 
Evoked pain: 
4. (Q8 + Q9 + Q10) =   (Q8 + Q9 + Q10)/3 =   
  /10 
 
Paraesthesia/dysaesthesia: 
5. (Q11 + Q12) =    (Q11 + Q12)/2 =    /10 
 
 




Hospital Anxiety and Depression Score (HAD) 
Emotions play an important part in most illnesses. This questionnaire is 
designed to help us know how you feel. 
 Read each item and tick the reply which comes closest to how you have been 
feeling in the past week. 
Don’t take too long over each response; your immediate reaction to each item 
will probably be more accurate than a long thought out response. 
 
A. I feel tense or ‘wound up’: 
3    Most of the time 
2    A lot of the time 
1    From time to time, occasionally 
0    Not at all 
 
D.    I still enjoy the things I used to enjoy: 
0    Definitely as much 
1    Not quite so much 
2    Only a little 
3    Hardly at all 
 
A. I get a sort of frightened feeling as if something awful is about to happen: 
3    Very definitely and quite badly 
2    Yes, but not too badly 
1    A little, but it doesn’t worry me 
0    Not at all 
 
D.    I can laugh and see the funny side of things: 
0    As much as I always could 
1    Not quite so much now 
2    Definitely not so much now 
3    Not at all  
 
A.   Worrying thoughts go through my mind: 
3    A great deal of the time 
2    A lot of the time 
1    From time to time, but not too often 




D.   I feel cheerful: 
3    Not at all 
2    Not often 
1    Sometimes 
0    Most of the time 
 
A.   I can sit at ease and feel relaxed: 
0    Definitely 
1    Usually 
2    Not often 
3    Not at all  
 
D.   I feel as if I am slowed down: 
3    Nearly all the time 
2    Very often 
1    Sometimes 
0    Not at all  
 
 
A. I get a sort of frightened feeling like ‘butterflies’ in the stomach: 
0    Not at all 
1    Occasionally 
2    Quite often 
3    Very often  
 
D.   I have lost interest in my appearance: 
3    Definitely 
2    I don’t care as much as I should 
1    I may not take quite as much care 
0    I take as much care as ever 
 
A. I feel restless as if I have to be on the move: 
3    Very much indeed 
2    Quite a lot 
1    Not very much 





D. I look forward with enjoyment to things: 
0    As much as I ever did 
1    Rather less than I used to 
2    Definitely less than I used to 
3    Hardly at all 
 
A. I get sudden feelings of panic: 
3    Very often indeed 
2    Quite often 
1    Not very often 
0    Not at all 
 
D. I can enjoy a good book or radio or TV program: 
0    Often 
1    Sometimes 
2    Not often 






















A: ____________    D: _____________ 




The visual analogue scale (VAS) is used to rate the intensity and the 
unpleasantness of the pain. The examiner should ask the patient how 
intense and how unpleasant is the pain in a scale between 0 (= no pain; = 
no unpleasant sensation) and 10 (= worst pain imaginable; = as 




Average Pain score in Last Month: 
 
Worst Pain score in Last Month: 
 
Lowest Pain score in the Last Month: 
 
Inconvenience due to Pain: 
 
 
